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Abstract 
 
Evidence suggests continuous subcutaneous insulin infusion (CSII) is an effective 
method of achieving glycaemic control in those with Type 1 diabetes (T1D). 
Among the advantages of CSII is the opportunity for patients to potentially discard 
the dietary inflexibility imposed by other regimes such as multiple daily injections 
(MDI). There are also reported improvements in quality of life. Furthermore, 
patients with T1D who achieve good glycaemic control may present a normal 
quantitative lipid profile; however, various qualitative atherogenic lipid 
abnormalities may exist, potentially leading to increased cardiometabolic (CM) 
risks. Literature investigating this in those using CSII is sparse and frequently 
dated; as is evidence regarding their eating behaviours and quality of life and is 
therefore worthy of further research. 
To investigate these issues an initial audit of CSII patients’ medical records 
spanning 8 years was performed, with a focus on routinely measured clinical 
markers of risk (n = 260). Then a cross-sectional study was carried out to compare 
those using CSII (n = 40) vs. MDI (n = 40). This involved the use of a food diaries 
and food frequency questionnaires to determine eating behaviours; semi-
structured interviews and questionnaires were used to ascertain quality of life and 
CM risks were assessed by further interrogating participants’ medical records and 
analysing a sample of plasma for lipoprotein quality. Finally, using similar 
methods, longitudinal case studies (n = 5) were performed to elucidate the 
transition from MDI onto CSII over one year. 
The results indicated that upon commencing CSII HbA1c was significantly reduced 
from 8.3 to 7.6% (p = <0.001) and insulin dose significantly lowered from 54.5 to 
46.4 IU (p = <0.001) after using CSII for 12 months and these improvements were 
maintained over the following 3 years. There were few changes in both 
quantitative and qualitative lipids; however, systolic blood pressure decreased 
significantly and unexpectedly both over the 4 year audit period (128.2 to 122.1 
mmHg; p = 0.003) and when comparing those using CSII against their MDI 
counterparts (123.5 mmHg vs. 135.3 mmHg; p = 0.023). Significant reductions 
 
 
were also shown in diastolic blood pressure (75.2 to 72.0 mmHg; p = 0.027). 
There was little variance in the diets of the two treatment groups; however, subtle 
differences existed and the intake of certain nutrients such as fibre and iron in 
females failed to meet the RNI. Many qualitative themes emerged from the 
interviews regarding participants’ quality of life and in particular highlighted how 
the device was largely held in positive regard for its ability to improve glycaemic 
control and offer unprecedented flexibility which allowed a largely unrestricted 
lifestyle.  
Despite limitations, this study offers useful information for those working in the 
field, allowing, for the first time, a deep insight into the eating behaviours, 
cardiometabolic risks and quality of life of a group of patients using contemporary 
CSII therapy. It is hoped these findings will assist with decision making processes 
in clinical practice, thus improving the lives of those with T1D. 
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1 - Introduction 
 
1.1 Background of T1D 
Introduction 
Type 1 diabetes (T1D) is a chronic disease affecting a significant number of 
people worldwide; often having a severe impact upon the lives of those diagnosed 
with the condition. Physiological, psychological and social issues are among those 
which frequently challenge patients; however, over recent years our understanding 
of T1D has grown exponentially and improved knowledge and novel innovations 
have emanated in enhanced strategies for prevention and treatment. One such 
treatment is continuous subcutaneous insulin infusion (CSII) therapy. This 
employs a small, electronic pump device to facilitate the administration of insulin. 
The benefits of the therapy include the hypothetical ability for the patient to relax 
their diet, as well as potential improvements in quality of life and certain 
cardiometabolic (CM) risks. Unfortunately, evidence regarding these benefits and 
their impact upon the lives of patients is lacking. This thesis aims to correct this 
and will explain a study carried out to investigate these three key areas. This 
introduction section will offer the reader a broad overview of T1D and CSII therapy 
as well as briefly outlining the research problems and describing the structure of 
the thesis.  
Epidemiology 
Diabetes is thought to affect almost 387 million people worldwide (International 
Diabetes Federation, 2014). It is commonly cited that 10% of this population will be 
diagnosed with T1D, therefore equating to approximately 3.87 million people, with 
equal rates of incidence found in males and females (International Diabetes 
Federation, 2014; Krischer, 2004). Previous literature also suggests that global 
incidence rates have been increasing for decades and are predicted to rise by 3% 
annually, despite high levels of variability between countries (Gale, 2002; 
International Diabetes Federation, 2014). Results from the DiaMond study 
highlight this variability. This epidemiological study was the largest standardised 
survey for any disease and examined global T1D incidence rates in children less 
10 
 
than 14 years of age living in 50 countries. Differences were estimated to be 350-
fold, with age-adjusted incidence ranging from as little as 0.1 per 100,000 in 
Venezuela and China through to 40.9 in Finland (The DiaMond Project Group, 
2006). Although this study highlighted increased incidence in all observed 
countries, more pronounced increases were seen in those with low incidence 
(Ibid). While evidence such as this is useful to determine the global rates and 
patterns of T1D, there is a lack of good quality data originating from some 
developing countries due to poorly established research and surveillance 
infrastructures and current efforts focussed largely on infectious diseases (Maahs, 
2010, International Diabetes Federation, 2014). This is an area of concern for the 
research community, with existing diabetes prevalence rates for these countries 
largely based upon age-specific estimations (Wild, 2004). Furthermore, little 
mortality data is also available for these countries with estimations usually based 
on the assumption that life expectancy is worse than in developed countries, 
meaning documented rates are thought to be conservative and the true extent of 
the disease in these areas is currently unknown (Ibid).  
Large variances in the prevalence of T1D have also been observed within Europe. 
The European Prospective Complications Study: Aetiology of Childhood Diabetes 
on an Epidemiological Basis (EURODIAB ACE) study was based upon 16,362 
reported cases of T1D out of a population of 28 million children and highlighted 
how rates ranged from 3.2 cases per 100,000 in Macedonia to 40.2 cases per 
100,000 in Finland, with an average annual increase in incidence of 3.4% (95% 
C.I. 2.5-4.4%) (EURODIAB ACE Study Group, 2000). Despite these findings being 
15 years old, more recent evidence from Diaz-Valencia (2015) shows how these 
variances remain and that differences even occur between countries with 
comparable healthcare systems; for example Sardinia presented incidence of 37.8 
per 100,000, whereas its neighbour Italy had only intermediate prevalence of the 
disease (Diaz-Valencia, 2015). This intermediate prevalence was shown to be 
typical of Europe as a whole and occurred in 18 of the 39 populations examined, 
with the remainder displaying high or very high incidence and posing questions of 
concern for the continent as a whole (Karvonen, 2000).  
The UK is no different in terms of high prevalence, with T1D accounting for 10% of 
all cases of diabetes, equating to approximately 320,000 out of the 3.2 million 
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people diagnosed with the disease (HSCIC, 2012; Quality and Outcomes 
Framework, 2013). Diagnosis most frequently occurs between the ages of 10 and 
14 and incidence in children under 14 is high, with rates estimated at 28.2 per 
100,000 (NHS, 2007; International Diabetes Federation, 2014). Additionally, it 
should also be noted that T1D incidence in the UK has doubled every 20 years 
since 1945 and that the greatest increases are in children under 5 (JDRF, 2010; 
NICE, 2008). These concerning figures are also met with equally troubling cost 
implications. An economic evaluation of T1D by Hex (2012) revealed that diabetes 
burdens the NHS with direct costs of approximately £9.6 billion and indirect costs 
of £13 billion, with T1D alone accounting for £1 billion of direct costs and £0.9 
billion of indirect costs. These figures are forecasted to rise in line with the 
expected increases of disease prevalence, with projected 2035/36 costs for T1D 
predicted to be £1.8 billion for direct costs and £2.4 billion for indirect costs and 
with total diabetes costs expected to consume 17% of the NHS budget (Ibid). 
These projections offer a bleak glimpse into the future if the prevalence of T1D 
continues unchallenged.  
Aetiology  
T1D is a complex disease characterised by the progressive failure of the 
pancreatic, insulin-producing ß cells which reside in the islets of Langerhans, 
rendering skeletal muscle and fat cells unable to take up blood glucose. 
Autoimmunity appears to be the predominant mechanism by which ß cells are 
destroyed, resulting in a lifelong reliance on exogenous insulin as a therapeutic 
remedy (Atkinson, 2012). The current understanding of the natural history and 
pathology of this phenomenon remains incomplete, however great strides have 
been made in recent decades and existing evidence indicates that a combination 
of complex genetic, autoantibody and metabolic factors working in concert 
encourage this destructive process to take place (Figure 1.1).  
12 
 
 
 
 
It was first proposed by Eisenbarth (1986) that those with genetic predispositions 
for T1D who were exposed to certain environmental provocations could be at risk 
of initiating this autoimmunity and that the destructive process is not immediate, 
but can be measured in months and years. Despite providing a valuable signpost 
for the research community, recent evidence has further elaborated and refined 
this model and it is now estimated that 40-50% of ß cell death is required for the 
onset of hyperglycaemia and that some cells may actually remain in patients 
diagnosed with T1D (Akirav et al. 2008; Meier et al. 2005). Furthermore, the 
decline in ß cell function is not linear and is in fact stepwise in nature, with 
recurrent, brief relapses of remission as described by Von Herrath et al. (2007). It 
is these typical elements of decline into T1D which may explain how insulin 
secretion can remain stable despite ongoing autoimmunity and why symptoms 
usually only develop after considerable damage has already been done. 
Figure 1.1 – Diagram showing events leading to ß cell death (Adapted from: Hober, 2010) 
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The cascades of interacting events leading to ß cell death, as illustrated in Figure 
1.1, although not fully understood, often appear to occur in those who are at an 
increased risk of the disease via a genetic predisposition. There are various 
candidate genes associated with T1D and the majority of loci appear to encode 
products implicated in immune function and to a lesser degree insulin expression 
and ß cell function (Noble, 2012). It is also apparent that there are a small number 
of genes which infer a larger risk of developing the disease and a large number of 
genes which infer a smaller risk. The commencement of research in the 1970’s 
focussing on the Human Leukocyte Antigen (HLA) were of particular importance in 
determining this risk, with alleles such as DRB1*03-DQB1*0201 (DR3) or 
DRB1*04-DQB1*0302 (DR4) inferring risk, whereas others such as DQB1*0602 
appearing to offer protection (Morran, 2015).  
Another important genetic marker of interest is that of the IDDM2 locus which is 
implicated in insulin regulation (Kantárová, 2007). Although this insulin gene 
region is of primary importance in T1D pathogenesis (after the HLA region); it only 
confers approximately 10% of susceptibility to the disease and is highly variable 
between ethnicities (Bell, 1984). Various other candidate non-HLA and non-insulin 
regulating genes have also been implicated in T1D, albeit to a lesser degree. 
Examples being cytotoxic T lymphocyte-associated protein 4 (CTLA-4), protein 
tyrosine phosphatase nonreceptor type 22 (PTPN22) and interleukin (IL)-2 
receptor–α (IL2RA) (Nisticò, 1996; Steck, 2011; Lowe, 2007). Although this 
overview has only briefly outlined a handful of selected candidate genes, the 
discovery of markers such as these have improved our understanding of the 
genetic basis of T1D and continue to hold promise for the future.  
Despite well documented genetic circumstances predisposing individuals to 
develop T1D, many people with these genetic risk markers often fail to develop the 
condition. In fact as rates of T1D continue to increase the number of cases 
triggered by the high risk HLA genotype remain virtually static, which is in 
agreement with the hypothesis that environmental factors may be driving 
incidence rates (Gillespie, 2004). Furthermore, investigations into monozygotic 
twins with the disease have revealed a pairwise concordance of only 13-33% 
(Knip, 2005). This coupled with migration studies highlighting how the movement 
of people from low incidence areas to high incidence areas are frequently 
14 
 
accompanied by increased rates of T1D further emphasise how environmental 
elements may be at work (Åkerblom, 1998). With this in mind the research 
community has placed great importance on the investigation of many of these 
potentially diabetogenic triggers which may account for the disease. This has 
resulted in the production of a considerable body of evidence and many diverse 
and often contradicting rationales for the initiation of T1D.  
Perhaps the most compelling environmental culprit for the development of T1D is 
that of a viral infection. Large-scale epidemiological studies have highlighted 
potential associations, with both the DiaMond study and the EURODIAB study 
suggesting that geographical differences of disease incidence could indicate a 
viral trigger (The DiaMond Project Group, 2006; EURODIAB ACE Study Group, 
2000). Furthermore, the Finnish Type 1 Diabetes Prediction and Prevention 
(DIPP) study found disease onset was strongly associated with the seasons; with 
higher incidence occurring in the autumn and winter months, leading the authors 
to suggest that the autoimmunity preceding disease onset may be mediated by a 
viral infection (Kimpimäki, 2001). In addition Patterson et al. (1996) described a 
curious positive correlation between the incidence of T1D and poor household 
hygienic conditions. The authors suggested that this so-called ‘hygiene hypothesis’ 
was likely due to an increased probability of exposure to infections in 
environments with lower standards of hygiene, thus further emphasising the 
possibility of a viral component in the development of the disease. Furthermore, 
viruses such as rubella, mumps, rotavirus and cytomegalovirus have all been 
weakly implicated in the development of T1D; however, enteroviruses in particular 
are thought to be the most likely candidates (Coppieters, 2012; Honeyman, 2000; 
Pak, 1988; Hober, 2013). Gamble et al. first suggested the potential association of 
this genus of viruses with T1D in 1969 and since then many workers have 
attempted to further investigate this proposition, with evidence derived from 
epidemiological studies often being used to underpin the hypothesis. For example, 
a meta-analysis by Yeung (2011) illustrated a significant association with the virus 
and T1D; with children diagnosed with the disease displaying 10 times greater 
odds of having contracted an enterovirus than controls. Furthermore, histological 
studies utilising these human pancreatic tissue collections have clarified 
enterovirus mediated damage to ß cells and have illustrated ‘hallmark’ features of 
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T1D including insulitis and the upregulation of major histocompatibility complex 
(MHC) class 1 (Richardson, 2011; Foulis, 1987). It is thought that these processes 
create a suitable ‘landscape’ allowing a series of multifaceted inflammatory ‘hits’ to 
occur to the pancreatic islets, which over time ultimately promote the destruction of 
ß cells and the progression of T1D (Schneider, 2013).  
Even with great strides being taken to understand the aetiology of T1D and initially 
convincing evidence suggesting the implication of enteroviruses it should be noted 
that important controversies in the literature remain. Despite large scale 
epidemiological studies providing compelling evidence in favour of viral triggers, 
there are others which present a different picture. The Diabetes Autoimmunity 
Study in the Young (DAISY) project, for example, found no viral association with 
islet autoimmunity in children with genetically high risk (Graves, 2003). This lack of 
association was also seen in stool samples collected from children in Norway and 
more recently The Environmental Determinants of Diabetes in the Young (TEDDY) 
study, which examined 8677 children with a high risk genotype for evidence of a 
viral causative agent also failed to find any association (Tapia, 2011; Lee, 2013). 
Furthermore, a systematic review of 26 published case-control studies by Green 
(2004) also concluded that there is insufficient evidence to implicate the coxsachie 
virus in the development of T1D. Moreover, research conducted in animal models 
suggests that the contraction of enteroviruses may actually infer protection against 
the disease (Filippi, 2008). This protective nature of enteroviruses has also been 
seen in a paradoxical twist of the ‘hygiene hypothesis’ described previously, where 
authors have described that it is in fact the absence of infection exposure, usually 
caused by near-sterile living conditions, which may increase risks of developing 
T1D and that contracting these viruses may therefore infer an element of 
protection from the disease (Bach, 2002). When weighing up conflicting evidence 
such as this it is clear that many of the findings concerning viral triggers are 
controversial and further research is certainly required. 
T1D is frequently regarded as a disease which often (although not exclusively) 
presents in the young. As such there are various environmental factors associated 
specifically with early life which have been linked with the progression of the 
disease. Perhaps the most immediate of all potential factors is the actual birth 
process itself. It is widely documented that children born using a caesarean 
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section may be at an increased risk, with a meta-analysis by Cardwell et al. (2008) 
suggesting that rates of T1D are 20% greater in those who have been delivered 
using a caesarean section and that increased incidence of T1D has also been 
rising in parallel with rates of the procedures use. This increased risk was also 
illustrated in the BABYDIAB study where children born via caesarean section were 
shown to have a twofold greater risk of developing T1D than those born by vaginal 
delivery with incidence rates being 4.8% and 2.2% respectively (Bonifacio, 2011).  
Parental behaviours may vary from family to family after child birth and in 
particular feeding patterns may be prone to differences. The scientific community 
at present is divided over the impact this may have upon T1D risk with some 
authors suggesting that breastfeeding has no effect on the development of the 
disease (Viner, 2008). Conversely, other authors propose that breastfeeding could 
in fact be an environmental candidate and that the length of time breastfeeding 
takes place is a key indicator of risk (Pereina, 2014; Alves, 2012). Furthermore, 
the early introduction of complex proteins such cow’s milk (often in the form of 
infant formula) has also been implicated as an important factor in the development 
of T1D during early life, with the late introduction of cow’s milk in conjunction with 
long duration breastfeeding being shown to reduce the incidence of T1D (Virtanen, 
1991). However, findings from the TRIGR study are in disagreement with this. The 
authors found that that when comparing hydrolysed infant formula against cow’s 
milk in infants at risk of developing T1D there was no difference in incidence after 
7 years (Knip, 2014). However, the trial did not distinguish between the effects of 
breastfeeding versus consuming formula milk (as randomisation to either 
breastfeeding or formula feeding would pose ethical issues) and its impact on 
disease progression therefore remains unclear. 
Recently there has been interest in the potential association between childhood 
obesity and the incidence of T1D, with the resulting ‘accelerator’ hypothesis being 
formed. This theory proposes that an increased demand for insulin overloads ß 
cells and that the subsequent weight gain and insulin resistance further 
propagates the disease and act as ‘accelerants’ (Vehik, 2011). This proposal has 
been investigated by various studies with mixed results. Some suggest that a 
raised BMI and insulin resistance in childhood is indeed associated with the 
development of T1D (Ljungkrantz, 2008; Kordonouri, 2005; Nokoff, 2012; Wilkin, 
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2006). Despite the research remains equivocal. For example Fourlanos (2008) 
and Raab (2013) both suggest that there is no association with insulin resistance 
and T1D and larger studies such as the BABYDIAB study concur that there is no 
link with either insulin resistance or BMI and islet autoimmunity (Winkler, 2013). 
This conflicting evidence suggests that the story is far from clear regarding the 
influence that early life growth may have upon the incidence of T1D. 
Despite many environmental factors implicated in the decline of ß cell function 
occurring during early life, several may persist from childhood through to 
adulthood. One of perhaps the most prominent and frequently encountered is that 
of dietary intake; in particular the consumption of proteins. Specifically, the 
consumption of gluten may be an important factor. Gluten sensitivity has 
previously been shown to be a potentially important factor in the development of 
T1D, with various mechanistic hypotheses being proposed, usually centred around 
increased intestinal permeability or ‘leaky gut’, thus allowing peptides and even 
proteins to be absorbed into the circulation (de Kort, 2011). These infiltrating 
particles may then be presented as antigens which have been implicated in the 
immune response preceding T1D, a process which is further exacerbated by the 
habitual intake of gluten (Barbeau, 2007). This was demonstrated in the 
prospective cohort BABYDIAB study where Ziegler (2003) found babies at risk of 
T1D fed a gluten supplement were associated with a significant increase in islet 
autoantibody risk compared to controls, illustrating the impact gluten may have on 
those predisposed to the disease. Furthermore, those with T1D are at an 
increased risk of coeliac disease (also an autoimmune disorder) compared to the 
general population, with a meta-analysis by Elfström (2014) showing how 1 in 20 
people with T1D are diagnosed with coeliac disease; strong enough evidence to 
make the case for routine screening. 
Foods which are digested rapidly cause large glycaemic excursions which require 
a greater production of insulin, causing ß cell stress (Pickup, 2004). The varying 
effects carbohydrates have upon this process and their potential role in islet 
autoimmunity has been previously examined by other groups. Both Pundziute-
Lycká (2004) and Dahlquist (1990) concluded that high intakes of carbohydrates 
(especially disaccharides and sucrose) increased diabetes risk and both suggest ß 
cell stress may be a catalyst for this response. Lamb (2008) investigated this 
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hypothesis in more detail and concluded that high glycaemic index (GI) foods in 
particular are associated with progression to T1D and a follow up study by the 
same author in 2015 investigating sugar intake as part of the DAISY study further 
corroborated this hypothesis. Specifically, the consumption of sugar sweetened 
beverages may be detrimental in those at the highest risk of developing the 
disease. This is reminiscent of the ‘accelerator’ hypothesis mentioned earlier and 
could potentially be a contributing factor for the development of T1D. 
Vitamin D has also been identified as having a key role in the aetiology of various 
autoimmune diseases such as multiple sclerosis and arthritis (Cantorna, 2000). 
T1D is no exception. Many countries with higher incidence of T1D are frequently of 
a higher latitude north of the equator (see Figure 1.2) (Whiting, 2011). This pattern 
alludes to a ‘north-south gradient hypothesis’ where vitamin D status may not only 
be associated with these levels of incidence, but may actually be the cause 
(Karvonen, 2000; Atkinson, 2012). A meta-analysis by Feng (2015) further 
implicated vitamin D by demonstrating that those with T1D also had lower levels of 
serum 25 (OH) D concentrations than healthy controls. For the proposed ‘north-
south gradient’ of T1D to be plausible the assumption has to be made that it is 
actually UV-B exposure which is modulating vitamin D levels; however, a cross-
sectional study by Bierschenk (2009) illustrated that this was not the case and at a 
population level all study groups actually had suboptimal vitamin D regardless of 
equatorial position and recommended vitamin D supplementation. Although 
sounding like a sensible suggestion observational evidence remains undecided 
whether supplementation does or does not have a protective effect in the 
development of T1D (Mishra 2015; Stene, 2003). 
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Although an exclusive cause of T1D is currently unknown there are various factors 
which may be implicated. Due to the stark contrasts in the geographical incidence 
of the disease and the large variations and disagreements in hypotheses it is likely 
that the cause may be multifactorial. It is clear that some populations are at a 
higher risk of developing T1D than others, making prediction easier but not 
definitive. With future research the elusive origins of T1D may hopefully be 
revealed in their entirety; however, in the meantime improving treatments to 
improve patients’ lives remain of primary importance.  
1.2 Therapies and treatments  
Methods of achieving glycaemic control using insulin 
Since insulin was first used to treat T1D it has remained a therapeutic cornerstone 
for the maintenance of glycaemic control. Just as there are a variety of insulin 
products for differing circumstances, there are a similarly diverse range of insulin 
administration methods; some may be more appropriate for the treatment of 
certain individuals than others. The most common method of insulin administration 
is subcutaneous injections, which traditionally consisted of drawing a desired 
quantity of insulin into a prepared syringe before injecting. During the 21st century 
Figure 1.2 – Global incidence of T1D (IDF Atlas, 2015) 
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Figure 1.3 – Insulin action of twice daily conventional insulin therapy (Adapted from: Accu-
Chek, 2016) 
the advent of insulin pens have made the process more convenient, less painful 
and have been generally well accepted by patients (Pickup, 2004).  
Conventional insulin therapy 
Injection regimens using these devices vary and may consist of the patient taking 
2 or 3 injections of pre-mixed insulin per day. This ‘twice or thrice-daily’ regimen is 
commonly referred to as ‘conventional insulin therapy’ and involves varied doses 
consisting of either a neutral protamine Hagedorn (NPH) or lente insulin which is 
given in the morning and with the evening meal and occasionally before lunch (see 
Figures 1.3 and 1.4). There are few studies comparing the two methods of 
conventional insulin therapy in terms of glycaemic control; however, an RCT by 
Razavi (2011) showed little different in the level of HbA1c of patients using either 
twice or thrice daily injections, indicating that twice daily may be superior due to its 
simplicity and cost effectiveness. Furthermore, fewer injections may also be an 
advantage for those with needle phobias. 
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 Multiple daily injections 
Another typical injection strategy consists of basal (long-acting) and bolus (short-
acting) injections to account for both glucose which is hepatically produced and 
that which is derived from the diet. This intensive ‘basal-bolus’ regimen is 
commonly known as ‘multiple daily injections’ (MDI) and mimics the pancreatic 
secretion of insulin more closely than conventional injections and has been shown 
in the literature to be superior at achieving glycaemic control whilst reducing the 
likelihood of hypoglycaemia (Kähler, 2014; Fullerton, 2014). As a result NICE now 
recommend that this MDI strategy is offered to all adults with T1D as opposed 
twice daily injections (NICE, 2015). An illustration outlining a typical daily schedule 
of MDI injections can be seen in Figure 1.5.  
Figure 1.4 – Insulin action of thrice daily conventional insulin therapy (Adapted from: Accu-
Chek, 2016) 
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 Continuous subcutaneous insulin infusion 
If suitable glycaemic control cannot be achieved in an adult patient using MDI, the 
physician may recommend continuous subcutaneous insulin infusion therapy 
(CSII). To be considered for this intensive treatment NICE guidelines indicate adult 
patients and children over 12 must either be experiencing disabling hypoglycaemic 
episodes, or high HbA1c levels (over 8.5% or above) on MDI therapy, even with a 
high level of clinical care (NICE, 2008).  
The therapy itself consists of a small, electronic pump devise which injects a rapid-
acting insulin analogue into the patient subcutaneously via a cannula attached to 
the skin. The pump is connected to the patient on a permanent basis, although the 
cannula must be changed every 3 days to avoid infection and the patient is 
permitted to remove the device for no longer than an hour (for example, whilst 
taking part in sporting activities etc.). Although there are various manufacturers of 
insulin pumps, all follow this basic premise and a diagram visualising this can be 
seen in Figure 1.6.  
Figure 1.5 – Insulin action of multiple daily injections (Adapted from: Accu-Chek, 2016) 
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Over the years insulin pumps have undergone many changes and become smaller 
in size, waterproof, more robust and significant advancements in the algorithms 
which control the insulin delivery process have been made which now allow for 
more complex basal and bolus injections (Skyler, 2010). Examples of these 
sophisticated algorithms are programmable basal rates which allow the patient to 
account for exercise or night time changes in glycaemia and split boluses such as 
those illustrated in Figure 1.7 which now allow mealtime doses to be injected over 
longer time periods, therefore meaning foods such as those high in fat which may 
take longer to digest can be easily accounted for (Ibid).  
Figure 1.6 – Basic principle of CSII 
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Before patients can take advantage of the features that CSII can offer they must 
be fully educated about how the device works. This is an important step as CSII 
therapy is very much unlike the injection therapies patients will often be used to. 
Patients will firstly be advised to take part in a DAFNE (or similar) carbohydrate 
counting programme to ensure an appropriate amount of insulin is injected per 
meal. Although current guidelines recommend all newly identified patients attend 
the course within 6-12 months of diagnosis it should be noted that many patients 
living with T1D may never have participated (NICE, 2015). It is well documented 
that the 5 day programme can improve glycaemic control and reduce 
hypoglycaemic events and whether the programme is delivered intensively over 5 
consecutive days or spread over 5 weeks makes no difference to glycaemic 
outcomes (DAFNE Study Group, 2002; Elliott, 2014; Elliott, 2015).  
After attendance at a carbohydrate counting course compulsory CSII structured 
education sessions developed in accordance with NICE guidelines should then be 
attended. These sessions should include information about how to use the pump, 
its limitations and very importantly, information about how to correctly determine 
the ‘insulin to carbohydrate ratio’ (ICR) and ‘insulin sensitivity factor’ (ISF). The 
importance of these factors is often underappreciated as small changes to these 
parameters may have large impacts upon glycaemic control (Morrison, 2013). The 
American Diabetes Association (ADA) suggest an estimated ICR of 1 unit of 
insulin per 10-15 g of carbohydrate; and an estimated ISF of 1:2.8 mmol/L for 
Figure 1.7 – Bolus options available with CSII (Adapted from: Healthline, 2016) 
 
 
The image originally presented here cannot be made freely available via LJMU Digital 
Collections because of copyright. The image was adapted from one sourced at 
http://www.healthline.com/diabetesmine/brushing-up-on-advanced-pumping-
techniques#1. 
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adults; however, these can only be accurately checked when an appropriate basal 
rate has been set, therefore the temporary impact on glycaemic control which may 
occur during the commencement of the therapy should be fully explained to the 
patient during the education (ADA, 2003). Due to the multidisciplinary nature of 
CSII the sessions should ideally be developed by a specialist team involving 
consultant diabetologists, diabetes specialist nurses and dietitians (NICE, 2008). 
That said it is unfortunate that in the recent UK insulin pump audit only 40% of 
participating centres were found to actually provide or have access to CSII 
courses (White, 2013). Furthermore, in 72% of these centres courses were also 
shown to be delivered by representatives from pump manufacturers rather than 
clinical staff, although the audit did acknowledge that reliance on these trainers 
was decreasing (Ibid).  
Due to this relatively steep learning curve a certain amount of discipline is required 
from patients and it is acknowledged that in addition to NICE criteria healthcare 
professionals may also subjectively select patients for the therapy who they 
believe to have certain psychological and personal attributes (Lawton, 2014). It is 
debatable whether using this applied clinical experience is a help or a hindrance, 
for example, on one hand patients with psychological disorders may be at an 
increased risk of manipulating their insulin dose, thus increasing their risk of 
diabetic ketoacidosis and therefore clinicians may initially be apprehensive (Fanik, 
2014). Yet on the other hand, the recent RESPOSE trial found some staff had their 
assumptions challenged when they saw patients who they believed would struggle 
with the therapy actually have success (Ibid). The impact that these 
preconceptions have upon patients’ access to the therapy is unknown, but would 
certainly make an interesting area for further research. 
This issue of patient access to CSII spans further than the consulting room alone 
and in particular concerns about funding for the therapy have been previously 
raised (The Medical Technology Group, 2010). Due to the complex technology 
involved in the pumps, together with the expense of associated consumables, CSII 
is a costly therapeutic option. The average cost of a pump, assuming a 4 year 
lifespan, is £430 to £720 per annum with additional consumables totalling 
approximately £1800 to £2000 per year, producing an extra annual cost of £1700 
compared to MDI (Cummins, 2010). Despite these expenses cost-effective 
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analysis reported the therapy as being favourable to MDI and a recent meta-
analysis concluded that the higher direct costs are offset by reduced treatment 
costs associated with complications caused by poor glycaemic control and/or 
disabling hypoglycaemia (Cummins, 2010; Roze, 2015).  
Unfortunately neither these benefits, nor guidance from NICE have prevented the 
so-called ‘postcode lottery’ of funding for CSII. Data by The Medical Technology 
Group (2010) illustrated significant inequalities in the provision of insulin pumps, 
with large disparities between regions within the UK with 13% of patients in Halton 
and St Helens receiving the therapy compared to 0.4% in Luton, totalling a 
nationwide average of only 3.7%. The insulin pump audit published 3 years later 
showed slight improvements with 6% of adult patients with T1D using the therapy 
(equating to 13,428 patients); however, this is still far below NICE targets of at 
least 12% (White, 2013).  
When considering this low uptake of CSII, it is useful to remember that the audit 
also described how 80% of centres were constrained by fixed amounts of pump 
starts; however, this caused few problems with only 5% of centres experiencing 
commissioners decline applications for funding, affecting a total of 47 patients 
(Ibid). This therefore produces the conundrum of why the use of CSII is so rare, 
which might be answered in part because of a lack of available staff to deal with 
both the introduction of patients to the therapy and their subsequent management. 
The audit explored this and mentioned concerns about a shortfall in appropriate 
healthcare staff and that the professional time needed to manage a CSII service is 
often severely underfunded, with estimates suggesting 39% of consultant, 61% of 
diabetes specialist nurse and 60% of dietitian time is underfunded (White, 2013). 
These factors are likely to create barriers preventing patients access to CSII and 
may explain the ‘selectiveness’ healthcare professionals display when choosing 
suitable patients to commence the therapy. It is hoped that in time these issues 
may be appropriately dealt with to allow the therapy to be opened up to a greater 
number of patients.  
Much has been discussed in this chapter regarding the hardware and software 
attributes of insulin pumps and the typical introduction that patients may receive 
when commencing the therapy; however, little has been mentioned in terms of the 
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benefits it may offer. CSII has been shown to have advantages for patients with 
T1D when compared with alternative intensive insulin treatments. These 
advantages include better control of blood glucose, indicated by reductions in 
HbA1c and a decrease in hypoglycaemic episodes (NICE, 2008). A review of the 
literature also illustrates some reduction in insulin requirements and a decrease in 
high early morning blood glucose levels; often associated with growth hormone 
and referred to as the dawn phenomenon (Cummins, 2010).  
The use of CSII may also allow patients to potentially break free from relatively 
inflexible mealtimes and carbohydrate requirements imposed by the fixed insulin 
regimes of multiple daily injections (MDI) (NICE, 2008). Previous research 
indicates patients with T1D frequently gravitate towards the consumption of 
additional carbohydrate rich foods during hypoglycaemia; a trend which suggests 
hypoglycaemic episode reductions may lead to a potential decrease in 
carbohydrate consumption (Strachan, 2004). Conversely, other studies provide 
evidence illustrating how when an opportunity is presented for patients to liberalise 
the diet, for example when participating in intensive insulin treatments such as 
CSII where the incidence of hypoglycaemia is reduced, increased carbohydrate 
consumption frequently occurs (Mühlhauser, 2009). Despite this conflicting 
evidence, available literature focussing on eating behaviours, particularly relating 
to patients using CSII therapy, is sparse and often dated. Therefore, due to the 
dearth of data this area warrants further research, hence the rationale for the 
present study. The current literature surrounding this area will be discussed in 
more detail in the Literature Review chapter (see page 30) and within the 
appropriate experimental chapter (see page 95).  
Although the theoretical opportunity for patients to relax their diet is a potential 
benefit of CSII, there are additional quality of life implications associated with the 
therapy. Examples are greater freedom, decreased physical complaints and a 
reduced sense of physical restriction (Ritholz, 2007). However limited literature 
exists to convincingly support this premise and specific qualitative research into 
adult CSII users’ quality of life is even less well documented. The available studies 
tend to observe small numbers of people over short periods of time and others 
often utilise problematic methods (Todres, 2010). More rigorous and extensive 
research would be beneficial to not only help increase the existing knowledge 
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base, but also to improve the quality of research in this area and allow a better 
understanding of how insulin pumps may affect the quality of life of patients. 
Again, the existing evidence surrounding this will be critically appraised in the 
following literature review chapter (see page 30) and investigations made by the 
author will be described in the appropriate experimental chapter (see page 173).  
This underrepresentation in the literature is not exclusive to the previously 
described issues. Research investigating the cardiometabolic (CM) risks of this 
population is also lacking. This term is used to describe a loosely defined ‘cluster’ 
of risk factors associated with cardiovascular disease (CVD) and Type 2 diabetes, 
such as blood pressure, BMI and glycaemic control, but it is the dearth of literature 
investigating lipids and lipoproteins in those with T1D using CSII which is perhaps 
most striking. T1D is associated with several lipid abnormalities, with quantitative 
disorders often present in patients with poor glycaemic control. However, in 
patients with good control, lipid profiles are regularly comparable to those without 
diabetes, yet even in this well controlled population rates of CVD remain the 
principle cause of mortality (Vergès, 2009). Interestingly, despite this apparent 
normality, several potentially atherogenic, qualitative abnormalities may reveal 
themselves. These measures of lipid and lipoprotein quality may be important 
markers above and beyond standard clinical measures used to determine CM risk 
in those with T1D and further investigation focussing on this at risk population is 
therefore warranted. In a similar manner to the eating behaviours and quality of life 
of patients using CSII, the literature surrounding their CM risks will also be 
discussed in the following literature review (see page 30) and the appropriate 
experimental chapter (see page 134).  
In the light of these problems, the objectives of this study are therefore to 
investigate the eating behaviours and cardiometabolic risks of patients with T1D 
upon the commencement of CSII therapy and compared to those using MDI. 
Furthermore, the study design will also incorporate a qualitative investigation into 
patients lived experiences and quality of life with a view to generating hypotheses 
about the impact of CSII.  
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1.3 Organisation of the Thesis 
As previously mentioned, this introduction is designed to offer the reader a broad 
overview of T1D and CSII therapy and the overarching problems which are tackled 
herein. A review of the literature, described in chapter 2, makes a case for the 
research questions in more detail and aims to give the reader an understanding of 
the ‘state of the art’ regarding these issues. A broad overview of the methods 
used, in particular the chosen methodology, is described in chapter 3. Chapter 4 
illustrates in detail the recruitment strategy and the problems which were 
encountered. The author feels it is important to include this as it helps to explain 
any irregularities which may be encountered in later chapters. An initial clinical 
audit which was carried out by the author prior to commencing the research can 
be found in chapter 5. The research carried out to investigate the eating 
behaviours, cardiometabolic risks and quality of life is presented in chapters 6, 7 
and 8, where detailed descriptions of the research questions, the methods used, 
the findings and accompanying discussions can be found. Chapter 9 outlines a 
series of case studies based upon a small number of patients and Chapter 10 
offers a conclusion to the thesis by synthesising the findings, outlining any general 
limitations and offering recommendations for future research.  
1.4 Aim and Objectives 
Aim:  
To investigate the eating behaviours, quality of life and cardiometabolic risks of 
adult patients with T1D using CSII. 
Objectives: 
 To determine dietary intake of patients using CSII, both over time and 
compared to their counterparts using MDI. 
 To explore the quality of life of patients using CSII, both over time and 
compared to those using MDI. 
 To assess selected cardiometabolic risk markers of patients using CSII, 
both over time and compared to others using MDI. 
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Literature review 
 
 
 
 
 
 
 
 
 
 
31 
 
2 - Literature Review 
 
2.1 Introduction 
Due to the continuous manner in which rapid acting insulin is administered, 
patients using CSII therapy have the potential to liberalise their dietary practices. 
This is possible as basal programmes can be quickly reduced or suspended and 
bolus injections can easily be adjusted in accordance with a multitude of 
programmes suitable for different food items and volumes. The impact dietary 
choices may have upon CSII (or vice-versa) is an important area which has been 
overlooked in the literature and is surprising given the potential influence on 
diabetes and wider health.  
2.2 Eating Behaviours 
The earliest evidence focussing specifically on the role of diet in CSII therapy is a 
study by Chantelau et al. (1982). This study investigated 10 patients with T1D who 
were educated in the use of CSII and who had been initiated with the therapy for 4 
- 5 weeks. After this time 6 of the patients were asked to adhere to a ‘conventional’ 
diabetes diet (as recommended at the time by the ADA), consisting of 5 – 6 meals 
per day containing mainly unrefined CHO (50 – 60%), few saturated fats and an 
adequate amount of energy for the individual (Nuttall, 1979). The diet was adhered 
to for 2 - 3 days whilst recording CHO intake, blood glucose measurements and 
insulin intake. After this time patients were allowed to either remain on the 
conventional diet or liberalise their food intake, allowing the free choice of meal 
timing and number and the intake of CHO (although rapidly absorbed CHO was to 
be avoided in both diets). All patients chose to consume a liberalised diet. Patients 
were then visited at home or work where food intake was assessed for CHO 
consumption and blood glucose and insulin dose measurements were recorded 15 
minutes before and 60 minutes after every meal. Serum lipids and body weight 
were also recorded and all measurements were repeated in all patients 4 - 5 
months after initiating the therapy. The results showed that patients enjoying a 
liberalised diet consumed 3 - 4 meals per day as opposed to 5 - 6 when adhering 
to a conventional diet and CHO intake was reduced (from 183 ± 60 g/day to 149 ± 
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50 g/day respectively). Moreover, the resulting relaxed diet was largely composed 
of fat (51 ± 5% fat, 34 ± 5% CHO & 15 ± 2% protein). A larger variation in meal 
times was also observed in those using the liberalised diet; however, this did not 
result in any changes to glycaemic control, with the HbA1c of patients on both diets 
remaining similar. In fact patients using both diets enjoyed an improvement in 
blood glucose levels upon the commencement of CSII which is in agreement with 
more recent evidence affirming that these changes are indeed a hallmark of the 
therapy (Pickup, 2002). Furthermore, dietary liberalisation also appeared to result 
in little change to serum lipids and body weight despite the increased consumption 
of dietary fats, leading the authors to hypothesise that the stabilisation of blood 
glucose levels resulted in a subsequent normalisation of blood lipids; a finding also 
described elsewhere (Vergès, 2009). In summary the findings suggest that the 
liberalisation of diet in those with T1D whilst using CSII does not result in any 
metabolic changes despite failing to meet best practice guidelines.  
It should be noted that whilst shedding light for the first time on the impact of 
dietary liberalisation during CSII therapy the study only observed the participants 
for a relatively short duration (4 – 5 months). To resolve this issue the same group 
performed an additional study comprising of 2 parts (Chantelau, 1983). Part 1 
investigated 10 patients using conventional insulin therapy (CIT) who were 
intending to commence CSII. These patients were asked to record their food 
intake for 3 days whilst using CIT. Then after using CSII for 4 weeks the patients 
were asked to record their diet again for 7 days. To determine the impact of dietary 
liberalisation over time part 2 required 15 patients already using CSII to record 
their food intake for 7 days after engaging with the therapy for 14 months. Both 
groups were educated about dietary liberalisation via a 5 day course prior to 
commencing CSII in a similar manner to patients who participated in the previous 
study. Standard clinical measurements (such as HbA1c and lipid profile etc.) were 
collected from all participants at the same time dietary intakes were recorded. The 
results highlighted various similarities with the earlier study by Chantelau et al, 
with patients adopting a liberalised diet whilst using CSII and again enjoying 
improved HbA1c (from 9.5% to 8.3% in group 1 and 7.9% in group 2) and no 
detrimental change in blood lipids or body weight. Furthermore, after 4 weeks 
patients were shown to deviate from recommendations and consume less CHO 
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(43% to 38%) and more fat (36% to 42%) (Nuttall, 1979). In addition to these 
short-term similarities the study also illustrated that after 14 months very few 
changes took place, thus confirming the study hypothesis that long-term 
liberalisation of the diet whilst using CSII would not result in any metabolic 
disturbances. 
An additional study was also performed by Capper et al. (1985), focusing on the 
dietary practices of patients using CSII. This study was retrospective in nature and 
baseline HbA1c data was firstly collected from 15 patients prior to commencing the 
therapy. After gaining experience with the device patients were then asked to 
complete a questionnaire designed to determine dietary intake and take part in a 
short interview with a nutritionist. The length of time between commencing the 
therapy and completing the questionnaire and interview varied between patients 
(mean 16.2 ± 2.3 months). The results from this study were very similar to the 
previous studies by Chantelau et al.; HbA1c decreased after commencing the 
therapy and mealtimes appeared to be more varied in patients using CSII and 
patients suggested that this variability was easier to manage using the pump. 
Furthermore, upon commencing CSII CHO consumption was below ADA 
guidelines (38% of total energy intake as opposed to recommendations of 50%) 
and dietary fat intake was above (42% of total energy intake as opposed to 
recommendations of 30%) (Nuttall, 1979). Despite similarities to Chantelau et al. 
Capper’s findings offered some intriguing differences. Although mealtimes were 
varied yet well managed, meals were actually larger and snacking was more 
prevalent which resulted in an average weight gain of 7.2 lb. Patients also 
compensated for food intake changes by raising their insulin bolus frequency to 
8.8 times per month as opposed to 2.8 times on conventional injections and it was 
also apparent that patients tended to estimate their insulin dose more whilst using 
CSII rather than checking postprandial glucose levels. This subsequent relaxation 
of meal structure and insulin administration may be indicative of motivational 
benefits prevailing from the potential for dietary relaxation inferred by CSII. Indeed, 
an appreciation by patients for dietary liberalisation has been shown in the 
literature and if this can be achieved with no metabolic disturbances (as is 
suggested by the studies described above) illustrates an additional positive benefit 
associated with the therapy (Nicolucci, 2008).  
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Despite these studies providing valuable information there are various limitations. 
Primarily, the promoted dietary liberalisation in the studies mentioned above was 
not specifically a ‘free diet’ due to the prohibited intake of refined CHO and 
suggestions to adhere to ADA guidelines. It is therefore unlikely that food intake 
was truly selected at will. Furthermore, the failure to meet these guidelines by 
those consuming a liberalised diet was also met with concern; however, little 
thought was given to the wider perspective. For example, although total fat intake 
increased after the commencement of CSII in all studies leading to speculation 
about an increased CVD risk, there was a failure to consider the types of fat 
consumed. It was also unacknowledged that the reduced CHO intake observed 
may result in a decreased requirement for insulin which has been described in 
more recent literature which may in turn be of physiological benefit (Pickup, 2002; 
Wang, 2013). Moreover, it should also be noted that the studies all advised 
patients to restrict simple sugars in line with recommendations of the time and only 
reported the total CHO intake; however, distinctions between the types of CHO 
and their influence upon blood sugars is important (Nuttall, 1979).   
It is with this specific point in mind that Venhaus (1988) performed a study to 
determine the impact of CHO type (refined vs unrefined) in patients using CSII. 
This randomised cross-over study investigated 10 patients who were well 
acquainted with CSII therapy and who were asked to adhere to either a refined or 
an unrefined CHO diet, each for a 6 week period in a random order. Those 
consuming an unrefined diet had a lower energy intake (2372 ± 669 kcal/day vs 
2757 ± 654 kcal/day) and also consumed a lower quantity of CHO  (211 ± 62 
g/day vs 249 ± 59 d/day respectively). Despite this the patients on the unrefined 
diet consumed a considerably larger amount of dietary fibre (35.3 ± 13.0 g/day vs 
17.9 ± 5.1 g/day). Although there were differences in dietary composition there 
were few metabolic changes. Blood glucose levels in those consuming unrefined 
CHO remained similar to their counterparts (7.3 ± 0.8 mmol/L vs 7.2 ± 0.5 mmol/L) 
and there were no changes in blood pressure, lipids and lipoproteins and HbA1c. 
Patients consuming a diet of refined CHO experienced a slight weight gain (69.1 ± 
11.0 kg to 70.2 ± 12.3 kg), but this did not reach statistical significance and there 
were no changes in insulin dose. These were somewhat surprising findings, 
particularly with regard to glycaemic control, as more recent evidence suggests 
35 
 
that the type of CHO does indeed modulate glycaemic response in T1D (Giacco, 
2000). Despite largely neutral findings it is important to note that previous studies 
reporting the influence of fibre on glycaemic control generally administered 
unpractically large doses typically exceeding dietary recommendations and it is 
therefore unlikely that doses below the RNI, such as those used by Venhaus 
(1988), would modulate glycaemia (Giacco, 2000). Furthermore, Venhaus also 
suggests that the smaller total CHO amount consumed by the unrefined diet group 
may be reflective of a decreased intake of low glycaemic index (GI) and low 
glycaemic load foodstuffs which are hypothesised to have influenced results. This 
may be a more probable explanation for the similar glycaemic control observed 
between groups as a Cochrane meta-analysis concluded a low GI diet may result 
in HbA1c decreases of up to 0.5% (Thomas, 2009). Therefore if patients decrease 
their intake of low GI foods (such as those approved for consumption in the 
unrefined group) then it may be reasonable to expect predicted improvements in 
glycaemic control to diminish.  
Collectively these four studies provide an insight into the potential impact of dietary 
liberalisation at a time when CSII was a novel therapy for the treatment of T1D. 
Since their publication circa thirty years ago CSII has become a commonly used 
tool in clinical practice and the theory and practice regarding its implementation 
and that of diabetes in general has evolved considerably. For example, patients 
are now routinely informed about the importance of regular blood glucose 
monitoring regardless of which insulin therapy they may be using and are given 
the resources to do so in an effective manner. This was not the case in the study 
by Capper et al. (1985) where patients using conventional injections were not 
practicing the technique at all and so it is perhaps unsurprising that the CSII group 
enjoyed reductions in HbA1c. Moreover, even though the other studies educated 
patients about how to self-test blood glucose it should be remembered that the 
equipment to carry out the tests (likely by using test strips) may have been 
somewhat rudimentary compared to today’s standards. This again casts potential 
doubt on the findings and whether they could be replicated with patients using the 
blood monitoring equipment of today. Also, it should be noted that the insulin 
pumps themselves have advanced greatly, as has insulin, and again it is difficult to 
speculate if the dated studies described above could be replicated using the 
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modern pumps and insulin analogues which are now commonplace. Moreover, the 
studies also compare patients using CSII vs those using CIT. This was appropriate 
at the time of publication; however, multiple daily injections (MDI) are now 
recommended as a standard insulin therapy for the treatment of T1D and offer 
superior glycaemic control and so the therapy comparisons outlined in the 
previous studies may no longer be appropriate (NICE, 2015). Furthermore, it is 
also useful to remember that the education sessions preceding all of these studies 
advised patients based upon nutrition recommendations outlined at the time by the 
ADA. Like other areas of diabetes nutrition guidelines have also changed over the 
past thirty years (as previously discussed). This therefore poses the problem of 
patients in these studies attempting to attain dietary ideals of which some are now 
contentious (as discussed in more detail in chapter 6 (see page 95)). These 
limitations combined with those described earlier present strong doubts about how 
these studies represent the current diabetes topography. Furthermore, since their 
publication in the 1980s there has been little literature of note regarding dietary 
liberalisation in patients using CSII and given the limitations of existing literature 
outlined herein and the strong influence diet may infer upon the management of 
T1D presents an important gap in the research which requires filling. 
2.3 Cardiometabolic Risks 
In addition to a dearth of data concerning eating behaviours, the impact CSII may 
have upon cardiovascular risk markers is also not well understood, which is 
surprising given the attention bestowed upon T1D in a broader context and the 
ability of insulin pumps to successfully alter glycaemic control. Despite this there 
are a small number of studies investigating the use of CSII in patients with T2D, 
with Li (2004) reporting significant improvements in all traditional lipid parameters 
(low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol 
(HDL-C), plasma or serum triglycerides and total cholesterol) after 2 weeks of CSII 
therapy. Also, Noh (2008) described similar effects over a longer period (30 
weeks) in patients with poorly controlled T2D using CSII, as well as a decreased 
proportion of patients with dyslipidaemia at the end of the study (33.3% to 13.3%). 
Furthermore, a study by Megson (2015) investigated oxidative stress in patients 
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with T2D who were engaging with CSII and found oxidation of LDL lipoproteins 
was reduced by 10.5% after using the therapy for 16 weeks.  
Despite these promising findings the evidence in those with T1D is sparse, even 
though CSII is both recommended for use and most often adopted by those with 
this form of the disease. That said, previous work by Krönert (1987) has shown 
that treatment with CSII therapy improved autonomic nerve dysfunction which in 
turn has the potential to positively impact upon cardiac function; however, this 
study only investigated 9 participants over a 4 week period. To improve on this 
similar research by Jakobsen (1988) utilised 24 patients undergoing CSII therapy 
and found that over 2 years improvements in autonomic nerve function were 
sustained. Thuesen (1986) also emphasised improvements in cardiac function in 
24 patients with T1D using CSII, which translated into an increased capacity for 
exercise, possibly as a result of reduced cardiovascular resting state demands 
caused by improved glycaemic control. There have also been studies focussing 
directly on lipids, all showing either a normalisation or decrease of LDL, 
triglycerides and total cholesterol and an increase in HDL-C; in particular the HDL2 
subfraction (Falko, 1982; Helve, 1987; Pietri, 1980; Bagdade, 1991). Although this 
modicum of evidence highlights generally positive cardiovascular benefits 
associated with CSII it should be recognised that they all are small in scale and 
dated. Furthermore, all compare CSII vs CIT and this is no longer a relevant 
comparison as CIT is no longer the standard treatment of T1D. 
Although it is clear that these studies suffer from a number of limitations, primarily 
due to their age, a small number of more modern studies exist regarding the 
impact CSII may have upon specific markers of CVD. Work by Tołwińska (2013) 
illustrated how in a group of 32 children with T1D the use of CSII resulted in a 
decrease in intima media thickness and an increase in flow-mediated dilation over 
6 weeks. Interestingly, a similar but larger study by Rosenlund (2014) involving 
601 adult patients with T1D (58 treated with CSII and 5543 treated with MDI) 
showed significantly lower arterial stiffness, which is again suggestive of potential 
benefits to the arterial wall associated with the therapy. Controversially though, 
these cardiovascular benefits inferred by CSII appeared to disappear. 
Furthermore, a study by Cetinkalp (2015) found that when comparing 25 adult 
patients with well-controlled T1D using either CSII or MDI against a group of 13 
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controls there was no difference in a host of markers associated with 
atherosclerosis, including oxidised LDL, C-reactive protein, homocysteine and 
fibrinogen. Despite these neutral findings, the study did reveal the CSII group to 
have significantly higher levels of HDL-C, which in turn was negatively correlated 
with C-reactive protein, therefore highlighting a potential degree of 
atheroprotection. However, caution should be taken when evaluating these results 
due to the cross-sectional study design and small sample size.  
Despite offering valuable insights these small scale modern studies have been 
largely eclipsed by perhaps the most noteworthy research to date regarding the 
implications of CSII on CVD risk in those with T1D. This particular study by 
Steineck (2014) retrospectively observed 18,168 patients with T1D (2441 who 
were using CSII and 15,727 who were using MDI) from the Swedish National 
Diabetes Register between 2005 and 2012. The authors found that when using 
MDI as the reference group patients using CSII were at a significantly lower risk of 
fatal/non-fatal coronary heart disease, fatal cardiovascular disease and all-cause 
mortality (hazard ratios: 1.0 vs 0.55; 1.0 vs 0.58 and 1.0 vs 0.73 respectively). 
Despite this large scale study, which is notable in its singularity, showing 
favourable associations between the use of CSII and CVD risk, causation cannot 
be implied. The authors acknowledge this and although attempting to speculate on 
potential driving mechanisms behind these positive findings they make clear that 
further research is needed before CSII can be promoted as an effective tool for the 
prevention of CVD and that the underlying processes need elucidating.  
Although evidence, albeit rather sparsely, exists regarding the cardiovascular 
scenario encountered by those using CSII, it is remarkable that there is a dearth of 
modern data focussing on the impact CSII may have upon plasma 
lipids/lipoproteins directly given their important role in CVD. Only one study of this 
nature appears to exist by Derosa (2009). This was longitudinal in nature and 
focused on 32 patients with both T1D and T2D using either CSII or MDI over a 12 
month period. The study found that in those using MDI there was no change in 
LDL and HDL but increases in both total cholesterol and triglycerides; a trend 
which others suggest may also represent an increase in very low density 
lipoprotein cholesterol (VLDL-C) and potential shift from larger to smaller LDL 
particles (Krauss, 2010). The CSII group; however, displayed significant 
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decreases in total cholesterol and LDL after 9 months of engaging with the therapy 
as well as significant decreases in triglycerides and increases in HDL after 12 
months, possibly as a result of steadily managed insulin administration.   
Collectively these studies make up a small body of work within which many gaps 
exist. Particularly intriguing is the lack of research focussing on lipid abnormalities 
in patients who are using CSII, given that that those with well controlled T1D do 
not appear to be immune from changes in lipid quality, such as a predominance of 
small, dense LDL particles, despite improvements in lipid quantity. It could 
therefore be presupposed that if CSII improves glycaemic control and lipid levels 
improve or plateau then patients may still remain at an increased risk of CVD. 
Furthermore, these risks may remain undiscovered and therefore not 
communicated to the patient as they fall ‘below the radar’ of standard lipid panel 
tests used by physicians. This presents an interesting area for further research 
which needs to be probed.  
2.4 Quality of Life 
Although biological measures provide useful information regarding the 
effectiveness of treatments or the risk of complications they offer little insight into 
patients’ experiences of living with the condition. Although patient quality of life has 
been previously researched in those with T1D, remarkably few detailed 
understandings of the lived experience have emerged. Despite this, studies 
conducted over the past decade, the majority of which being quantitative in nature, 
have had reasonable success in highlighting generalised predictors of poor quality 
of life. For example, complications associated with the disease have been 
correlated with reduced quality of life outcomes (Coffey, 2002). Also, low levels of 
social support to deal with these issues, combined with the emotional burden of 
living with T1D have been shown by Joensen (2015) to be associated with 
reduced quality of life in a cross-sectional survey of 2419 Danish patients. 
Furthermore, work by Solli (2010) indicated that in 1000 adult patients in Norway 
the fear of hypoglycaemic episodes remains a strong determinant of anxiety and 
depression. This has in turn has been shown to predispose patients to increased 
risks of ischemic heart disease, stroke and neuropathy, which no doubt further 
perpetuate reductions in quality of life (Ibid). Conversely, the provision of 
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structured education and self-management training has been shown to 
significantly improve quality of life outcomes, as have lifestyle factors such as 
participating in physical activity, abstaining from smoking and consuming a healthy 
diet (Cooke, 2015; Cochran, 2008; Imayama, 2011).  
Unfortunately the survey-based methods used to measure these determinants 
serve only to quantify and tell very little of the patient perspective, which is likely to 
be the reason for the dearth of evidence pertaining to patients actual thoughts and 
feelings. Despite this, a limited number of qualitative studies do exist regarding 
patients with T1D and span a variety of quality of life related areas, thus offering 
richer insights than their quantitative counterparts. An example is work by Browne 
(2014) which investigated 27 patients with T1D residing in Australia and found 
stigma from others to be a catalyst for reduced life quality, along with being 
frequently compared to those with T2D by an uneducated general public. A further 
qualitative study by Balfe (2007) echoed quantitative research mentioned earlier 
showing associations between lifestyle choices and quality of life; however, this 
study does so in a more intimate and subtle manner than metrics can achieve. 
This is illustrated when patients explain how participating in sports and eating 
healthily is not a conscious effort to improve immediate quality of life, but rather an 
attempt to minimise the risks of future complications. However, the process of 
exercise often comes at a risk of hypoglycaemia and is often seen by patients as 
‘not worth it’. These brief glimpses into patients’ worlds are also seen again in a 
study by Rankin (2014) which investigated the effectiveness of diabetes education 
groups. The link between these groups and improved glycaemic control have 
already been previously mentioned in the introduction chapter (see page 8); 
however, this qualitative, longitudinal work revealed how patients who attended a 
DAFNE training course also reported how skills developed on the course 
prompted them to obtain further knowledge and social support. These nuanced 
understandings have culminated in arguably the most compelling and robust piece 
of work in this area. This is a metasynthesis by Vanstone (2015) which 
consolidated 31 qualitative studies regarding glycaemic variability. The authors 
concluded that glycaemic variation, whether it is hypo or hyperglycaemia, was 
responsible for great declines in patients’ physical, social, emotional and practical 
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quality of life; primarily resulting from substantial psychological stress thus 
illustrating the true burden of poorly controlled diabetes.  
These quantitative and qualitative studies, although offering useful insights into the 
risk factors which may influence quality of life in those with T1D and offering 
unique, humanistic glimpses into patients’ lived experiences with the disease, 
typically do not differentiate between treatment types. Furthermore, those that 
exist which do discriminate between treatment principally focus on children or 
adolescents (presumably due to the high prevalence of T1D in this population and 
the known biological, emotional, psychological and social difficulties of 
transitioning through these life periods) (Bridgett, 2015). As such little attention is 
given to adult patients, which is surprising when considering that they typically 
form the largest category of CSII users and therefore research focussing on this 
specific population would be welcomed. As this forms the rationale for the present 
study this review will focus on literature concerning adults where possible; 
however, to properly evaluate the literature it would be unreasonable to totally 
discount those that do not. 
In a similar manner to the broader spectrum of research concerning T1D, it is 
quantitative measures which have been largely used to determine quality of life in 
those using CSII. In particular, various studies have revealed that the 
improvements in glycaemic control enjoyed by those using CSII are often 
accompanied by increased quality of life, with work by Bayrakdar (2014) showing 
this in adolescents. These correlations were further demonstrated in adult 
populations by Franciosi (2010) and Hoogma (2006), who conducted large-scale 
studies investigating CSII patients over 43 sites in Italy and 11 European centres 
respectively. Other large-scale studies, such as that by Nicolucci (2008), also 
suggest that the flexible nature of CSII may also improve prognosis by enabling 
patients to feel less restricted in terms of their lifestyle choices. Despite these 
positive findings, they are confounded by research which has found little difference 
between CSII and MDI treatments and the development of quality of life issues. 
For example, a cross-sectional study by Birkebaek (2014) found that despite CSII 
showing improvements in quality of life there was no difference between CSII and 
MDI after using either therapy for a year or longer. Admittedly, this study only 
investigated an adolescent population and was cross-sectional in nature; however, 
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similar results were again revealed by a long-term study by van Dijk et al. (2014). 
After a follow-up period of 15 years the research group also found that there were 
no differences in health related quality of life between patients using either CSII or 
MDI. In an attempt to distinguish between this conflicting evidence Barnard (2007) 
performed a systematic review. This incorporated 17 studies (including 5 RCTs) 
and again found that much of the evidence was indeed conflicting. Additionally, 
many of the study designs were found to be flawed with poor methodologies that 
inconsistently assessed quality of life and which are likely to be responsible for the 
lack of reported benefits. The authors of the review therefore concluded that based 
upon the available evidence it is difficult to determine the superiority of CSII over 
MDI in terms of quality of life.  
In addition to this quantitative research a series of qualitative studies have also 
been performed; however, these are small in number, with a proportion of these 
actually assessing the impact of CSII on patients’ lives from the perspective of the 
Healthcare Professional. An example of this is a study by Lawton (2016) in which 
Healthcare Professionals mentioned during interviews how they felt the therapy 
improved the quality of patients’ lives and that it is ideal for those ‘with really 
unpredictable lifestyles where things are changing at the drop of a hat’ and active 
individuals such as ‘sporty patients, long distance cyclists, hill climbers….’. These 
comments were reiterated in a study by Shulman (2016) who found that 
Healthcare Professionals believed that the benefits of these improved lifestyle 
choices may also apply to children; which may then in turn transpire to increased 
levels of independence. 
In addition to evaluating quality of life benefits from a Healthcare Professional 
perspective there is also a small body of qualitative evidence investigating this 
from the point of view of parents whose children are using the therapy as well as 
family members and significant others. Work by Barnard (2016) found that various 
issues were expressed, mainly related to sleep disturbances for both the patients 
and those around them by the noise of the pump alarms, as well as a fear of 
hypoglycaemia which remained from previous incidences. However, despite these 
issues the overall consensus was CSII was generally viewed in high regard. 
Positive views were again expressed in work by Rankin (2015) and Alsaleh (2014) 
who both found that when interviewing the parents of child patients it was often 
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cited that an improved ability to manage physical activity was an advantage which 
could lead to improved lifestyle choices and how despite the pump not being a 
panacea, the medical benefits of the device act as a reassurance for the parent, 
thus demonstrating wider quality of life implications aside from those which benefit 
the patient alone.  
Although these studies highlight interesting aspects pertaining to quality of life 
from the point of view of others there are only a handful, to the author’s 
knowledge, which relate directly to patients’ experiences. An example of this is a 
study by Low (2005), which although focussing on children and adolescents only, 
again reported issues with disturbed sleep due to alarms as well as the physical 
size of the device causing minor body image issues. However, despite these 
concerns the therapy was largely viewed favourably and that the positive aspects 
of the treatment outweighed the negative. Positive findings were also mentioned in 
a small study by Todres (2010) which investigated the lived experiences of 4 adult 
patients switching to CSII from MDI. Additional benefits compared to MDI with 
relation to quality of life were found which stemmed initially from the clinical 
benefits inferred by the therapy, but the ultimate impact on patients’ lifestyle was 
above and beyond. The final qualitative study focussing on CSII which is known to 
the author is by Barnard (2007). This larger study interviewed 80 patients and 
again found that the overwhelming majority reported benefits associated with the 
therapy, that it improved quality of life and that they were using the therapy by 
choice. Despite these positive findings it is interesting to point out that over half the 
interviewees also reported negative findings, largely regarding the device itself, 
with issues ranging from blocked cannulas to the physical size of the pump. 
However, before forming a judgement of this it should be noted the interviewers 
used in this study were briefly trained call centre staff from insulin pump 
manufacturers and the interviews were carried out when patients phoned the 
company to reorder consumables. The potential for bias here is clear and serve to 
illustrate the methodological issues which may confound findings.  
The small amount of existing qualitative studies which focus both on patients’ lived 
experiences with CSII and how the therapy has impacted upon their quality of life 
illustrate an area of research which is urgently in need of further exploration. 
Furthermore, the conflicting existing research in this area needs resolving and 
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together with the high rates of psychological disorders related to diabetes further 
perpetuate requirements for additional research investigating the patient 
experience. 
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3 - General Methods 
 
3.1 Introduction 
This chapter will firstly focus on the overall framework of the study, primarily 
involving the methodological paradigm. Also, the theoretical and pragmatic notions 
underpinning the chosen individual methods will be discussed and it is hoped that 
by navigating through this in detail will enlighten and clarify the process from 
commencement to conclusion. Furthermore, the reader will be guided through the 
study design and process with not only justification in mind, but also transparency 
with a view to ensuring reproducibility. Detailed methods pertaining to specific 
techniques will be outlined in the appropriate experimental chapter. 
3.2 Methodological Considerations 
Although a kaleidoscope of research methods exist, it is imperative the most 
appropriate overall methodology is chosen to address the specific research 
questions and ensure the successful completion of study objectives. As the 
research aims of the study described herein were intended to inform rather than 
test an existing hypothesis, the study was carried out following an inductive 
approach, with a view to producing new knowledge and theories about patients 
using CSII to subsequently inform clinical practice. Despite the inductive nature of 
the study the research team decided that it would have been inappropriate to 
adopt either a fully quantitative or qualitative stance. Although quantitative findings 
are useful for the objective determination of variables, such as physiological 
markers of risk which can then be generalised to a population, they reveal nothing 
of the patient experience (Flick, 2015). On the other hand, purely qualitative 
research, although offering insight into the thoughts and feelings of patients, above 
and beyond that which can be inferred from quantitative methods alone, cannot 
measure associations or determine causality (Ibid). Other research projects may 
find one or the other acceptable to address specific research aims; however, the 
lines between approaches may sometimes become blurred and after consideration 
it was decided that a multiple methods approach would be more suitable. 
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Multiple methods refer to the combination of at least one quantitative and one 
qualitative approach within the same study and have become popular over recent 
years; leading to what Tashakkori and Teddlie (2003) refer to as a ‘third 
methodological movement’. This act of combining methods has been justified as a 
way of extending beyond constraints and introducing new dimensions which can 
then be connected to offer a better understanding above and beyond that which 
would come from the use of a single method (Somekh, 2011). Some of the specific 
benefits of this approach, as outlined by Brannan (2008), are that researchers may 
develop their skillset by being open to novel ways of addressing study questions, 
thus expanding their methodological horizons. Similarly, they may also find that 
this broad minded approach may encourage creative thinking which is outside of 
the traditional ‘box’. This attribute, particularly in a research community where 
cross-disciplinary studies are now frequently encouraged, may prove to be more 
fruitful than simply following accepted methodological norms. An example being 
that scientific studies utilising a multiple methods approach may resonate with the 
‘political currency’ of policymakers and funding bodies in ways which may be 
distinct from those using basic science methods alone. Similarly, with the advent 
of large-scale studies spanning multiple countries (such as EU funded projects), 
multiple methods may allow opportunities for comparative analysis above and 
beyond those offered by the contextualisation of quantitative data alone. In 
addition to these benefits, more effective dissemination of study findings may also 
be achieved. This is described by Brannan (2008) who suggests that the modern 
researcher needs to be equipped with two ‘languages’, consisting of a technical 
language to appreciate the detail of a study’s principle concepts and a second 
language to facilitate the effective diffusion of these concepts to broad audiences. 
A multiple methods approach may therefore help with the explanation of these 
technical concepts and allow meanings to be conveyed in a straight-forward 
manner in situations where words may be just as important as numbers.  
The combinatory approach typified by multiple methods research, despite benefits, 
has also aroused concerns regarding incompatibility, leading to a ‘paradigm war’ in 
which some researchers were deeply embattled during the 1980’s. Although 
pragmatists contended that there exists a false dichotomy between 
methodologies, purists on the other hand maintained the assertion that there are 
48 
 
distinct reasons for keeping methods separate and that ‘never the twain shall 
meet’ (Cameron, 2007). Although the purist argument was largely focussed on the 
presumption that the differences in paradigms were too great to allow a 
complementary overlap to be successfully obtained, this outlook has since been 
shown to be somewhat short-sighted. Guba and Lincoln (2005 p.200) discuss this 
and conclude that methods can in fact be ‘retrofitted to each other in ways that 
make the simultaneous practice of both possible’ and that ‘at the paradigmatic, or 
philosophical, level, commensurability between positivist  and  postpositivist  world  
views  is  not  possible,  but  that  within  each  paradigm, mixed methodologies 
(strategies) may make perfect sense’.  
Since this acceptance of multiple method study design in the research community 
various theorists have produced typographies in an attempt to categorise and 
classify the often abstract concepts which are involved in a specific methodology. 
The resulting theoretical structures are too numerous to review individually; 
however, one in particular by Creswell (2009) resonated with the author. This 
typology presents four aspects which should be considered and have been 
summarised in Table 3.1. 
 
This particular typology invites the researcher to consider firstly the timing of their 
methodological components. In brief this refers to whether the study will use 
quantitative data to inform subsequent qualitative work (or vice-versa) in a 
‘sequential’ design, or if all components will be carried out at the same time 
Table 3.1 - Multiple methods typology (Adapted from Creswell, 2009). 
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‘concurrently’. Secondly, the researcher must determine if either quantitative or 
qualitative elements will dominate or if the sum of both parts will be equal. Thirdly, 
the typology also demands that the type of ‘mixing’ be deliberated and whether the 
resulting data will be kept separate yet ‘connected’ (for example in a 2 phase-
study using a quantitative stage to inform later qualitative stage),  merged together 
and ‘integrated’, or using one (usually smaller) set of data to support another in an 
‘embedded’ manner. The fourth and final consideration for a researcher is if the 
study will be guided by a larger, overarching theory which is ‘explicitly’ mentioned, 
or whether any influencing theories will be omitted, in accordance with an ‘implicit’ 
model. 
In the case of the present study, a sequential model was unfeasible due to time 
constraints and therefore a concurrent design was followed. Furthermore, due to 
the nature of the research questions it was deemed more appropriate to select a 
number of quantitative methods to gauge the treatment outcomes associated with 
CSII and to utilise a smaller qualitative element to elucidate patients’ lived 
experiences with T1D. This resulting qualitative data was then used to support the 
quantitative findings, from which hypotheses could be generated. Due to the 
inductive nature of the study theories were not outlined prior to the 
commencement of the study and therefore it could be said that an ‘implicit’ model 
was followed. When comparing this design with Creswell’s model it is clear that 
the study therefore followed a ‘concurrent embedded strategy’. Furthermore, it 
should also be noted that rather than comparing the data derived from these 
different paradigms directly against one another, the typological strategy will be 
adhered to within this thesis by sitting the results together to provide an ‘overall 
composite assessment of the problem’ (Creswell, 2009).  
3.3 Overall Study Design 
The following section describes the methods used to address the study aims and 
objectives (see page 29). The project consisted firstly of an audit of patient 
medical records which was followed by the recruitment of participants to two 
research study designs. Firstly, there was a longitudinal study which observed 
CSII patients over time. This consisted of three outcome measures (eating 
behaviours, quality of life and cardiometabolic (CM) risks) running concurrently 
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over five time points (baseline, 3, 6, 9 and 12 months). Secondly, there was a 
cross-sectional study which compared CSII patients against those using MDI. This 
examined the same three outcome measures as the longitudinal study; however 
only one time point was used. The methods used to observe the three outcomes 
differed slightly between the studies and an overview is given herein.  
3.3.1 Pre-study audit 
The first component of the project was an audit of medical records pertaining to 
patients undergoing CSII therapy at the Royal Liverpool Hospital Diabetes Centre. 
Audits are commonly used tools within the NHS and other sectors for the 
evaluation and improvement of services; however, clinical audits involve more 
than simply gathering data alone and it is important to realise that this process is 
not the same as research. Although research is typically carried out to gain new 
knowledge a clinical audit should principally collect data in a systematic manner in 
accordance with agreed standards which should be then compared to certain 
criteria and any identified areas for change should be implemented (UHBristol 
Clinical Audit Team, 2009). Furthermore, an audit should not incorporate any kind 
of intervention or treatment and the data should not be randomised (Health 
Research Authority, 2013). The principle components of an audit, which in their 
totality should be cyclical, are illustrated below in Figure 3.1:- 
 
 
Figure 3.1 – NHS clinical audit process (Adapted from UHBristol, 2009) 
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After considering the attributes of an audit the research team together with 
colleagues at the Royal Liverpool Hospital, realised that it was unknown if CSII 
patients in particular were meeting the current clinical care standards for patients 
with T1D with regards to traditional markers of cardiovascular disease (i.e. lipids, 
lipoproteins and blood pressure). It was therefore decided that it would be useful 
for an audit to be performed focussing on these markers together with other 
standard markers of risk for those with the disease. Details regarding the audit 
method will be clarified in the appropriate chapter. 
3.3.2 Research Study Participants 
Whilst data for the audit collection was underway the author also recruited 
participants to take part in the two research studies from the Diabetes Centre at 
the Royal Liverpool Hospital. Participants taking part in the longitudinal study had 
all recently been approved for CSII therapy and were pending the supply of an 
insulin pump. Participants taking part in the cross-sectional study had been using 
either CSII or MDI for over 1 year. All participants were aged 18 years or over and 
lived in Liverpool or the surrounding areas. A note was also taken if a participant 
was taking any kind of medication which could alter lipid/glycaemic control to 
inform any statistical corrections which may need to be made during data analysis. 
Furthermore, participants were told that they may be excluded if they did not give 
permission for their healthcare professional to be contacted, or if they had been 
involved in any other research over the previous 3 months which may affect 
lipid/glycaemic control. 
3.3.3 Research Study Sample Size 
Due to the nature of this single-site study, the clinic dictated the sample size. The 
study therefore acted as a pilot; however, the findings may potentially lead to more 
robust multi-site studies using appropriately powered sample sizes at a later date. 
A sample size of 20-25 was originally estimated for the longitudinal study. This 
was determined from forecasts expecting approximately 50 patients to be offered 
CSII therapy at the Royal Liverpool Hospital over 12 months. The recruitment 
period for this study lasted for 6 months meaning a convenience sample of 
approximately 25 patients should have been potentially accessible. It was taken 
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into account that not all patients would meet the inclusion criteria and that some 
would be unwilling to take part in the study; however, all suitable patients were 
approached.  
A subsample of around 5-8 participants were also required for qualitative 
interviews and were selected via convenience sampling from the existing study 
population as participants had already met all inclusion criteria and given consent. 
Each participant was informed that they would be interviewed after recruitment 5 
times in 3 month intervals, producing a total of 25-40 interviews. The work of 
Hancock suggests theoretical saturation may be achieved by performing 20-60 
interviews using a constant comparison approach, therefore a sample size of 
approximately 5-8 participants was deemed appropriate (Hancock, 2009). 
For the cross-sectional study a convenience sample of 30 patients using CSII and 
30 using MDI was agreed based upon the pilot nature of the study and the small 
clinic size. A subsample of approximately 10 patients using CSII and 10 using MDI 
was also considered appropriate to take part in additional optional activities such 
as food diaries and interviews. These activities will be explained in more detail in 
the following section and in the respective experimental chapters. Again, due to 
the pilot, exploratory nature of this study and the limitations of the clinic this small 
subsample size was thought to be appropriate. The recruitment process is 
discussed in more detail in the Recruitment Feasibility chapter (see page 65). 
3.3.4 Research Study Data Collection 
Longitudinal Study 
To investigate participants’ eating behaviours weighed food diaries were 
employed. 
This is a commonly used method which involves participants recording the mass 
or volume of all food and drink items at the time of consumption in a diary booklet 
along with any waste. This technique has been used extensively throughout the 
literature and is a cheap and easy to produce and distribute method of assessing 
dietary intake. That said the method is not without limitations. Although some 
authors regard the open-ended nature of food diaries to be a benefit which assists 
with the reduction of recall bias, there are those who are in disagreement 
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(Thompson, 2008). These disparities in opinion result from evidence 
demonstrating how food diaries may be prone to underreporting and urge vigilance 
to be taken when analysing findings (Bingham, 2001). Although these concerns 
are not unfounded it is important to note that underreporting is a commonly 
encountered issue with dietary assessment methods in general, with the OPEN 
study illustrating how both males and females routinely underreport energy intake 
when using a variety of assessment methods (Subar, 2003). Furthermore, 
Livingstone (1990) demonstrated how the sample population may in fact be a 
better indicator of underreporting than assessment method per se by highlighting 
incidence specifically in adolescents and the obese. Moreover, food diaries have 
shown agreement against the ‘gold standard’ doubly labelled water method of 
determining energy intake when used in an adult parent population, thus 
demonstrating their reliability when used in appropriate circumstances 
(Livingstone, 1990). Although methodological issues such as underreporting 
should of course be acknowledged it is important to note that they are no more 
prevalent in food diaries than when using other methods of retrospective nutritional 
assessment (Lentjes, 2014). This has likely contributed towards their common use 
throughout nutrition research and together with pragmatic reasons is why the 
author chose to use food diaries as a method of determining dietary intake.  
Patients taking part in the longitudinal study were required to complete a food 
diary (see appendix 12.7) at each of the five study points (every three months) and 
to fill in each diary for five days; ensuring two of the days were over a weekend. 
This strategy was chosen to not only provide a suitable timespan to capture typical 
eating behaviour changes in participants’ weekly routines, but also to compromise 
with evidence illustrating potential participant fatigue and motivation issues (de 
Castro, 2007; Livingstone, 1990). The diaries were given out at routine clinic 
sessions or posted to participants’ home addresses at each of the study time 
points previously mentioned. To enhance accuracy participants were required to 
weigh all consumed food. Where this was not possible participants were asked to 
provide the type of food and brand name or label which could be later checked 
against supermarket websites. They were also asked to provide a portion size 
comparison made in conjunction with a food atlas. This involved associating 
portion size with colour photographs printed inside the cover of the diary (Turconi, 
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2005). To further ensure details were correctly entered the participants were also 
briefly interviewed.  
As previously mentioned, a small number of patients (5 - 8) were invited to 
participate in quality of life interviews. These were ‘semi-structured’ in nature, 
meaning that a series of open questions were loosely adhered to which formed the 
‘structure’ of the interview; however, unlike survey based methods or ‘fully-
structured interviews’ the participants were given freedom to discuss and 
elaborate upon their answers (Bryman, 2004). Although this method typically 
requires considerably more post-interview transcribing and processing than fully-
structured interviews or surveys it is arguably a superior way of understanding the 
lived experience due to the lack of constraints regarding the responses 
participants may give (Flick, 2015). From a practical standpoint interviews are also 
relatively cheap, straightforward and easy to organise and given the time 
constraints of the study these were important aspects to consider. Aside from 
interviews the reader may initially consider that other qualitative methods could 
also have been employed. Indeed focus groups in particular have been widely 
used throughout health research to develop an understanding of participants’ 
thoughts and feelings and may appear to be a complimentary method (Somekh, 
2011). This could be argued as the group dynamic is often regarded as a useful 
tool to enable participants to feel comfortable and to assist with the generation of 
ideas; however, it should be noted that depending on the members of the group 
strong personalities can overshadow others meaning some may be left feeling 
unable to voice personal issues (Bryman, 2004). It is for this reason specifically 
that the author felt a focus group, rather than encouraging free discussion, may 
actually have hindered it, particularly regarding sensitive matters; therefore 
individual interviews were deemed to be more appropriate.   
Prior to commencing the study the author devised a brief interview outline (which 
is typical in qualitative research) to highlight the areas of discussion which were to 
be covered with each patient (see appendix 12.6). The structure of this interview 
outline followed suggestions made in the literature and the preliminary questions 
were designed to initially build rapport with the patient and develop a picture of 
their life history living with the disease (Leech, 2002). The next questions which 
followed were more specific to quality of life itself and whilst being based around 
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the main study objectives were also designed to provoke elaborative responses. 
Four main themes were covered by these questions, the first three were ‘activities’ 
(i.e. leisure activities, mobility etc.), ‘health’ (i.e. general health, self-help, self-
esteem etc.) and ‘relationships’ (i.e. partner, healthcare professional, family etc.). 
These particular questions were directly related to quality of life and were inspired 
by the University of Toronto’s quality of life model, which after reviewing alternative 
definitions of the term the author felt was the most appropriate to apply. This 
particular model defines quality of life as being ‘the degree to which a person 
enjoys the important possibilities of his or her life’ and can be further refined into a 
conceptual framework of 3 categories each consisting of 3 subcategories as 
shown in Table 3.2 (Quality of Life Research Unit, 2016). The overarching 
categories of ‘being’, ‘belonging’ and ‘becoming’ provided an anchor from which 
the interviews were grounded and which the chosen themes were ultimately based 
upon.  
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Being Who one is 
Physical Being 
 physical health  
 personal hygiene  
 nutrition  
 exercise  
 grooming and clothing  
 general physical appearance  
Psychological Being 
 psychological health and adjustment  
 cognitions  
 feelings  
 self-esteem, self-concept and self-control  
Spiritual Being 
 personal values  
 personal standards of conduct  
 spiritual beliefs  
Belonging 
Connections with one's 
environments 
Physical Belonging 
 home  
 workplace/school  
 neighbourhood  
 community  
Social Belonging 
 intimate others  
 family  
 friends  
 co-workers  
 neighbourhood and community  
Community Belonging 
 adequate income  
 health and social services  
 employment  
 educational programs  
 recreational programs  
 community events and activities  
Becoming 
Achieving personal goals, 
hopes, and aspirations 
Physical Belonging 
 home  
 workplace/school  
 neighbourhood  
 community  
Social Belonging 
 intimate others  
 family  
 friends  
 co-workers  
 neighbourhood and community  
Community Belonging 
 adequate income  
 health and social services  
Table 3.2 - Conceptual quality of life framework (Adapted from Quality of Life Research Unit, 
2016) 
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The fourth and final theme which was discussed during the interviews involved the 
‘diets’ (i.e. eating behaviours, appetite etc.) of patients. The author felt that it was 
essential to discuss this in more detail as the primary objective of the study was to 
investigate the impact of CSII upon patients’ eating behaviours. Furthermore, 
investigation using a qualitative paradigm is likely to reveal data and subsequent 
understandings which may otherwise have been ‘missed’. It should also be noted 
that all questions were formed in an open manner to encourage thoughtful 
responses and probing questions were occasionally used to provoke further 
discussion. The author used active listening techniques throughout to ensure 
rapport was built and maintained with each patient.  
Although quality of life was assessed qualitatively through semi-structured 
interviews it was also quantitatively measured using Euroqol EQ-5D 
questionnaires (Euroqol, 2016). This questionnaire is a standardised measure of 
health outcomes and consists of a series of brief descriptive questions concerning 
5 dimensions (mobility, self-care, anxiety/depression, pain/discomfort and usual 
activities), with each dimension having 3 levels (no problems, some problems and 
extreme problems). Additionally the questionnaire also contains a visual analogue 
scale which asks participants to self-rate their health. An example can be seen in 
appendix 12.4. The questionnaire has been fully validated and has been used 
extensively throughout the literature and in populations with T1D (Solli, 2010). All 
participants were asked to complete the survey and the responses were 
triangulated with the findings from the interviews. 
In addition to eating behaviours and quality of life the final study objective was to 
investigate CM risk. Although standard definitions of CM risk are in their infancy, 
the literature often associates specific clustered markers with increased risks of 
CM diseases (Van der Meer, 2013). To determine patients’ risks the study 
compared various markers falling under the ‘CM risk’ umbrella, both before and 
after the commencement of CSII therapy at the time points previously described. 
These risk factors consisted of age, sex, anthropometrics, HbA1c level, blood 
pressure and the standard lipid profile. This information was found within 
participants’ medical records which are continually updated after every hospital 
appointment and a note was taken of these measurements at each designated 
study visit. In addition to medical record access, a 20 ml volume of blood was also 
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required from participants after 12 hours of fasting. This sample was required for 
the additional analysis of lipoprotein subclasses (Davies, 2003). General 
information pertaining to this analysis can be found later in this chapter and the 
methods used are described in detail in chapter 3 (see page 45). 
The reader should note that there were various recruitment issues for this 
longitudinal study which resulted in the findings being instead presented as a 
series of brief case studies. This is explained in more detail in the ‘Recruitment 
Feasibility’ chapter (see page 65).  
Cross-Sectional Study 
To examine the eating behaviours of patients taking part in the cross-sectional 
study food frequency questionnaires (FFQ) were used. A FFQ is a method of 
describing food consumption patterns over a reference period using standardised 
responses, which in turn allow data to be inexpensively collected and quickly 
analysed (MRC, 2013). Despite these advantages, FFQ’s have been shown in the 
literature to be less reliable than other dietary assessment methods, such as food 
diaries and although they provide an important overview of dietary habits, it should 
be acknowledged that under or over reporting may occur (Day, 2001). The author 
appreciates this limitation; however, the pragmatic issues associated with using 
tools such as food diaries on a larger population were deemed too great for a 
study of this nature. It was therefore decided that a small subsample of 
participants would be asked to complete food diaries, whereas all participants will 
be asked to complete a compulsory FFQ. The FFQ chosen was the European 
Prospective Investigation of Cancer (EPIC) FFQ (see appendix 12.5), which was 
designed to measure participants’ food intake over the previous year and may also 
be used to determine food group data (University of Cambridge, 2014). It is a fully 
validated questionnaire and has been extensively used in previous studies 
incorporating a variety of populations, including patients with T1D (Matteucci, 
2004). The FFQs were mailed out to potential participants, along with a cover 
letter, information sheet, informed consent form and quality of life questionnaire. It 
should be noted that patients taking part in the longitudinal study were not required 
to complete a FFQ as it is felt that adequate eating behaviour data will already be 
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collected using the food diary alone and that the study may become too 
burdensome with the incorporation of additional data collection tools.  
Participants were also asked to complete the EQ-5D quality of life questionnaire 
mentioned previously. This only needed to be completed once after consent. 
Furthermore, to take part in the study the participants had to allow the research 
team access to their medical records so risk factors could be recorded in the same 
way described previously for the longitudinal study; however, measurements were 
only recorded once when consent was given, rather than over numerous time 
points.  
Participants in the cross-sectional study were also able to ‘opt in’ during the 
consent procedure to participate in various additional tasks. These tasks consisted 
of completing weighed food diaries, taking part in semi-structured interviews and 
giving a sample of blood. The requirements for patients participating in these tasks 
was the same as those previously described for the longitudinal study, but only 
took place once after giving consent rather than at various time points. It should 
also be noted that the patients using MDI therapy were asked slightly different 
questions during their semi-structured interviews to determine their opinion of CSII 
therapy rather than their experience using it; however, the key interview themes 
remained the same. Examples of the interview questions can be seen in appendix 
12.6.  
The following flow charts present the process each participant went through upon 
consenting in a visual form. Figure 3.2 illustrates a general overview of the studies 
and Figures 3.3 and 3.4 clarify the processes in more detail for both cross-
sectional and longitudinal studies. 
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Patient already 
using CSII
Patient not using 
CSII and not 
intending to
Patient accepted 
onto CSII
Patient offered 
entry to cross-
sectional study
Patient offered 
entry to longitudinal 
study
Patient asked to 
engage once
Patient asked to 
engage during 5 
time points over 1 
year
CSII users and non-
CSII users can now 
be directly 
compared
CSII users outcomes 
can be compared 
over time
Study outcomeStudy outcome
Figure 3.2 – Flow chart outlining the general study procedure for longitudinal and 
cross-sectional studies. 
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Patient accepted onto 
pump
Patient approached 
about study
Patient has 
‘thinking’ period
Patient consents  
and joins study
Food diary (1)
Gives blood sample
Lipid & lipoprotein 
analysis (1)
Food diary (2)
Food diary (3)
Food diary (4)
Food diary (5)
Qualitative 
interview* and 
survey (1)
Type transcript and 
analyse
Qualitative 
interview* and 
survey (2)
Type transcript and 
analyse
Qualitative 
interview* and 
survey (3)
Type transcript and 
analyse
Qualitative 
interview* and 
survey (4)
Type transcript and 
analyse
Qualitative 
interview* and 
survey (5)
Type transcript and 
analyse 
Final analysis and 
evaluation
Gives blood sample
Lipid & lipoprotein 
analysis (2)
Gives blood sample
Lipid & lipoprotein 
analysis (3)
Gives blood sample
Lipid & lipoprotein 
analysis (4)
Gives blood sample
Lipid & lipoprotein 
analysis (5)
(3 months)
(3 months)
(3 months)
(3 months)
(3 months)
(3 months)
(3 months)
(3 months)
(Clinic or 
home)
(Clinic or 
home)
(Clinic or 
home)
(Clinic or 
home)
(Clinic or 
home)
Figure 3.3 – Flow chart detailing the procedures for the longitudinal study 
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Patient already 
using CSII
Patient not using 
CSII and not 
intending to
Patient approached 
about study
Patient has 
‘thinking’ period
Patient joins the 
study
Patient asked to 
complete FFQ and 
quality of life survey 
(all participants)
Patient asked to 
take part in a 
quality of life 
interview 
(Subsample only)
Patient asked to 
complete a food 
diary (Subsample 
only)
Patient asked to 
give blood 
(Subsample only)
Analysis and 
evaluation
Figure 3.4 – Flow chart detailing the procedures for the cross-sectional study 
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3.3.5 Research Study Data Analysis 
All data were analysed after each study time point (baseline, 3, 6, 9 and 12 
months for participants in the longitudinal study and immediately after data 
collection for the cross-sectional study) and were summarised upon the 
completion of both studies. 
Dietplan 6 software (Forestfield Software Ltd., West Sussex, UK) using standard 
McCance and Widdowson food tables was used to analyse dietary intake data 
obtained from food diaries (Food Standards Agency, 2002). Data obtained from 
the FFQ’s employed in the cross-sectional study was analysed using FFQ EPIC 
Tool for Analysis (FETA) software (University of Cambridge, 2014). 
Fasting plasma from venous blood samples was prepared for analysis by low-
speed centrifugation. The resulting plasma was aliquoted equally into two 
samples. One portion of aliquoted plasma was rapidly separated into LDL and 
HDL subclasses using ultracentrifugation and then divided into fractions (Davies, 
2004; Harman, 2013). Each fraction was then analysed for lipid content and 
categorised into different density classes and atherogenic phenotypes. The 
second portion of whole plasma was also analysed for lipid content. More details 
of these procedures are described in chapter 7 (see page 134). 
Statistical analysis 
Descriptive and inferential statistics were used to describe all quantitative data 
obtained. Descriptive statistical analysis was carried out on data obtained from 
blood samples, food diaries and risk markers found in participants’ medical 
records, as well as data collected from food frequency questionnaires and the 
Euroqol EQ-5D questionnaires. Frequencies and percentages were calculated for 
categorical variables. Furthermore, continuous variables were tested for normality 
using Q – Q plots and the Shapiro-Wilks test and any non-normal data was then 
transformed logarithmically prior to further analysis using either Student’s t-tests or 
Mann-Whitney U tests. Correlations between variables pertaining to CM risk 
derived from the analysis of plasma samples were established using the non-
parametric Spearman’s rank correlation coefficient. Linear repeated measure 
models were also used when analysing the clinical audit data to determine the 
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influence of CSII therapy over time. Statistical Package for Social Sciences 
(SPSS) (v.21) was used for all quantitative data analysis throughout the study.  
Qualitative data analysis 
Qualitative data generated during interviews was subjected to a thematic analysis 
as described by Gubrium and Holstein (2009), Riessman (2008), and Sparkes and 
Smith (2014). This involved transcribing the anonymous interview data into a 
Microsoft Word 2010 document. The data then underwent a number of readings 
prior to being broken down into categories of meaning. This led to the 
development of key themes both within and between the participants as individual 
cases and allowed for the theoretical elaboration of data to occur. NVivo 10 
software was used to assist this analytical process. 
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4 - Recruitment Feasibility 
 
Effective participant recruitment is greatly important for the success of any human-
based study and this section will give an overview of the recruitment issues 
pertaining to studies in general and those involving patients with diabetes along 
with potential remedies. It will also explain in detail the recruitment process for the 
present study from its commencement to its conclusion. In doing so the author 
hopes that the reader will gain a sense of the challenges which were faced 
throughout the study and that this may help to explain some of the irregularities 
which may appear in the following chapters. Furthermore, it may also offer hints at 
how the study may have been improved and how future similar studies may be 
more effective; however, these issues will be discussed in more detail in later 
chapters.  
4.1 Introduction 
Given the importance of effective recruitment and the weight of significance relying 
upon this fundamental process the literature regarding the recruitment of study 
participants is remarkably scarce. This is both surprising and concerning, 
especially when much research is funded by public money and its success is of 
great importance to society as a whole.  
Despite this it is reassuring that the few existing studies have generally been 
conducted in a robust manner and the available reviews are extensive. Although 
this literature offers promise it is important to note that much of the research tends 
to focus largely on the recruitment of participants to randomised control trials 
(RCTs). These highlight various issues, in particular concerning the frequent 
failure of studies to meet proposed recruitment rates. For example, Copeland 
(2016) attempted to recruit participants to a large physical activity trial and found 
that only 47% of the target sample was ultimately enlisted. These disappointing 
figures were echoed by Carter (2015) who also found that when recruiting for a 
multiple sclerosis RCT only 120 patients from a possible 369 actually took part, 
thus producing a recruitment rate of only 32.5%. Additionally, work by Campbell 
(2007) assessing a database of trials which took place between 1994 to 2003 
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highlighted that even those in the UK which benefited from the assistance of a 
clinical trial centre failed to recruit successfully, with approximately half being 
unable to recruit 100% or more of the original target and 45% failing to recruit 
within 80% of their original target.  
The reasons for these shortcomings appear to be multifaceted with commonly 
cited issues often being associated with a lack of staff and resources as well as 
frequent difficulties both communicating and maintaining relationships with 
participants after randomisation (Copeland, 2016; Carter, 2015; Campbell, 2007). 
Furthermore, research staff being unprepared and untrained in how to deal with 
problems arising from the complexities of carrying out human-based studies also 
appears to be a problem (Ibid). A qualitative study by Newington (2014) attempted 
to further unpick these issues through interviews with research workers and found 
there were four reoccurring themes regarding recruitment. Firstly, a suitable 
‘infrastructure’ has to be in place to ensure recruitment is organised rather than a 
secondary thought. Secondly, the ‘nature of the research’ must be considered. For 
example, clinical trials have been shown to be more difficult to recruit for than 
observational studies due to the extra commitment required by participants and as 
such measures should be considered to compensate for this, such as incentives 
etc. Thirdly, adequate thought should be given to the ‘recruiter characteristics’. For 
example, patients are more likely to consent to take part in a study when 
approached by a doctor rather than a research nurse and the recruiter should 
therefore be considered in the design phase. The final point discovered by 
Newington (2014) was regarding the ‘participant characteristics’. For example, 
patients are more likely to participate in a study when they are likely to gain a 
clinical benefit from doing so. Interestingly, in the present study it also became 
apparent that the reason for patient participation, from the researchers’ 
perspective, was typically and perhaps unsurprisingly altruism and conversely 
logistical considerations appeared to be the most important catalyst for not taking 
part. To determine optimum strategies of dealing with complex recruitment issues 
such as these a meta-analysis by Treweek (2013) was performed, investigating 45 
trials with over 43,000 participants. This study revealed that there are in fact 
promising methods which can be used to increase both recruitment and retention, 
such as the use of open-trial designs, opt out strategies and telephone reminders; 
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however, the authors emphasise that there remains a large gap in the knowledge 
in this area and that there is little evidence surrounding commonly used 
alternatives, such as financial incentives. 
Despite the majority of existing research in this area focussing specifically on 
RCTs, it is incorrect to say that this is absolute. Observational studies also get a 
degree of attention by authors, although this is often of a smaller magnitude than 
their RCT counterparts. For example, work by Pickering (2010) which focused on 
recruitment to three observational studies, all involving patients with stroke, found 
that the recruitment rates after screening for all studies varied between 10% and 
50% and that all were significantly lower than expectations. Furthermore, in one 
study where a history of stroke was the only required eligibility criteria recruitment 
was still found to be only 50%, illustrating how even studies with few design 
barriers may still find recruitment a challenging process. Large and multicentre 
studies also appear to suffer from the same issues but on a greater scale. This 
was illustrated in research conducted by Stone (2013), which investigated 
recruitment to a palliative care study and revealed that only 8.2% of referral 
patients who were originally deemed eligible to participate actually ended up 
taking part in the study. This was found to be due to a variety of reasons, similar to 
those discussed previously by Newington (2014), and fell under three main 
themes involving patient ‘availability’, ‘accessibility’ and ‘consent’ and concluded 
by stating that recruitment ‘bottlenecks’ such as these need acknowledging to 
ensure effective study outcomes.  
Although this evidence is useful, research specifically focussing on recruitment to 
diabetes studies is rare. Despite this a diminutive collection of literature does exist 
and in particular a ‘rapid review’ by Cooper (2015) offers a useful example to 
highlight some of the unique issues pertaining to the recruitment of participants 
with diabetes. This review shows how those studies which offer a treatment (such 
as drug trials) tend to have higher rates of recruitment than those which offer some 
form of prevention (for example dietary and exercise interventions). Furthermore, 
Herbert (2015) showed that in a paediatric population with Type 1 diabetes (T1D), 
even after consenting to a longitudinal study (lasting 6 months) there were 
reductions in the retention of patients ranging from 58 – 90% and that there were 
variations within patients. In particular those who were older, had worse glycaemic 
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control, lower household income and who belonged to families with unmarried 
parents were associated with a higher chance of failing to complete the study. To 
ensure that recruitment is maximised in studies involving patients with diabetes 
there have been various attempts to produce databases of patient details forming 
clinical research networks which researchers can then use to contact potential 
relevant participants. An example of this is the TrialNet programme which 
originated from the US, but now has registrants with T1D from 21 centres based in 
many countries including the UK (TrialNet, 2016). Furthermore, there has also 
been the creation of the Diabetes Research Registry which is a similar endeavour; 
however, despite being a smaller venture it has still managed to enrol 5000 
patients with both T1D and T2D residing in the US and over the past 5 years has 
facilitated the recruitment of participants for 31 studies (Tan, 2016).  
Although the literature suggests there are many recruitment related issues 
associated with most human-based studies, not least those involving patients with 
diabetes, there also appear to be pitfalls which can also be avoided through proper 
planning and ensuring the study is designed appropriately. The following section 
will describe the recruitment process for the present study in detail and will 
conclude by explaining the potential issues which arose, how they may have been 
prevented and their implications for the study moving forward.  
4.2 Recruitment Process and response rates 
 Clinical Audit 
As previously mentioned, a clinical audit was performed whilst preparations were 
being made for the subsequent research studies. This audit was approved by the 
NHS and data was collected retrospectively by examining patients’ medical 
records. More details can be found about this audit in chapter 5 (see page 79); 
however, it should be noted that the NHS audit approval gave the author access to 
the medical records of every patient using CSII at the Royal Liverpool Hospital. As 
data was retrieved from 100% of the patients using the therapy at the Trust at that 
particular time with no issues no further attention is required regarding recruitment 
and hence the audit will not be referred to again throughout this chapter. 
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 Longitudinal Study 
As mentioned in the General Methodology chapter, the author was initially aiming 
for the longitudinal study to obtain a sample size of 20 – 25 CSII patients. This was 
deemed both reasonable and attainable after considering the pilot nature of the 
study and data from previous years suggesting approximately 50 patients are 
typically offered the therapy at the hospital over the course of a year.  
Unfortunately immediately after NRES NHS ethical approval was granted for this 
study and recruitment was about to begin a key member of hospital staff fell ill. 
The implications of this were that no new patients were offered CSII treatment and 
therefore recruitment was stopped. After waiting for a number of months for the 
individual to return to work and for recruitment to resume it became apparent that 
this would be unlikely. In response to this the author and research team decided 
that a different strategy would be required and thus the idea for a cross-sectional 
study was formed which would recruit patients well established with either CSII or 
MDI for comparison. It was planned that this would run concurrently with the 
longitudinal study which patients could be recruited to at a later date should new 
patients start to be offered CSII again. 
As patients eligible for CSII have to attend a compulsory, week long, intensive 
education session prior to them being given the device recruitment for the 
longitudinal study was relatively straightforward. This consisted firstly of the 
Consultant Diabetologist informing the author of the next scheduled education 
session. Before this took place the author then delivered the appropriate number 
of recruitment ‘packs’ (containing participant information sheets and consent forms 
etc.) to the CSII specialist nurse who would be facilitating the education sessions. 
The nurse then verbally informed patients during the sessions about the study and 
handed out the packs to any interested patients. If a patient decided they would 
like to take part or find out some more information they could then contact the 
author directly using the contact details contained within the pack. Recruitment 
using this method meant that the author did not know any patient details unless 
they decided to make contact first.  
Unfortunately, due to the hospital staffing issues described above the education 
sessions became consultant-led and were significantly less frequent than usual. 
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As a result during the course of the study only two sessions took place, each 
consisting of five patients. Out of these 10 patients who commenced CSII therapy 
only five agreed to take part in the longitudinal study. When using the recruitment 
target of 20 patients this indicates that there was a recruitment success rate of 
only 25%. Furthermore, during the course of the study one patient withdrew for 
personal reasons and another became uncontactable. The recruitment rates and 
retention over time can be seen in Figure 4.1. 
In the light of this it is obvious that the data which was collected would not be 
statistically meaningful; however, it was decided that some of the results may still 
be of interest and that they may instead lend themselves better to being used as 
case studies. These are described in more detail in the ‘Case Studies’ chapter 
(see page 206). 
 
 
  
 
Figure 4.1 –Recruitment rate to longitudinal study and participant retention over time. 
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 Cross-Sectional Study 
As mentioned previously, the cross-sectional study was devised partly in response 
to staffing issues at the hospital which prevented initial recruitment to the 
longitudinal study. This therefore meant that NRES NHS ethical approval again 
had to be sought to allow this new study to take place. This was eventually 
approved and recruitment began immediately.  
In a similar manner to the longitudinal study the author was prevented from 
knowing the patients identity until they had agreed to take part and as this study 
was targeting patients who had been using either CSII or MDI for a year or longer 
and who may only have annual check-ups it was unfeasible to ask the healthcare 
professionals to approach the patients during their clinic appointments. The 
recruitment process therefore involved the author instructing an IT technician 
responsible for managing the Diabetes Register at the hospital to filter the 
database according to the studies inclusion and exclusion criteria. The resulting 
patient contact details were then emailed to the Consultant Diabetologist’s 
secretary. At this point the author delivered the appropriate number of blank 
recruitment packs to the secretary who then labelled and posted each pack to the 
patients’ homes. If a patient then decided they would like to take part or find out 
some more information they were free to contact the author. This method, 
although slightly convoluted, enabled the identity of any patient who did not want 
to take part to remain anonymous and for all patient details to remain within the 
hospital.  
Given the small amount of available patients imposed by the single clinic and the 
pilot nature of the study described previously, a sample size of 30 patients using 
CSII and 30 using MDI was thought appropriate and agreed. It should also be 
noted that a small subsample of approximately 10 CSII and 10 MDI patients were 
required to take part in further optional activities such as food diaries and 
interviews. These activities are explained in the General Methods chapter (see 
page 45) and will be explained in more detail again in later chapters. Again, due to 
the pilot, exploratory nature of this study and the limitations of the clinic this small 
subsample size was thought to be appropriate. 
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A total of 50 patients using CSII and 50 using MDI were initially approached during 
a first mailshot. These patients were chosen at random from the list produced from 
the Diabetes Register. The randomisation process involved potential participants 
from each treatment group being assigned a numerical code. These codes were 
then ordered randomly using the Microsoft Excel ‘random’ function and the first 50 
from each group were then contacted. Unfortunately it quickly became clear that 
this mailshot had not been successful. During the month following the mailshot 
only 7 patients returned consent (6 of these were using CSII and 1 was using 
MDI). The research team then decided that recruitment should be significantly 
increased and an amendment was submitted and approved by the NRES ethics 
committee allowing the author to approach a further 255 patients using CSII 
(which when including the 50 already approached made up the entire population of 
patients using CSII at the hospital). This was then matched by an equal amount of 
packs sent out to appropriate patients using MDI (whose identities were chosen at 
random using the procedure previously outlined from the filtered list derived from 
the Diabetes Register). The packs were sent out in the same manner as 
previously described in order to preserve patient identity.  
This second mailshot was far more successful and a total of 60 responses offering 
informed consent were ultimately received. These came from 40 patients using 
CSII and 20 patients using MDI. This equated to 133% of the target CSII patients 
being recruited and 67% of the target for MDI patients being recruited and is 
illustrated in Figure 4.2. These patients all completed a food frequency 
questionnaire and a quality of life questionnaire which were included in the final 
analysis. Unfortunately, 16 of the patients that initially gave consent did not go on 
to take part in the rest of the study as they were lost to follow up. This equated to 
20% of consented patients using CSII and 40% patients using MDI and is shown 
in Figure 4.3. The questionnaire data for these participants remained in the final 
analysis. There were also a number of participants who did not agree to take part 
in some of the optional aspects of the study. It should also be noted that as soon 
as a patient gave consent to take part in the study the author sent a letter to their 
G.P. along with a participant information sheet to explain what they had agreed to. 
No G.P. replied to object to their patient taking part in the study. After the 
subsample of 10 CSII and 10 MDI patients had been reached interested 
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participants were then only offered the opportunity to take part in the donation of a 
blood sample. The reason for this was that whilst the author had a valuable 
opportunity to receive more food diary and interview data, the analysis of this 
excess data would be both out of the remit of this study and the scope of feasibility 
for the author to manage alone and was therefore deemed an unnecessary burden 
for the participants. 
 
 
 
 
 
 
 
  
 
 
Figure 4.2 – Cross-sectional study recruitment rates by treatment type. 
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4.3 Discussion 
Although the recruitment strategy was in some ways successful, with 133% 
percent of the recruitment target for patients using CSII being achieved, there 
remained various issues in other areas. For example, the recruitment of MDI 
patients was less impressive, with only 67% of the target sample size being met. 
Furthermore, when considering that a significant amount of patients had to be 
approached through the mailshot the effectiveness of the strategy leaves a lot to 
be desired. The mailshot reached 305 patients with CSII and an equal number of 
patients using MDI. This equates to only 13% of those using CSII who were 
initially contacted offering consent and just 7% of those using MDI. These rather 
disappointing figures are followed by poor retention rates, with 20% of those using 
CSII and 40% of those using MDI subsequently either withdrawing from the study 
or becoming uncontactable after offering consent. 
Figure 4.3 – Graph showing cross-sectional study withdrawal rates after consent by treatment 
type. 
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Furthermore, with respect to the longitudinal study it can be seen that the 
recruitment rates were also poor; however, it is clear that this is largely down to 
uncontrollable and unusual staffing issues which could not have been forecasted 
by the research team. Unfortunately, the reasons for poor recruitment remain 
elusive as the identities of patients were blinded from the author until consent was 
given and no follow-up was proposed to determine why some were unwilling to 
take part. It can be hypothesised; however, that the patients perhaps may have 
had issues akin to those found by Newington (2014) and Stone (2013) which may 
have prevented or discouraged them from taking part. Also, it is interesting to note 
that the study is observational in nature and would not be offering any form of 
treatment, which Herbert (2013) found often plays a role in deterring patients with 
diabetes from participating. Furthermore, a lack of monetary incentive may also 
have contributed towards patients feeling unmotivated to take part, although this 
remains speculative as the influence a financial reward may have is debatable, 
with altruism often cited as a more prominent driving force for participation 
(Treweek, 2013; Newington, 2014). It is also interesting to note that despite the 
amount of patients consenting being relatively low compared to the overall amount 
approached, it is clear that those using CSII appeared to be far more willing to 
participate and were less inclined to withdraw. It is difficult to say with certainty 
why this could be, but patients offered CSII have to meet strict criteria and 
evidence of working together with a healthcare professional to improve their health 
must be shown. In short it could be said that because of this eligibility criteria 
patients using CSII may on average typically be more disciplined and health-
conscious group than their MDI counterparts and as such potentially more 
motivated to take part in research studies.  
Although these reasons are purely hypothetical there were various pragmatic 
issues which almost certainly contributed towards recruitment problems. The clinic 
size was an important influencing factor with recruitment bound by this limitation. 
Although patient numbers are dynamic the Royal Liverpool Hospital consistently 
has one of the largest populations of patients with T1D using CSII in the UK. 
Despite this all eligible patients using CSII (n = 305) were contacted and the only 
way this could have been expanded would have been to recruit from multiple 
centres. To pursue this would have been troublesome, primarily because a 
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consequence of the hospital’s large CSII clinic is that the remaining local pump 
centres only support small numbers of patients. The next largest clinics are based 
in Harrogate and Cambridge and recruiting from these centres would have been 
unfeasible for a small pilot study of this nature. Furthermore, even if staff were in 
place to recruit from these sites the resources needed to pursue this were 
unavailable; for example, the costs of carrying out a larger mailshot etc. These 
issues embody comments made by Campbell (2007) that common problems with 
recruitment are often associated with a lack of research staff and resources 
needed to carry out the process effectively.  
Despite these issues it is also important to acknowledge that there were ways in 
which the study could have recruited patients more effectively using the existing 
resources and staff. In hindsight asking healthcare professionals to assist with 
vocalising the existence of the study to patients in clinics may have helped to 
improve awareness. The evidence suggests that this may have proved to be an 
effective method as shown in work by Carter (2015) who found that when 
performing a trial involving patients with multiple sclerosis 60% were recruited from 
clinic appointments as opposed to 29.2% from a mailshot. Furthermore, the use of 
posters in clinics may also have further improved numbers. Finally, the use of a 
purpose made recruitment database may also have helped; however, examples 
such as TrialNet which was discussed earlier in this chapter, despite being 
affiliated with centres in the UK, are not yet available for use by the Royal 
Liverpool Hospital, but an NHS equivalent is currently being rolled out. 
In summary similar future studies in this area may therefore benefit from 
expanding their recruitment strategy to incorporate various other opportunities 
aside from a mailshot alone and take advantage of the increased scope. Also, 
attempting to gain access to a purpose-made clinical research network may help 
to identify patients already willing to take part in studies. Furthermore, it is 
imperative that researchers attempt to understand their proposed sample 
population before study recruitment commences so that nuances can be 
recognised and exploited. For example, in the present study it is now clear that 
patients using MDI may be more difficult to recruit than their CSII counterparts, 
therefore perhaps more effort should have been made to find creative ways of 
reaching out to them. Despite an initial struggle to recruit participants the research 
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team feel that the final sample size for the cross-sectional study is appropriate for 
the purposes of a pilot study. The team also feel that the small number of recruited 
patients to the longitudinal study, although not statistically meaningful, still make 
for interesting and valuable case studies and offer an original contribution to the 
existing literature. 
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5 - Clinical Audit 
 
5.1 Abstract 
The long-term effects of continuous subcutaneous insulin infusion (CSII) therapy 
on traditional clinical markers of risk such as glycated haemoglobin (HbA1c), insulin 
dose, lipid profile, blood pressure and body mass index (BMI) is under-researched. 
An evaluation of 260 patients (33.8% male; 66.2% female) engaging with CSII 
therapy at the Royal Liverpool Hospital was carried out. Medical records spanning 
8 years were interrogated and analysed. Over 4 years significant reductions were 
seen in systolic blood pressure from borderline hypertension to within the 
normotensive range (128.2 to 122.1 mmHg; p = 0.003). This was also shown in 
diastolic blood pressure (75.2 to 72.0 mmHg; p = 0.027). HbA1c and insulin dose 
also decreased upon commencing the therapy (from 8.3 to 7.9%; p = <0.001 and 
54.5 to 45.0 IU; p = <0.001 respectively), reflecting previously reported data. There 
was little change in BMI (from 26.1 to 26.0 kg/m2; p = 0.288) and lipid profile, with 
total cholesterol and triglycerides decreasing slightly (4.3 to 4.2 mmol/L; p = 0.440 
and 1.1 to 1.0 mmol/L; p = 0.018 respectively) and HDL-C and LDL-C remaining 
static (1.7 mmol/L; p = 0.639 and 2.1 mmol/L; p = 0.990 respectively). The results 
illustrate patients undergoing CSII therapy enjoy improvements in glycaemic 
control and blood pressure whilst using less insulin and that these changes have 
little or no adverse impact upon BMI or lipid profile. In fact, from a lipoprotein 
perspective patients appear to be well protected against cardiovascular disease. 
Despite these positive findings further work remains to be done to elucidate their 
validity, the mechanistic components which may be driving them and potential 
improvements to enhance patient outcomes. 
5.2 Introduction 
It is well known that patients with Type 1 diabetes (T1D) are at an increased risk of 
macrovascular complications compared to the general population, with 
cardiovascular disease accounting for 44% of fatalities in the UK (Diabetes UK, 
2015). Furthermore, increased microvascular risks are also apparent, such as 
nephropathy which accounts for 21% of deaths in those with T1D; retinopathy 
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which presents in nearly all patients within 20 years of disease onset and 
neuropathy (Morrish, 2001; Scanlon, 2008). Fortunately, the progression of these 
microvascular risks may be slowed or prevented through attaining optimal 
glycaemic control (The Diabetes Control and Complications Trial Research Group, 
1993). Similarly, more effective insulin treatments have also been associated with 
reductions in cardiovascular disease (CVD) risk, with Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions and Complications 
(DCCT/EDIC) data highlighting incidence rates of 14% in those using a 
conventional injections compared to 9% in those using an intensive therapy 
(Nathan, 2009). 
One such intensive treatment is continuous subcutaneous insulin infusion (CSII), 
which has been shown to be an effective method of achieving glycaemic control in 
those with T1D (Pickup, 2002). Since its introduction in the 1970’s the therapy has 
undergone many changes with modern pumps offering the ability to set multiple 
basal rates, bolus profiles and temporary insulin delivery programmes, which may 
all potentially contribute towards further glycaemic improvements (Skyler, 2010). 
Opportunities to disconnect the pump, the introduction of waterproof cases and the 
advent of patch pumps may too impact upon long-term overall health through 
improved lifestyle (Ibid). There have also been significant advances in both T1D 
and CSII knowledge and education. As such patients are now frequently offered 
skills courses to enable effective carbohydrate counting and the appropriate 
management of diet and lifestyle, as well as structured CSII education sessions 
delivered by specialist healthcare professionals (NICE, 2008). Improvements in 
insulin quality have also occurred with new analogues being produced together 
with better patient access to these innovations (Owens, 2014; Woo, 2015). The 
sum of these advancements mean patients can now enjoy an improved state of 
health which was neither previously available nor accounted for in past studies. 
Despite this progress there is a dearth of literature focusing on the long-term 
effects the therapy may have upon routine markers of CVD risk. Existing studies 
typically focus on children or adolescents and are frequently performed over short 
time periods with few robust studies following up adult patients for 24 months or 
more (Jeitler, 2008). Furthermore, they are often dated and therefore do not take 
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into account the technological advancements of insulin pumps over recent years 
and the benefits these may have upon patient health.  
Although rare, there are important exceptions to this scarcity of literature. A study 
by Melidonis (2016) investigating 94 Greek patients using CSII over a 3 year 
period found that in addition to improved glycaemic control the therapy was also 
associated with a reduction in hypoglycaemic episodes whilst inferring a neutral 
effect on BMI. Furthermore, work by Rosenlund (2015) illustrated that over 4 years 
a cohort of 193 patients utilising CSII compared to 386 patients using MDI 
displayed a significantly improved urinary albumin/creatinine ratio. As this measure 
is associated with the production of microalbuminuria these findings may therefore 
be suggestive of reductions in kidney and cardiovascular disease risk. This 
potential for CSII to reduce cardiovascular risk was further investigated by 
Steineck et al. (2015) in the largest existing long-term study regarding this 
population. This observational study, spanning nearly 7 years, revealed that in 
18,168 Swedish patients using CSII the therapy was associated with significantly 
lower adjusted hazard ratios for fatal cardiovascular disease, fatal coronary heart 
disease and all-cause mortality compared to MDI. 
Despite this modicum of studies suggesting favourable long-term benefits 
associated with CSII there are none, to the authors’ knowledge, which focus 
specifically on a UK adult population. Furthermore, recent evidence revealing how 
many patients with T1D do not receive adequate care and that only 15% of these 
under the age of 65 meet HbA1c, blood pressure, and cholesterol treatment targets 
compound the need for an evaluation of both historical and present outcomes, 
particularly at a Trust level (NHS England, 2015; Diabetes UK, 2015). It was 
therefore decided that carrying out an audit of CSII patients’ medical records at the 
Royal Liverpool Hospital would be beneficial. Clinical audits are useful to 
determine whether healthcare is being provided in line with standards and in this 
case would also offer an overview of standard clinical markers of risk within the 
sample population prior to the commencement of the research study (UHBristol 
Clinical Audit Team, 2009). This report therefore describes the aforementioned 
audit with a view to elucidating the long-term impact CSII may have upon standard 
clinical markers pertaining to the the whole population of patients using CSII at the 
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Royal Liverpool Hospital, thus enabling informed changes to be implemented (if 
needed) and to improve future care.  
5.3 Aims and Objectives 
Aim 
To evaluate the long-term impact CSII may have upon routinely taken clinical 
measures of risk. 
Objectives 
To perform a clinical audit of medical records belonging to adult patients with T1D 
who are using CSII under the care of the Royal Liverpool Hospital.  
5.4 Methods 
After gaining NHS audit approval the medical records of 260 patients using CSII 
therapy at the Royal Liverpool Hospital were interrogated. Data from these 
patients spanning 8 years (4 years prior to the commencement of CSII and the 
subsequent 4 years after) were collected and comprised of total cholesterol, 
triglycerides, low density lipoprotein cholesterol (LDL-C) and high density 
lipoprotein cholesterol (HDL-C). Additional body mass index (BMI), HbA1c, insulin 
dose and systolic and diastolic blood pressure information was also recorded; 
however, data for these risk markers were only available for the 4 years after 
patients commenced the therapy. The age and gender of each patient was also 
noted. All identifying patient details were anonymised. 
Statistical Analysis 
Data was inputted between January 2013 and November 2014 and descriptive 
statistics were used to initially scrutinise the data. Normality was determined using 
Q - Q plots and Shapiro-Wilks tests and a linear mixed model analysis was then 
employed, using SPSS version 21 (SPSS, Chicago, IL, USA). This statistical 
method was chosen specifically as a number of data points were found to be 
missing throughout the dataset. Although repeated measures tests are typically 
used to determine differences between time points in longitudinal data this may 
have been problematic as each participant with missing data would be 
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automatically excluded (thus severely minimising the sample size). A linear mixed 
model was therefore chosen due to its ability to retain every participant and 
account for missing data in the analysis. This test was used to determine 
differences between baseline measurements (taken upon the commencement of 
CSII) and measurements taken after 12 and 48 months of treatment. Additionally, 
the relationship between insulin dose and other variables was also determined 
using Spearman’s rank correlation coefficient. A p-value <0.05 was used to denote 
statistical significance in all tests and correlation strength was determined using r-
value criteria devised by Evans (1996), as shown in Table 5.1. 
 
 
5.5 Results 
Patients 
From the 260 patients’ interrogated data 33.8% were male and 66.2% were female 
with a mean age of 45 ± 14 years and all patients were using CSII therapy. It 
should be noted that after examining the medical records it became clear that 
there was a significant amount of missing data as clinic appointments were often 
unattended. This may possibly be due to patients disengaging with the service for 
periods of time or clinic appointments being fully booked. Additionally, it was also 
found that variables of interest to the audit were not always habitually measured 
for each patient during each clinic appointment. In the light of this sample sizes (n) 
have been given in Table 5.2 concerning every variable at each time point.  
The observed course of treatment parameters are presented in Table 5.2 and the 
estimated clinical parameters for 0 - 12 months and 0 - 48 months using linear 
mixed models analysis are presented in Table 5.2.  
Table 5.1 – Correlation r-values and their corresponding levels of association (adapted from Evans, 
1996). 
 
The image originally presented here cannot be made freely available via LJMU Digital Collections 
because of copyright. The image was sourced from Evans J.D. (1996) ‘Straightforward Statistics 
for the Behavioral Sciences’ 1st ed. Brooks/Cole Publishing, California. 
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HbA1c, Insulin Dose and BMI 
Mean HbA1c decreased significantly from 8.3 to 7.6% 12 months after the 
commencement of CSII [mean difference: -0.7%; 95%CI: 0.5-1.0; p < 0.001] and 
was maintained until month 48 where it slightly increased to 7.9%. Mean insulin 
dose also decreased significantly from 54.5 to 46.4 IU during the 48 months which 
followed the commencement of CSII [-8.1 IU; 95%CI: 2.7-13.5; p < 0.001]. These 
trends are illustrated in Figure 5.1. Upon engaging with CSII very little change in 
patients’ BMI was observed over the following 48 month period [-0.3 kg/m2; 
95%CI: 1.0-1.1; p = 0.288]. 
Blood pressure 
Statistically significant reductions in systolic blood pressure were observed during 
48 months of engaging with CSII from 128.2 to 122.1 mmHg [-6.1 mmHg; 95%CI: 
1.9-10.3; p = 0.003]. Significant reductions from 75.2 to 72.0 mmHg were also 
observed in the diastolic blood pressure of patients who engaged with CSII over a 
48 month period [-3.2 mmHg; 95%CI: 0.3-6.0; p = 0.027]. These trends are 
illustrated in Figure 5.2. 
Lipid profile 
There were few changes in patients’ total cholesterol [-0.1 mmol/L; 95%CI: -0.2-
0.5; p = 0.771] and LDL-C [0.0 mmol/L; 95%CI: -0.3-0.3; p = 0.990] after 48 
months of CSII therapy. Triglycerides, however, significantly decreased over 48 
months of CSII use [-0.1 mmol/L; 95%CI -0.1-0.4; p = 0.018] and HDL-C showed a 
significant increase from 1.7 - 1.8 mmol/L [0.1 mmol/L; 95%CI: -0.2-0.1; p = 0.025] 
during the first 12 months of CSII use and this was maintained for a further 36 
months as shown in Figure 5.3. The total cholesterol/HDL-C ratio remained largely 
static during 48 months of commencing CSII [0.0; 95%CI: -1.0-1.0; p = 0.978].  
Data was also collected for lipids and lipoproteins covering the 48 months prior to 
initiating with the therapy. This illustrated no significant changes with: total 
cholesterol increasing from 4.0 to 4.3 mmol/L, LDL-C increasing from 1.9 to 2.1 
mmol/L, HDL-C remaining between 1.6 and 1.7 mmol/L and triglycerides 
increasing from 1.0 to 1.1 mmol/L. The total cholesterol/HDL ratio increased from 
2.5 to 2.7 during this period.  
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Insulin Dose Correlations 
When looking at Table 5.3 it can be seen that insulin dose was significantly 
correlated with BMI; however, this positive relationship was weak [baseline: r = 
0.443, p < 0.001; 12 months: r = 0.434, p < 0.001; 48 months: r = 0.252, p = 
0.022]. There was also a significant negative relationship with HDL, the strength of 
which grew from weak to moderate as the treatment time progressed [baseline: r = 
-0.262, p = 0.014; 12 months: r = -0.472, p < 0.001; 48 months: r = -0.575, p = 
0.001]. A significant but weak positive relationship between insulin dose and 
triglycerides was also demonstrated at baseline and after using the therapy for 48 
months a moderate yet significant association was seen [baseline: r = 0.291, p = 
0.006; 48 months: r = 0.513, p = 0.004].  
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Table 5.2 - Clinical characteristics before and after the commencement of CSII (Data are presented as means with 95%CI and the appropriate n values) 
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Figure 5.1 – HbA1c (%) and insulin dose (IU) over a 48 month period after the commencement of 
CSII therapy. 
Figure 5.2 – Systolic and diastolic blood pressure (mmHg) over a 48 month period after the 
commencement of CSII therapy. 
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Figure 5.3 – Triglycerides (mmol/L) and HDL-C (mmol/L) over a 48 month period after the 
commencement of CSII therapy. 
Table 5.3 – Correlations of standard clinical measures against insulin dose at baseline and after 12 
months and 4 months of CSII use (Spearman correlation used for all tests and significance <0.05 
denoted by *). 
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5.6 Discussion 
This audit is one of the few pieces of evidence focussing on clinical parameters of 
risk in patients with T1D using CSII over an extended time period. Our findings 
indicate HbA1c is significantly reduced within the first 12 months of engaging with 
the therapy and that this is maintained throughout the majority of the treatment 
(Figure 5.1). Despite these positive improvements mean HbA1c remained 
marginally above the national treatment target of between 6.5 and 7.5%. It is 
debateable whether this is a failure or an achievement when considering only 
27.3% of UK hospitals documented the average HbA1c of their patients with T1D to 
be <7.5% (HSCIC, 2014). Furthermore, only 7.5% recorded an average of <6.5%, 
with the Royal Liverpool Hospital narrowly missing these targets for patients with 
T1D in general, and according to this data, those using CSII (Ibid). That said, the 
improvements shown may still transpire to clinical benefits such as reductions in 
microvascular disease, with previous research from the Diabetes Control and 
Complications Trial suggesting a 10% lower HbA1c may relate to a 43% reduction 
in retinopathy risk (DCCT Research Group, 1995).  
In addition to HbA1c reductions, the amount of insulin used by patients also 
significantly decreased during the anterior 12 months of CSII therapy and was 
maintained thereafter (Figure 5.1). This is a welcome finding as the large insulin 
doses typically used by patients with T1D are often regarded as above 
physiological norms and potentially detrimental (Unger, 2010). Although reductions 
in both HbA1c and insulin dose upon commencing the therapy are positive findings 
they are somewhat unsurprising as initial improvements are well documented 
(Pickup, 2002). Furthermore, the long-term maintenance of these parameters is in 
agreement with more recent literature also showing a sustained plateau of 
improved glycaemic control and insulin requirements over 3 - 4 years (Rosenlund, 
2015; Melidonis, 2016). 
These reductions in insulin dose may potentially lead to decreased fat deposition 
and subsequent weight loss and this postulate has been demonstrated in previous 
studies examining patients using CSII therapy (Bode, 2002; Pickup, 2005; 
Morrison, 2008). Unfortunately, our findings were not in agreement, with data at 48 
months highlighting how CSII patients’ BMI remained persistently above 25 kg/m2 
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throughout, indicating that the majority of patients were either overweight or 
obese. Similar findings have also been shown by Melidonis (2016) who reported 
no change in BMI over 4 years of CSII use; however, mean BMI also remained 
consistently >25. Although the patients in the current study did not gain weight 
upon commencing the therapy the findings are still of concern due to the risks 
associated with raised BMI; with some of which, such as CVD, being further 
exacerbated by T1D (Redondo, 2015). Furthermore, it should also be noted that 
our findings give little insight into patients’ lean mass status and it is possible that 
although BMI remained static lean mass may have altered as this is insulin 
mediated (Umegaki, 2015). In fact the correlations shown in Table 5.3 illustrate a 
weak/moderate, positive relationship between insulin dose and BMI which was 
statistically significant and although not demonstrating a causal link still serve to 
illustrate a potential avenue for future research in this population.  
In addition to quantitative reductions in patients’ HbA1c and insulin dose, the 
findings also demonstrate significant improvements in blood pressure after the 
commencement of CSII. As previously mentioned, the majority of patients were 
overweight or obese and their acceptance onto CSII may be suggestive of their 
inability to achieve glycaemic control, which could imply many may be suffering 
from metabolic syndrome (Chillarón, 2010). If this is the case the results suggest 
that prior to the commencement of the therapy the majority of patients were 
borderline hypertensive (according to NICE guidelines of 130/80mmHg); however, 
over the subsequent 48 months gradual reductions in blood pressure can be seen 
into the normal range (NICE, 2015). These significant decreases in both systolic 
and diastolic blood pressure, which can be seen in Table 5.2 and Figure 5.2, are 
favourable findings when considering that only 73.4% of patients with T1D achieve 
targets of 140/90mmHg and the associations of blood pressure with micro and 
macro-vascular diseases (HSCIC, 2014; Maahs, 2005). Despite this it should be 
noted that these long-term changes in blood pressure are atypical and have not 
been previously reported elsewhere. Furthermore, it is difficult to accurately 
hypothesise an influencing mechanism. Medication would usually appear an 
obvious candidate to facilitate such a decrease in blood pressure; however, 
pharmacologically driven changes would typically be expected to occur over a 
much shorter time period than 48 months and would almost certainly be more 
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dramatic than the gradual demonstrated decline. Moreover, correlation tests were 
carried out to determine if the reduced insulin requirements of CSII therapy were 
associated any of these changes. The findings from these tests, shown in Table 
5.3, revealed that only the relationship between insulin dose and systolic blood 
pressure at baseline reached statistical significance and that the relationship was 
weak. The deleterious effect of hypoglycaemia upon blood pressure has also been 
previously shown in the literature; therefore, another reasonable proposition may 
be that any reduction in hypoglycaemia mediated by the blood sugar stabilising 
effect of CSII may too be contributing towards these improvements in blood 
pressure (Sommerfield, 2007). Other potential influencing factors may be lifestyle 
improvements such as increased physical activity and positive dietary change 
together with increased education and more contact with healthcare professionals; 
however, none of these were measured but their possible influence justifies 
additional attention.  
On examination of the patients’ lipid profiles it can be seen that for 48 months prior 
to the initiation of CSII total cholesterol, LDL-C, total cholesterol/HDL-C ratio and 
triglycerides changed very little (although the change in triglycerides was 
statistically significant). Likewise, these levels were maintained throughout the 
initiation of the therapy, indicating a generally well-managed group in this respect. 
This profile was further accentuated by data, illustrated in Figure 5.3, showing that 
both before and after the commencement of CSII levels of HDL-C were much 
higher than current recommendations of >1.0 mmol/L, possibly suggestive of a 
group somewhat protected against CVD. Furthermore, Table 5.3 shows an initially 
weak but significant negative relationship between insulin dose and HDL-C and 
positive relationship between insulin dose and triglycerides. These relationships 
both became moderate after 48 months of treatment, possibly suggesting that the 
reduced insulin requirements of CSII may have a positive mediating effect. A weak 
yet significant positive association between insulin dose and total cholesterol/HDL-
C ratio further implies this. Despite these perceived positive findings research 
shows patients with T1D remain at an increased risk from CVD disorders (Brindisi, 
2010). Furthermore, this is not the first time raised levels of HDL-C have been 
reported in this population, with other authors highlighting its occurrence and how 
it is often observed in tandem with elevated levels of the atheroprotective HDL2 
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subfraction, therefore adding further substance to this unusual yet frequently 
observed clinical conundrum (Vergès, 2009). Recent efforts to investigate the 
mechanisms driving this phenomenon have revealed that not all HDL particles are 
the same and that interestingly in patients with T1D these particles often undergo 
glycoxidative changes causing abnormalities rendering them dysfunctional, thus 
reducing or abolishing their potential for reverse cholesterol transport, cholesterol 
efflux and in particular HDL’s antioxidant capabilities (Denimal, 2015). This leaves 
concern that these findings, despite presenting a positive depiction of patients’ 
cardiovascular state, may not be as they initially seem and warrant further 
investigation. 
Despite offering some interesting findings this audit is not without its issues. 
Patients’ medication data in particular would have been most useful to determine 
the role of pharmacological agents in the changes described herein; however, 
details were stored at patients’ G.P. surgeries and collection of these was out of 
the remit of this exercise. This was in part one of the main limitations of this audit 
as the authors only had access to data which was collected retrospectively and 
with little thought given to its future analysis. As such the conditions during which 
the original measurements were carried out are unclear and may therefore cast 
doubt over the quality of the results. A particularly palpable example is the 
measurement of blood pressure which is well known to be affected by various 
external influences (Pickering, 2005). In addition to this patients also invariably 
missed appointments, moved from the area, died or simply ‘disappeared’ for 
periods of time. The substantial amounts of missing data therefore explain the 
disparity in sample size before and after the commencement of CSII. Also, as 
structured education and increased contact with healthcare professionals was 
offered alongside the initial commencement of CSII the sample size can be seen 
to substantially increase; however, measurements taken for all markers diminished 
over the following years. Despite this caution should be taken before assuming 
specific causes for sample size variabilities and it may be useful to consider that 
this data reflects an intensive period of diabetes management which involves the 
fine tuning of insulin doses to ensure optimal care. Also, when comparing the 
findings to results from the National Diabetes Audit, which highlighted how only 
49.8% of patients attending the Liverpool CCG achieved screening for all care 
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processes (which is nevertheless above the national average of 41.3%) perhaps 
indicates that work must be done to investigate the reasons behind this reduced 
follow-up attendance and find ways of reducing future attrition (HSCIC, 2014). 
Furthermore, it should also be noted that the findings are from one trust and as 
such cannot be extrapolated to others.  
Despite these limitations the findings illustrate that patients undergoing CSII 
therapy can achieve improvements in glycaemic control and blood pressure whilst 
using less insulin and that these changes may be accompanied with little or no 
adverse impact upon BMI or lipid profile. It should also be made clear that 
regardless of these positive findings further work remains to be done to elucidate 
the validity of these trends, the mechanistic components which may be driving 
them and improvements to enhance patient outcomes. 
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Eating Behaviours 
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6 - Eating Behaviours 
 
6.1 Abstract 
Continuous subcutaneous insulin infusion (CSII) offers patients the potential to 
liberalise their dietary behaviours; however, research investigating this is sparse 
and dated. To remedy this food frequency questionnaires (FFQs) were given to 
patients from the Royal Liverpool hospital who had been using either CSII (n = 40) 
or MDI (n = 20) for a year or longer. A subgroup of CSII (n = 11) and MDI (n = 9) 
patients were also asked to complete a 5 day food diary. All patients gave 
permission for the author to examine their medical records to document their basic 
clinical parameters. After analysis, the findings showed that some nutrients such 
as fibre and iron in females failed to meet the RNI and that there were subtle 
differences between the treatment groups. For example, the results from the FFQ 
showed that mean energy intake was below the estimated average requirement 
(EAR) for both CSII and MDI groups (1717.7 kcal/day vs. 1886.4 kcal.day; p = 
0.416). This finding was also shown in the food diaries and given that both the 
majority of CSII and MDI patients were either overweight or obese (27.1 kg/m2 vs. 
25.9 kg/m2 respectively) suggests the occurrence of underreporting; which was 
confirmed by the Goldberg equations. Total carbohydrate (CHO) consumption was 
shown by both the FFQs and food diaries to be below the RNI of 50%, however it 
should be noted that consumption of total sugars was above the RNI for males 
and female using both CSII and MDI. This may be partly explained by the 
consumption of fruit which was also higher in those using CSII. Despite these 
differences the diets between the two groups were largely homogenous, with no 
statistically significant variables. This suggests that patients using CSII chose not 
to take advantage of the flexibility the device infers and did not change their diet to 
one more detrimental to health upon commencing the therapy.  
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6.2 Introduction 
Role of diet for the treatment of T1D 
Along with insulin, nutrition is delicately entwined in the management of T1D and 
the implication of diet in the quest for normoglycaemia is far reaching. On one 
hand the consumption of food and drink provides a complex ‘package’ of nutrition 
required for human survival and health, yet on the other foodstuffs are often a 
prominent source of carbohydrates (CHO); the component of food which most 
affects blood glucose and the management of which is of chief concern for 
patients with the disease. 
Although diabetes is not a recently discovered phenomenon, with Egyptian 
records of cases dating back to 1500BC, it was not until 1797 that a Scottish 
physician with an interest in diabetes named John Rolo had the pioneering notion 
that a diet high in fat and protein and low in vegetables and grains could be used 
to limit the symptoms of the disease (Stylianou, 2008). This was a success and 
this principle was elaborated on by L. Traube who confirmed in 1816 that it was 
indeed the dietary intake of CHO and its subsequent digestion which results in the 
increased amounts of sugar typically seen in the urine of patients with diabetes 
and that reducing CHO consumption can alleviate this (Guthrie, 2009). Over the 
following century this concept bloomed and a number of dubious ‘fad’ diets 
ensued, including the ‘milk diet’ and the ‘oatmeal cure’ (Moran, 2004). Little 
explanation is required to describe the substance of these diets and the fact that 
their use was relatively short-lived is perhaps an indication of the quality of their 
results (Ibid). 
Despite the obvious failure of many of these unconventional dietary approaches in 
1915 Frederick Allen, a diabetes specialist from the U.S., together with a physician 
named Elliott P. Joslin devised perhaps the most severe dietary approach to date 
for the treatment of diabetes. This consisted of extreme calorie restriction; often 
referred to as a starvation diet. Modern recalculations suggest that 70% of calories 
consumed by patients undergoing the diet were derived from fat, 10% from CHO 
and 20% from protein and although not providing a cure the pair had initial 
success in prolonging the lives of patients (Westman, 2006). Despite offering 
some respite from diabetes, the patients were instead condemned to the myriad of 
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new hazards associated with malnutrition and the obvious risk of death by 
starvation (Mazur, 2011). Adherence to the diet was understandably difficult and 
physicians (including Allen and Joslin) and patients alike resented the brutality of 
the therapy; however, it had a moderate amount of success in extending life and 
allowed many patients to survive, albeit miserably, until insulin came into 
production (Sawyer, 2009).  
After the treatment of diabetes with insulin became commonplace the medical 
community were slow to realise that dietary CHO could be increased without 
immediate risk of hyperglycaemia. Dr William Sansum took note of this and in 
1926 proceeded to increase the CHO intake of his patients to great effect 
(Tompkins, 1977). His patients appreciated the increased dietary flexibility and the 
ability to lead a conventional life (Ibid). This was further enhanced in 1930 when 
Karl Stolte developed a clear and easy to understand method of insulin therapy 
consisting of 3 or more injections before meals and in return patients were allowed 
to consume a ‘free diet’ which was recommended to be high in CHO (Howorka, 
1991).  
In the following years confusion reigned regarding the superiority of different 
dietary approaches for the treatment of T1D, with the ADA initially suggesting that 
a low CHO diet was an integral part of diabetes care which could not be avoided; 
yet 12 years later in 1971, based upon evidence implicating dietary fat in heart 
disease, the advice was changed to the promotion of a high CHO, low fat diet 
(Sawyer, 2009). These shifting recommendations were typical of the era and as 
the use of insulin became more established and patients routinely enjoyed longer 
lives it became clear that although mortality caused directly as a result of diabetes 
was decreasing, patients were now dying from complications; namely vascular 
disease (Ibid). This presented important questions regarding nutrition. What is the 
best diet for the treatment of T1D and what dietary advice should patients receive? 
Although over the years many combinations of macronutrient proportions have 
been tested, the stark reality remained. For the first time evidence based dietary 
guidelines were required with a view to improving not only glycaemic control, but 
also reducing the risks of mortality from these complications. This resulted in a 
series of guidelines developed by different agencies which have evolved over the 
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years as evidence has become available; however, rather than converging to a 
consensus these recommendations may have created even more confusion.  
Nutritional Guidelines 
Although the ADA had been producing dietary guidelines since 1971 it was not 
until 1982 that Diabetes UK (then known as the British Diabetic Association) 
developed the first evidence based dietary recommendations for those with 
diabetes (Nuttall, 1979; British Diabetic Association, 1982). Over the following 
years both organisations, along with the European Association for the Study of 
Diabetes (EASD), released subsequent ‘best practice’ guidelines as more 
research became available (Lean, 1991; DNSG Study Group, 2000; ADA, 2002; 
Connor, 2003; Mann, 2004; Bantle, 2008; Evert, 2013; Evert, 2014; ADA, 2015). 
Although this review will not describe the differences between each of these 
historical guidelines in detail a summary from the last 15 years can be seen in 
Table 6.1 – 6.3.  
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Table 6.1 – USA Dietary guidelines from the last 15 years devised by the ADA 
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 Table 6.1 (Con’t) 
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Table 6.2 – European Dietary guidelines devised by the EASD 
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Table 6.3 – UK Dietary guidelines devised by Diabetes UK 
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The most recent UK nutrition recommendations for patients with diabetes were 
outlined in 2011 by Diabetes UK (Dyson, 2011). These took into account the 
evidence which had accumulated since the publication of the previous 2003 
document. These guidelines are currently being used to inform best practice in the 
UK and as such it is important that some of the most prominent recommendations 
receive a more detailed description so the reader might understand the current 
guidelines in relation to the broader treatment of T1D. 
Carbohydrates  
CHO is often thought of as the nutritional mainstay of glycaemic control and ever 
since the first set of evidenced-based dietary guidelines by Diabetes UK were 
issued in 1982 the benefits of consuming a diet rich in CHO have been at the fore. 
Previous recommendations in 2003 suggested that 40 - 60% of total energy intake 
should comprise of the macronutrient; a challenging target to achieve which 
signified the end of guidelines advocating CHO restricted diets and instead 
represented a shift in focus towards recommendations similar to those offered to 
the general population. The recent guidelines from 2011 are no different; however, 
specific numerical recommendations were abandoned due to a lack of 
confirmative evidence, with intervention studies suggesting the dietary 
manipulation of CHO intake actually has little effect on glycaemic control (Dyson, 
2011). Despite this it is clear that the actual amount ingested very much 
determines post-prandial blood glucose and therefore the insulin required to 
metabolise this should be carefully considered; ideally through the use of an 
appropriate CHO counting strategy (Ibid). Additionally, it is also clear that the type 
of CHO is an important factor for glycaemic control and as such the guidelines 
suggest patients consume a diet rich in both low glycaemic index (GI) foods and 
fibre (Dyson, 2011). Furthermore, the recommendations also highlight that sucrose 
has no different effect on glycaemic control than other types of CHO and that 
fructose may be used as a replacement to decrease post-prandial glycaemia and 
sweeteners to reduce HbA1c, if consumed within the daily intake levels (Ibid).  
Fat 
The intake of fat for patients with diabetes is recommended to comprise of 35 - 
40% of total energy intake and that reductions in saturated and trans fats and their 
105 
 
replacement with monounsaturated fats is thought to be beneficial for minimising 
cardiovascular disease (CVD) risk (Dyson, 2011). Furthermore, previous 
recommendations for polyunsaturated fat intake to comprise of 10 – 20% total 
energy have been omitted from the most recent guidelines due to a meta-analyses 
by Ramsden (2010) suggesting that an increase in n-6 fatty acids without a 
corresponding increase in n-3 fatty acids is associated with increased mortality 
from CVD (Connor, 2003). Consequentially recommendations for the consumption 
of oily fish, high in n-3 fatty acids, has increased from 1 to 2 portions per week to 
at least twice per week and that despite conflicting evidence regarding adverse 
effects these oils may have on blood lipids the benefits are currently thought to 
outweigh the risks (Dyson, 2011). Despite recommendations it should be noted 
that this is an ongoing debate, with some research suggesting that the only 
adverse effects of n-3 fatty acids may be an increase in LDL-C; however, the 
particles have been shown to be less prone to oxidative modifications and 
therefore likely to be less atherogenic (De Caterina, 2007). Furthermore, fewer 
risks may also be posed if these changes are accompanied by an increase in 
particle size and without a corresponding increase in particle number; however, 
the evidence is still emerging regarding these aspects (Sneiderman, 2014).  
Protein 
As mentioned previously, the authors explain that there is no true consensus 
regarding the ideal proportions of macronutrients in the diet to achieve optimal 
glycaemic control and there is some evidence suggesting that excessive protein 
intake in the form of meat may be associated with an increased risk of T2D and 
CVD (Dyson, 2011). Therefore the protein recommendations offered by Diabetes 
UK have remained in a state of flux, with each set of updated guidelines differing 
as new evidence becomes available (British Diabetic Association, 1982; Lean, 
1991; Connor, 2003). The most recent 2011 recommendations do not deviate from 
this trend and rather than suggesting an optimal intake of protein instead opt to 
omit a recommendation altogether (Dyson, 2011).  
Fibre 
Although the health benefits of fibre upon lipid profile, gastrointestinal health and 
CVD risk are well documented there is little conclusive evidence to suggest a 
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beneficial effect on glycaemic control; as such there are no specific quantitative 
recommendations for those with diabetes (Dyson, 2011). The authors of the most 
recent Diabetes UK guidelines instead advise that efforts should be made for 
patients to attempt to meet the dietary reference values (DRV) for the general 
population (Ibid).  
Salt 
Diabetes UK stand by their long-standing recommendation of <6 g salt per day in 
the 2011 guidelines (Dyson, 2011) This has been a permanent fixture in the 
document since 1991 and the blood pressure lowering effects associated with 
decreasing salt intake are well documented (Ibid; He, 2007). In fact evidence 
suggests that reducing salt intake to <3 g per day would have further benefits, but 
the guideline authors illustrate that this would require significant contributions from 
the food industry (Ibid). Furthermore, recent National Diet and Nutrition Survey 
(NDNS) data highlighting how the UK population are still consuming an average of 
7.2 g salt per day and despite the beneficial effects, illustrates how 
recommendations of 6 g per day may not be an optimum target, but rather a more 
realistically achievable aim (NDNS, 2014).  
Implications of CSII upon diet 
Although a critical appraisal of the evidence concerning CSII and diet has already 
been presented in the Literature Review chapter (see page 30), it is important to 
briefly reiterate some of the most contentious points as these form the rationale for 
the present study. The introduction of CSII may be associated with the opportunity 
for patients to relax their diet and there is dated evidence to suggest that patients 
take advantage of this without detrimental effects; however, the treatment methods 
and technology used throughout these studies is now antiquated. Therefore it is 
unknown if commencing the therapy using modern CSII treatment regimens and 
technology has any impact upon the eating behaviours of patients.  
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6.3 Aims and Objectives 
Aim 
This aim of this section of the study is to determine if the use of CSII has any 
impact upon eating behaviours when compared to those using MDI. 
Objectives 
 To determine basic patient characteristics through an assessment of 
participant medical records. 
 
 To assess the eating behaviours of patients using either CSII or MDI 
therapy using food frequency questionnaires and food diaries. 
6.4 Methods 
An overview of the methods used to determine the eating behaviours of patients 
who participated in the cross-sectional study are described in the General 
Methods chapter (see page 45). In brief, food frequency questionnaires (FFQs) 
and 5 day weighed food diaries were used to elucidate the diets of patients using 
either CSII or MDI (Examples can be seen in appendices 12.5). The data resulting 
from these dietary assessment methods allowed the author to determine the mean 
dietary intake of a variety of macro and micronutrients which were then compared 
by treatment group against percentage energy intake and/or appropriate dietary 
reference values (DRV). Furthermore, data resulting from the FFQs enabled food 
items to be separated into discreet categories, allowing comparisons of consumed 
food types to be made between treatment groups.  
In addition to dietary information, basic characteristics (i.e. age and sex) of the 
participants were recorded from their medical records. This data allowed the 
author to not only recognise the attributes of the sample, but also split the dietary 
assessment data by gender to reveal any gender-specific differences.   
Written consent was taken from all participants who took part in this section of the 
study. It should also be noted this chapter will only describe the dietary findings 
from the cross-sectional study. Longitudinal dietary data will be described later on 
in this the in the ‘case studies’ chapter (see page 206). 
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 Statistical Analysis 
All data were analysed using Statistical Package for Social Sciences (SPSS) 
(v.21). Initially the data was subjected to descriptive statistics; after which 
normality was determined by using the Shapiro-Wilks test. Any data which could 
be normalised using a log10 transformation was then analysed using Student’s t-
test (the assumption of homogeneity of variance was also tested in this instance). 
Any data which could not be normalised was subjected to non-parametric Mann-
Whitney U tests. All findings with a p-value <0.05 were deemed to be statistically 
significant.  
To discover if any underreporting was occurring the Goldberg equations were 
used. The outcome of these equations were then used to determine if the ratio of 
reported energy intake compared to basal metabolic rate fell within or outside 
predefined cut-off values. Any ratios which fell outside these parameters indicated 
either under or over reporting.  
The formulas used to produce the cut-off values are shown in Figures 6.1 and 
6.2:- 
 
 
Before these formulas could be used the following values had to be determined 
and some assumptions made. 
EIrep - Energy intake (derived from findings). 
BMR - Basal metabolic rate (estimated using the Schofield equations) (Schofield, 
1985). 
Figure 6.1 – Goldberg equations (adapted from Black, 2000) 
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PAL - Physical activity level (estimated at 1.55 for light activity as the actual value 
was not known; however, this is an acceptable substitute) (Black, 2000). 
exp - Exponential function. 
s.d.min - -2 for 95% C.I. or -3 for 99.7% C.I. 
s.d.max - +2 for 95% C.I. or +3 for 99.7% C.I. 
n - Sample size. 
S – S-factor is calculated using the following equation:- 
 
 
Before this formula could be used the following values had to be determined and 
some assumptions made. 
CV2wEI - Within-subject coefficient of variation in energy intake (estimated at 23% 
which is an acceptable approximation) (Black, 2000). 
CV2wB - Coefficient of variation of repeated BMR measurements of precision of 
estimated compared with measured BMR (estimated at 8.5% which is an 
acceptable approximation) (Black, 2000). 
CV2tP - The coefficient of variation derived from the mean and standard deviation 
of a study and includes true between subject variation, an element of within-
subject variation and methodological errors (estimated at 15% which is an 
acceptable approximation) (Black, 2000). 
d – Number of days of dietary assessment. 
 
 
 
Figure 6.2 – S factor equation (adapted from Black, 2000) 
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6.5 Results 
 Sample Characteristics 
All patients (n = 60) (40 using CSII vs 20 using MDI) agreed to complete an FFQ. 
A subsample (n = 20) patients (11 using CSII vs 9 using MDI) agreed to complete 
a food diary. Selected sample characteristics are described in the tables below 
(see Tables 6.4 and 6.5).  
 
 
Food Frequency Questionnaire 
The macronutrient intake of patients who completed the FFQ can be seen in Table 
6.6 and the principle findings are as follows.  
Energy intakes for groups using both CSII and MDI were found to be below the 
estimated average requirements (EAR) (2550 kcal/day for males and 1940 
kcal/day for females) regardless of gender (COMA, 1991), although males using 
CSII in particular failed to meet recommendations by consuming only 61.6% of the 
EAR. 
The dietary intake of CHO for both CSII and MDI groups were marginally below 
the general population RNI guidelines of 50% energy intake per day (COMA, 
1991). This was not gender specific as males using CSII and MDI consumed 
Table 6.4 – Basic sample characteristics of participants who completed FFQs. (Data is either 
presented as frequencies or mean averages with standard deviation). 
Table 6.5 – Basic sample characteristics of participants who completed food diaries. (Data is either 
presented as frequencies or mean averages with standard deviation). 
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42.3% and 39.8% respectively and females using CSII and MDI consumed 44.4% 
and 44.3%. Despite this, the recommended RNI for total sugar currently suggests 
that it should not contribute to more than 90 g/day yet both groups exceeded this 
with those using CSII consuming 102.0 g/day and those with MDI consuming 96.0 
g/day (European Food Safety Authority, 2009). Both groups, irrelevant of gender, 
consumed less than the recommended consumption of 30 g of fibre per day, with 
the mean average consumed by those using CSII therapy being 15.9 g/day and 
16.2 g/day by those using MDI.  
Protein intake was slightly higher in those using MDI (89.7 g/day) compared to 
those using CSII (79.7 g/day) and when looking at the contribution this made to 
average energy intake it can be seen that the differences were not gender specific 
and non-significant (p = 0.802). 
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1 - percentage of daily EAR 
2 - percentage of daily RNI 
Table 6.6 – Mean intake of macronutrients (with 95% CI) of patients who completed a FFQ, percentage energy intake (those which are instead based 
upon DRVs are indicated) and p-values derived from Student’s t-test (or Mann-Whitney U test if data was non-normal). 
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The intake of total fat was close to Diabetes UK recommendations, which suggest 
the macronutrient should not contribute to more than 35-40% average energy 
intake per day (Dyson, 2011). This was shown to be regardless of treatment or 
gender, with males using CSII and MDI consuming 33.3% and 39.2% of their 
average energy intake respectively, whereas females using CSII and MDI 
consumed 36.8% and 34.5%. When looking at the intake of saturated fat it can be 
seen that consumption was slightly higher than the RNI which suggests it should 
contribute to no more than 11% of average energy intake. Males using CSII and 
MDI were shown to consume 12.5% and 14.4% respectively (Dyson, 2011). This 
was also shown in females using both CSII and MDI, with consumption being 
14.1% and 12.6%. 
None of the differences in macronutrient consumption between treatment groups 
reported by the FFQ were found to be statistically significant. To better visualise 
the differences of macronutrient consumption between treatment groups and 
gender in relation to average daily energy intake the findings have been 
consolidated into a graph (Figure 6.3). 
 
 
Figure 6.3 – Macronutrient consumption derived from FFQ data split by treatment and gender 
in relation to percentage energy intake. 
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The micronutrient intake of participants who completed the FFQ can be seen in 
Table 6.7 and please see Figure 6.4 for a visual comparison.  
When looking at the intake of sodium the data showed that both treatment groups 
were consuming considerably more sodium than RNI suggestions of 1600 mg/day, 
with those using CSII consuming 2684.5 mg/day and those using MDI consuming 
2927.3 mg/day. These findings were irrelevant of gender.  
Furthermore, all patients were shown to meet the RNI for calcium consumption 
with those using CSII on average consuming 928.7 mg/day and those using MDI 
consuming 974.8 mg/day. This was again not gender specific, with both groups 
consuming slightly above the RNI.  
Iron consumption, on average initially appears to meet the RNIs of 8.7 mg/day for 
males and 14.8 mg/day for females. However, a closer look at the gender 
differences reveal that the consumption of iron by males using both CSII and MDI 
was in excess of the RNI (by consuming 124.2% and 145.3% of the RNI 
respectively) and conversely female participants using both CSII and MDI failed to 
meet the RNI by consuming only 67.9% and 76.9%.  
The consumption of Vitamin C was found to be over double RNI suggestions of 40 
mg/day for adults, with those using CSII consuming on average 109.5 mg/day and 
those using MDI consuming 104.5 mg/day.  
This trend of excess consumption can also be seen in all B vitamins; however, it is 
Vitamin B12 which is perhaps the most striking due to the unusually high 
consumption throughout all treatment groups and across genders. For example, 
those using CSII consumed on average 6.8 µg/day and those using MDI 
consumed on average 7.7 µg/day, both of which far exceed recommendations of 
1.5 µg/day.  
None of the differences between micronutrient variables were statistically 
significant between the different treatment groups. 
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 Table 6.7 – Mean micronutrient intake (with 98% CI) of participants who completed an FFQ, percentage comparisons against daily RNI and p-values 
resulting from Student’s t-test or Mann-Whitney U test for any non-normal data. 
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In addition to macronutrient and micronutrient intake the output from the FFQ also 
estimates the type of food products consumed. These are split into broad 
categories and are summarised in Table 6.8 and have been consolidated into a 
graph (see Figure 6.5).  
The findings from this illustrate how although many of the variables were largely 
homogenous there were distinct differences with some food items. In particular the 
consumption of cereal and meat products was less in those using CSII compared 
to those using MDI (195.5 g/day vs 240.2 g/day and 99.0 g/day vs 129.9 g/day 
respectively). Also, the consumption of fruit was higher in those using CSII, with 
234.2 g/day being consumed, as opposed to 160.0 g/day by those using MDI. 
Furthermore, the consumption of vegetables was also shown to contribute greatly 
to the diets of both treatment groups, with 242.9 g/day being consumed by those 
using CSII and 247.9 g/day by those using MDI. 
Despite differences between groups none of the variables met statistical 
significance. 
 
Figure 6.4 – Micronutrient consumption derived from FFQ data split by treatment and gender in 
relation to percentage RNI. 
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Table 6.8 – Food item consumption between treatment groups (with 95% CI) and p-values 
resulting from Student’s t-test or Mann-Whitney U test for any non-normal data. 
Figure 6.5 – Food items consumed by participants using either CSII or MDI as described by FFQ. 
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Food Diaries 
The macronutrient intake of patients who completed the food diaries can be seen 
in Table 6.9 and to better visualise the differences between treatment groups and 
gender in relation to average daily energy intake the findings have also been 
consolidated onto a graph (Figure 6.6). The principle findings are as follows. 
The reported energy intake derived from the food diaries indicates that participants 
using CSII were consuming below the EAR (2500 kcal for males and 1940 kcal for 
females), with their average energy intake being 1866.6 kcal/day (COMA, 1991). 
When looking at the data in terms of gender it can be seen that whereas females 
using either CSII or MDI virtually met the EAR (by consuming 94.4% and 101.5% 
of the EAR respectively), the males using CSII failed to meet the recommended 
guidelines by consuming only 75.7% of the EAR. 
The reported consumption of CHO was shown to be slightly short of meeting RNIs 
suggesting that the macronutrient contribute towards 50% of average energy 
intake (COMA, 1991). Males using CSII and MDI consumed 49.3% and 44.3% 
respectively and females using CSII and MDI consumed 45.1% and 45.0%. In a 
similar manner, although daily recommendations of total sugar are 90 g/day the 
data revealed by both the FFQ and food diaries suggest that this may be 
exceeded by those in the CSII group and may be potentially suggestive of dietary 
relaxation (European Food Safety Authority, 2009). Those using CSII were shown 
to consume 99.8 g/day and those using MDI were shown to consume 88.6 g/day. 
Also similar to findings previously shown by the FFQ, the consumption of fibre was 
less than the RNI of 30 g/day, with those using CSII on average consuming 11.4 
g/day and those using MDI consuming 20.3 g/day. This difference was shown to 
be highly significant (p = 0.001).
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1 - percentage of daily EAR 
2 - percentage of daily RNI 
Table 6.9 – Mean intake of macronutrients (with 95% CI) of patients who completed a food diary, percentage energy intake (those which are instead 
based upon DRVs are indicated) and p-values derived from Student’s t-test (or Mann-Whitney U test if data was non-normal). 
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The consumption of protein was shown to be higher in the MDI group, who 
consumed on average 89.9 g/day compared to the CSII group who consumed 
69.0 g/day; however, these differences were not gender specific. When focussing 
on the nitrogen content it can also be seen that similar differences were again 
shown, with those using CSII consuming 12.4 g/day compared to 19.2 g/day being 
consumed by those using MDI and this was shown to be statistically significant (p 
= 0.016).  
The consumption of total fat was in virtual agreement with Diabetes UK dietary 
guidelines suggesting that it contribute to no more than 35 – 40% of average daily 
energy intake, with males using CSII and MDI consuming 31.4% and 34.6% 
average daily energy intake respectively and females using CSII and MDI 
consuming 37.9% and 33.9% (Dyson, 2011). When looking at the consumption of 
saturated fat it can be seen that males using CSII and MDI slightly exceeded 
recommendations suggesting the nutrient contribute to no more than 11% of the 
average daily energy intake. The consumption was 12.1% and 14.0% respectively. 
Females using MDI consumed 11.9%; however, it should be noted that females 
Figure 6.6 – Macronutrient consumption derived from food diary data split by treatment and 
gender in relation to percentage energy intake. 
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using CSII consumed considerably more than recommendations as their dietary 
intake contributed to 17.1% of their average daily energy intake. 
Similarly to the results previously described from the FFQ, the majority of 
differences regarding macronutrient consumption between treatment groups were 
found not to be statistically significant (apart from those previously described).  
The micronutrient intake of participants who completed the food diaries can be 
seen in Table 6.10 and Figure 6.7 offers a visual comparison. 
The dietary intake of sodium exceeded the RNI of 1600 mg/day in a similar 
manner to findings revealed by the FFQ. Those using CSII consumed on average 
2724.1 mg/day and those using MDI consumed 3287.0 mg/day. Even though both 
groups exceeded the RNI by a high percentage, males consumed more than 
females in both the CSII group (204.85% vs 150.5% respectively) and MDI group 
(242.4% vs 186.9% respectively).  
When looking at the intake of potassium it can be seen regardless of treatment 
less than the RNI (of 3500 mg/day) was consumed (COMA, 1991). This was 
particularly true in those using CSII and the difference between treatments was 
deemed statistically significant (p = 0.040). In particular it can be seen that females 
using CSII only consumed 58.7% of the RNI and are therefore are likely to be 
driving the reduced consumption in the CSII group. 
The findings also highlighted that both CSII and MDI groups exceeded the RNI for 
calcium intake; however, a closer inspection reveals that whilst males using both 
CSII and MDI may be driving this by considerably exceeding the RNI (with intakes 
of 152.0% and 128.6% respectively), females using CSII are failing to meet the 
recommendations with 85.2% of the RNI being consumed.  
The findings regarding magnesium consumption also present gender specific 
findings. Although both genders using CSII MDI meet the RNI it can be seen that 
females using CSII only achieve 63.1% of the RNI of 270 mg/day. The difference 
between groups is also statistically significant (p = 0.046); however, it is likely to be 
this female consumption which is promoting this difference. 
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When looking at the consumption of iron it can be seen that there were again 
gender specific differences. Females using CSII and MDI consumed considerably 
less (42.6% vs 79.1% of RNI) and males considerably more (182.8% vs 141.0% of 
RNI) than recommendations of 8.7 mg/day for males and 14.8 mg/day for females 
(COMA, 1991).  
Vitamin A data also shows that the regardless of treatment or gender there was a 
general failure to meet RNI suggestions of 700 µg/day for males and 600 µg/day 
for females (COMA, 1991). Males using CSII and MDI consumed only 30.8% and 
36.4% of the RNI respectively and females using CSII and MDI consumed 37.6% 
and 35.8% of the RNI. These differences were not shown in the data described 
previously from the FFQs.  
In a similar manner to findings from the FFQ, the food diary results show that the 
consumption of vitamin C was excessive when compared to the RNI of 40 mg/day, 
with those using CSII consuming 62.8 mg/day and those using MDI consuming 
71.0 mg/day. 
These excessive intakes were also seen throughout findings pertaining to the B 
vitamins, with consumption generally exceeding RNIs. In particular it is noteworthy 
that intake of vitamin B12 was more than double the RNI of 1.5 µg/day and is 
similar to findings previously shown from the FFQ data.  
Again, in a similar manner to findings from the FFQ, consumption of vitamin C also 
appeared to be excessive when compared to the RNI of 40 mg/day, with those 
using CSII consuming an average intake of 62.8 mg/day and those using MDI 
consuming on average 71.0 mg/day. 
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Table 6.10 – Micronutrient intake (with 98% CI) of participants who completed a food diary, percentage comparisons against daily RNI and p-values 
resulting from Student’s t-test or Mann-Whitney U test for any non-normal data. 
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Goldberg Equations 
As a number of participants have a BMI >25 and energy intakes were often 
reported as being below the EAR it is reasonable to suspect that a degree of 
underreporting may have occurred. Therefore the Goldberg equations were used 
to determine if this was the case. The findings can be seen in Table 6.11. 
 
 
As can be seen in Table 6.11, 23.3% of participants who completed the FFQ and 
20.0% of participants who completed the food diary were outside of the 
parameters (all below minimum cut-off) and therefore classed as under reporters. 
In both groups 50% of under reporters were males and 50% were female. 
Figure 6.7 – Micronutrient consumption derived from food diary data split by treatment and 
gender in relation to percentage RNI. 
 
Table 6.11 – Percentage participant EIrep : BMR ratios defined from FFQ and food diary responses 
which fall inside and outside predefined Goldberg cut-off parameters. 
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Goldberg equations could not be applied to 10.0% of participants who completed 
the FFQ and 5.0% of participants who completed the food diary due to a lack of 
appropriate weight data. 
6.6 Discussion 
The findings from both dietary assessment methods, although in many ways 
largely homogenous, serve to provide useful insights into the eating behaviours of 
patients using CSII therapy compared to those using MDI. Also, despite the 
general similarities it would be disingenuous to say that no differences exist at all. 
Between the two groups one can note a number of subtle yet interesting variances 
and an even smaller proportion of these which are unexplainable by the author. 
An example of this can be seen when looking at the average energy intake of the 
participants, where the majority were failing to meet the EAR for energy intake and 
that it was males using CSII in particular who were consuming the least calories of 
all. This was shown in data derived from both the FFQ and food diaries and the 
rationale behind this unexpected finding is unclear. It is interesting to note; 
however, a disparity between this failure to meet the EAR and a BMI >25 which 
was recorded for the majority of participants. This is suggestive of underreporting; 
a phenomenon widely cited in the literature, particularly in those who are 
overweight or obese and is a potential issue which required addressing (Black, 
2000). In response to this the author employed the Goldberg equations to 
determine any incidence of bias and discovered that there was indeed evidence of 
underreporting in 20.0 - 23.3% of responses. The implications of this are that the 
findings for energy intake may be conservative at best or unrepresentatively low at 
worst. Interestingly, when this incidence of underreporting was split by gender 
exactly 50% of biased respondents were found to be from males and 50% from 
females, which offers little insight into the curiously low energy intakes for male 
participants using CSII therapy. 
Total energy aside, the intake of CHO was found to occur in greater quantities 
than any other dietary variable and regardless of treatment the macronutrient 
contributed towards approximately 50% of the participants’ average daily energy 
intake; a figure recommended as being ideal for the general public (COMA, 1991). 
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This may initially appear favourable; however, it says little about the quality of 
CHO and closer inspection reveals that the consumption of total sugars, 
particularly in those using CSII, was above the RNI of 90 g/day (European Food 
Safety Authority, 2009). Interestingly, when looking at the types of CHO consumed 
it can be seen that the group using CSII ate substantially more fruit than both the 
public and those using MDI, who although preferring sugary foods consumed 
these in lower quantities. This high intake of fruit may have potential glycaemic 
implications and it is noteworthy that the participants using CSII who completed 
the food diary actually had higher HbA1c than the group using MDI. Despite this it 
remains difficult to say with certainty the impact this increased fruit intake had 
upon glycaemia as the sugars in these foods are generally prevented from rapid 
absorption by cell walls (unless destroyed in products such as smoothies etc.). 
Indeed, one wonders the effectiveness a dietary approach may have in patients 
such as these who are having issues with glycaemic control. After all, restricting 
the intake of dietary CHO results in the decreased requirement of insulin required 
to metabolise net glucose, thus improving glycaemia. This is not a new strategy, 
with examples discussed previously in the introduction of this chapter, and 
proponents gaining momentum within the modern literature, with studies showing 
rapid improvements in the blood sugar of patients with T2D who adhere to the diet 
(Yancy, 2005; Gannon, 2004; Boden, 2005). Despite these findings there is a 
dearth of literature focussing specifically on those with T1D, with the majority of 
evidence and indeed the guidelines citing that the manipulation of CHO has little 
impact upon HbA1c (Dyson, 2011). There are exceptions though; an example 
being a study by Nielsen (2012) which investigated 48 patients with T1D who were 
instructed to consume a CHO restricted diet (<75 g/day with a correspondingly 
adapted insulin dose) and to attend a supportive education course. The authors 
found that only half remained on the diet after 4 years, but those that did 
experienced improved glycaemic control and modestly decreased insulin 
requirements. In addition to adherence issues it should be noted that the 
appropriateness of a low CHO approach is a fiercely debated topic with potential 
adverse effects being cited, such as increased risk of CVD, liver and kidney 
damage and osteoporosis which supposedly result from an excess intake of fats 
and protein, often from animal sources (Bilsborough, 2003). In actual fact the 
evidence for the occurrence of these issues is dubious and existing studies 
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investigating this are sparse (Ibid; Feinman, 2015). If anything this dearth of 
research together with segments of patients such as those described in the 
present study that consume a diet high in total sugars and present unfavourable 
HbA1c levels illustrate the need for robust studies clarifying the risks or benefits of 
dietary approaches such as these which may improve treatment. Furthermore, it 
should also be remembered that individuals do not generally consume single 
nutrients and that the complex ‘food matrix’, consisting of an array of high and low 
GI foods, will have an overall impact upon glycaemic load and subsequent ability 
to control hyperglycaemia.  
As well as the increased consumption of sugars it is also interesting to note that 
the intake of fibre was only half the RNI of 30 g/day in patients using both 
treatments regardless of gender. Although previous data focussing on those with 
T1D is lacking, NDNS findings suggest the average fibre consumption by adults in 
the UK is only 13.7 – 13.9 g/day, which is far below recommendations that could 
be said are unrealistically high and potentially setting people up to fail (NDNS, 
2014; SACN, 2015). These low intakes may also be indicative of the types of food 
items consumed, in which fibre is not a naturally integrated component, with Bates 
et al. (2014) illustrating that the majority of dietary fibre is obtained from the 
consumption of cereals and vegetables. That said it is curious that the dietary 
intake of fibre was not only close to that achieved by the general population, but 
that the overall diet was also high in fruits and vegetables, with participants on 
average consuming far more of these food groups than the public. Furthermore, 
the participants’ diet also contained a large cereal component (although admittedly 
the types of cereal products were not specified in the FFQ). Despite this the issue 
of low fibre intake remains and questions regarding the quality of these fruit, 
vegetable and cereal products therefore spring to mind. Furthermore, it is well 
documented that the consumption of a fibre rich diet is associated with decreased 
risks of colorectal cancer, rectal cancer and T2D, whilst inferring no impact on 
body weight (Ibid). A number of RCTs also demonstrate a reduction in risk of CVD 
(although the majority use doses >30 g/day, which although being in line with 
recommendations far exceeds typical daily intake) (Van Horn, 2010). The 
particularly low consumption of fibre seen in the participants is therefore 
128 
 
concerning, particularly with regards to the inherent risks of complications 
bestowed upon those with T1D.  
In a similar manner to the total CHO findings described previously, total fat also 
appeared to be either within or very close to Diabetes UK guidelines which 
suggest the macronutrient should not contribute to more than 35 – 40% average 
daily energy intake. However, SFA consumption was shown to be higher than 
recommendations of not more than 11% of average energy intake per day (COMA, 
1991). In fact findings from the dietary assessments revealed general consumption 
to be at levels similar to those found in the general public, where SFA contributed 
towards 12.6% average daily energy intake (NDNS, 2014). That said, this was not 
the case for females using CSII who consumed 17.1%; considerably more than 
recommendations; however, given that energy intake was below the EAR it could 
be argued that perhaps the total amount may be more important that the 
percentage of energy intake. In the case of females using CSII who completed 
food diary this equates to 34.8 g/day (± 18.6 g/day) (data not shown in tables) 
which still exceeds recommendations of 20 g/day for females (British Nutrition 
Foundation, 2013). It is difficult to source the specific foods which may be 
responsible for this; however, despite the FFQ illustrating that meat consumption 
was not particularly high there was no indication of diary intake which could be a 
contributing factor. This is somewhat concerning, particularly for patients with T1D, 
as failures to meet guidelines may in turn have health implications. Findings from 
the EURODIAB study have made it clear how the high saturated fat and high 
cholesterol diets often favoured by European patients are associated with 
detrimental changes to serum lipids (Toeller, 1999). Furthermore, the study also 
highlighted how nutrient intake, in particular high fat and low fibre diets, are also a 
predictor of waist to hip ratio (Toeller, 2001). This measure of adiposity has been 
demonstrated to have an association with the development of atherosclerosis and 
when combined with evidence showing how poor dietary choices may also have a 
negative impact upon endothelial function and promote inflammation is an 
alarming cause for concern (Ge, 2014; Soedamah-Muthu, 2013; van Bussel, 
2013). This is particularly worrying as CVD is the major cause of death in those 
with T1D and patients are at an increased risk of vascular disease compared to 
the general population. Despite presenting alarming findings this evidence is not 
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without its critics. For example, it may be difficult to truly define a high fat diet and 
it has been argued that some ‘high fat’ diets may also be rich in refined CHO that 
may in turn cause their own issues (Hu, 2010). In addition there is also a current 
ongoing debate regarding the false demonization of saturated fatty acids, with 
proponents making the case that their role in heart disease has been exaggerated 
(Malhotra, 2013). Furthermore, recent evidence has illustrated that the specific 
type of saturated fatty acid can infer risk, with even chain fatty acids being 
positively associated with T2D, yet odd and long chain saturated fatty acids 
instead being negatively associated (Forouhi, 2014).  
In addition to these rousing current debates surrounding saturated fatty acids it is 
also interesting, given the high risk of patients with T1D, that diets which are rich in 
mono and polyunsaturated fatty acids; the so-called ‘Mediterranean diet’, have 
been shown to be associated with an inverse risk of CVD. This has been known 
for some time, with a meta-analysis by Sofi (2008) describing 9% risk reductions 
from CVD and cancer and a 13% reduction in incidence of Parkinson’s and 
Alzheimer’s disease. These benefits have been further confirmed in a diabetic 
population with the SEARCH study showing that adherence to the diet may 
improve not only CVD risk, but also glycaemic control (Zhong, 2015). Furthermore, 
in the light of this and in the absence of specific RNI guidelines for MUFA and 
PUFA, it is therefore promising to see that the dietary intakes of these fatty acids 
by participants, regardless of treatment, were higher than those being consumed 
by both the general public and recommendations and it is hoped that this may 
offer some degree of protection (NDNS, 2014).  
As well as differences in the intake of macronutrients between treatment groups 
the study also revealed differences in the consumption of micronutrients. In 
particular it was noticed that regardless of treatment the intake of sodium was 
much higher than recommendations of 1600 mg/day and in some cases 
(particularly with regards to those who completed the food diaries) over double the 
RNI was consumed per day. This is no surprise, with NDNS data showing that 
average sodium consumption in the general public is well above the RNI; however, 
in a population such as those with T1D who are already vulnerable to CVD this is 
especially concerning. Principally because cardiovascular disease has been 
associated with raised blood pressure and increases in blood pressure have been 
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in turn partly attributed to an excess dietary intake of salt (He, 2009). Although 
some (often dated) sources, such as a meta-analysis by the Cochrane group in 
1996, suggest that this statement is somewhat controversial, more recent literature 
illustrates that salt is likely to be a contributing factor and reductions, such as 
those suggested by the Diabetes UK nutrition guidelines, should be promoted 
(Adler, 1996; Graudal, 2014; Dyson, 2011). The benefits of this stance have been 
demonstrated previously when authors from the FinnDiane study, designed to 
determine risk factors for kidney disease in a large cohort of patients with T1D, 
concluded that both high and low dietary salt intakes were associated with 
increased incidence of cardiovascular and all-cause mortality in those without prior 
CVD (Thomas, 2011). Although not demonstrating causality these findings further 
support dietary salt recommendations for those with the disease (Ibid). In 
response to these associations the relationship between salt and CVD has also 
been investigated experimentally, with diabetic mice consuming either a low or 
high sodium diet being seen to develop atherosclerotic lesions at a greater rate 
than those consuming a diet consisting of a moderate amount of sodium, thus 
producing a ‘J-shaped’ relationship, similar to that observed in the FinnDiane study 
and further bolstering recommendations for a diet modest in salt (Tikellis, 2013).  
Furthermore, the high observed sodium intake, in addition to the high intakes of 
saturated fat described previously, may also be indicative of the quality of food 
items consumed and care should therefore be taken to consider the food matrices 
in which these nutrients are being held in as well as just focussing on the 
individual nutrients themselves. Indeed, it is well documented that the nutritional 
content of foodstuffs can be very much determined by their structure; which can in 
turn be governed by various factors such as bioavailability, bioaccessiblity and 
industrial processing, for example heat treatments, homogenisation and 
supplementation, which can all influence the nutrient quality of foods (Turgeon, 
2011). Also, preservation methods such as curing with salt and sodium or 
potassium nitrate can also influence the nutrient profile and is one example where 
the sodium content of foods can be increased during the production process. 
(FAO, 2016). As such, food items should be considered, where possible, in their 
entirety as an indicator of quality in addition to the focussing only on their 
constituent nutrients. 
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In addition to excessive intake of sodium there were also high intakes of other 
micronutrients. An example of this was vitamin C which was consumed in 
quantities greater than the RNI of 40 mg/day by the majority of participants, 
regardless of treatment or gender, with some consuming more than double the 
recommendations (COMA, 1991). Although this is above the optimum requirement 
it is unlikely that any ill effects will be experienced as only high doses over 1000 
mg/day tend to cause (minor) symptoms and it is generally unfeasible to consume 
such large doses without the use of supplements (NHS, 2016). These 
micronutrient excesses were also shown with participants exceeding 
recommendations for B vitamin intake. Not all will be discussed in detail, apart 
from the curious case of vitamin B12, which the findings suggested were 
consumed in large amounts, equating in some cases to over 600% of the RNI. It is 
difficult to specify which food items contained this vitamin as the participants only 
consumed slightly more that the recommended intakes of meat and fish products 
(which are rich sources of vitamin B12). Milk and milk products; however, 
contributed to a substantial segment of the participants diets and although not 
being the richest source of vitamin B12, sheer volume of consumption may be an 
important factor. Despite this it is it is important to note that although intake 
exceeded the RNI there is little data regarding the toxicity of vitamin B12, with 
even large oral doses over 2000 µg/day used to treat pernicious anaemia being 
well tolerated with no side effects (Miller, 2014). 
Although excesses pertaining to micronutrient intake have been discussed, there 
were also incidences of micronutrient consumption failing to meet 
recommendations. Examples being the intake of potassium and magnesium in 
which the differences shown by data derived from the food diaries were shown to 
be statistically significant. In particular these differences appear to be driven by 
females using CSII who only consumed 58.7% of the RNI of potassium and 63.1% 
of the RNI of magnesium. These electrolytes are important for biological process 
such as the growth and maintenance of muscle and neve function, control of the 
acid/base balance and regulation of blood glucose levels (Medline Plus, 2016). 
The poor intake of these nutrients is surprising given neither are lacking in the 
general public and the participants in general were shown to consume a diet rich 
in fruits and vegetables (NDNS, 2014). Furthermore, it is also important to note 
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that these findings were not reflected in data derived from the FFQs and therefore 
may potentially be subject to error. Additionally and perhaps more importantly 
calcium consumption, although generally being consumed in appropriate 
quantities, was not the case for female participants using CSII, whose intake 
equated to 85.2% of the RNI. Furthermore, the average intake of adults in the UK 
was shown by NDNS data to be above the RNI and therefore the findings show 
females using CSII are an exception to this. This is concerning as the mean age 
group of these patients was 42.8 and therefore if a reduced consumption 
continues beyond the menopause it may contribute towards increased risks of 
osteoporosis (particularly in older postmenopausal women) (NHS, 2016). This 
should not be underestimated as evidence suggests that, for reasons not entirely 
understood, patients with T1D frequently have a lower bone density than healthy 
counterparts and up to a six-fold increased risk of fracture, therefore further 
increasing the cause for concern (Hough, 2016). As well as inadequate calcium 
intakes it is also interesting to note that females using CSII were again shown to 
fail to meet RNIs for the consumption of iron. This is vitally important due to the 
amount lost through menstruation; however, was not particularly unexpected as 
NDNS data shows females typically fail to meet iron recommendations. However, 
what is surprising is that the NDNS cited the biggest contributor for iron intake in 
all ages was from cereal products and the intake of these, regardless of treatment 
group, was high. Furthermore, consumption of iron-rich products such as meat 
and vegetables was also shown to be generally above recommendations 
(although it is acknowledged that the breakdown of food items from the FFQ does 
not give details of the specific foods consumed). Although a number of 
micronutrients failed to meet the RNIs, perhaps the most spectacular failure 
involves the intake of vitamin A. Participants regardless of gender or treatment 
were shown by the food diaries to only consume between 30 – 38% of the RNI. 
While these particularly low intakes were not reflected by the FFQ results, the 
findings still generally failed to meet the RNI. Although deficiencies can develop 
into eye problems leading to blindness this is relatively rare, with no reports in the 
UK since the 1930s and a lack of these complications presented in the participants 
(WHO, 2016). Moreover, when considering this together with disputing evidence 
presented by the FFQs and the small sample size is suggestive that consumption 
may not be as poor as initially described by the food diary data.  
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Conclusion  
Although this study focused on the eating behaviours of patients with T1D using 
CSII and MDI therapy and revealed some interesting differences between the diets 
of the two groups it is important to note that in many ways the eating behaviours 
were also largely homogenous. Although not controversial this could be regarded 
as a somewhat positive finding as it indicates that patients can commence the 
therapy without fear of large, potentially detrimental deviations of diet.  
Furthermore, although the majority of dietary intake from both treatment groups 
remained close to RNI guidelines certain differences were revealed throughout the 
data. Whilst some may potentially increase the risks of long-term health issues it is 
important to consider some of the practical aspects of the study which may have 
influenced the findings before passing judgement. Firstly, the study was cross-
sectional in nature which only captured patients’ eating behaviours at a single time 
point and as such may not be truly representative of their actual lives. Although the 
food diaries attempted to deal with this by capturing data from 5 days it is unknown 
if these days are typical. Secondly, both the FFQ and food diary are retrospective 
tools which are only as accurate as the patients who complete them. Also, it 
should be remembered that the surveys were completed at the participants’ leisure 
in their own homes and that all measurements for food diaries were taken using 
uncalibrated top pan balances belonging to the participants in uncontrolled 
conditions and therefore despite all best intensions it is unknown how accurate the 
findings are. Finally, it should also be remembered that this is only a pilot study 
using small number of patients from one clinic and so it would be unwise to place 
too much weight upon the meaningfulness of any statistical outcomes and that 
care should be taken not to extrapolate the findings to the general population of 
those with T1D.  
Despite these limitations the study offers a unique insight for the first time into the 
eating behaviours of patients with T1D using a modern form of CSII and who have 
been educated using contemporary methods.  
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7 - Cardiometabolic Risks 
 
7.1 Abstract 
Cardiovascular disease (CVD) risk is elevated in those with Type 1 diabetes (T1D) 
and this is in part mediated by abnormal cardiometabolic risk markers. When 
focussing specifically on high and low density lipoprotein (HDL and LDL) particles, 
certain subclasses have been shown to infer increased levels of risk and may exist 
even if a patient achieves favourable glycaemic control. This risk may also prevail 
in patients with T1D, even if standard lipid measures suggest otherwise. Given the 
potential for CSII to improve glycaemia it is therefore prudent that the quality of 
lipoproteins in those using the therapy is investigated. Furthermore, there is also a 
dearth of literature in this area. Following ethical approval, the medical records of a 
group of patients using either CSII (n = 40) and MDI (n = 20) were interrogated for 
markers of cardiometabolic risk. Plasma from a subsample of patients using either 
CSII (n= 20) and MDI (n = 9) was analysed for total cholesterol, triglycerides and 
HDL and LDL subfractions. The findings showed patients using CSII had 
significantly less HbA1c than their MDI counterparts (7.8% vs. 8.5%; p = 0.072 
respectively). This was also the case for systolic blood pressure (123.5 mmHg vs. 
135.3 mmHg; p = 0.023). With regard to lipoproteins, those using CSII had 
comparable levels of LDL-C and HDL-C compared to MDI counterparts. Further 
similarities were shown with LDL subfractions with CSII and MDI groups displaying 
identical LDL I and II fractions and near-identical LDL III and IV. Those using CSII 
also had similar levels of HDL2 compared to patients using MDI and similar 
amounts of HDL3. Furthermore, the levels of HDL also indicated both groups were 
largely well protected. Despite this there was a significant difference in the ApoB / 
ApoA1 ratio between patients using MDI and those using CSII (0.70 vs. 0.60; p = 
0.025 respectively), which suggests the former may be at an increased risk of 
CVD. To conclude, although patients using MDI therapy appeared to be generally 
well-managed, the same could also be said to a slightly greater degree for their 
CSII counterparts and future research investigating other measures of lipoprotein 
quality would be beneficial.  
136 
 
7.2 Introduction 
The term ‘cardiometabolic’ (CM) risk is used to describe a cluster of markers which 
may predispose an individual to an increased risk of diabetes and/or 
cardiovascular disease (CVD) (Van Der Meer, 2013). The specific factors which 
contribute towards a preponderance of CM risk are loosely defined, with the 
general consensus being that typical measures should include body mass index 
(BMI), waist circumference, smoking habits, blood sugar, insulin resistance, blood 
pressure, high density lipoprotein cholesterol (HDL-C), low density lipoprotein 
cholesterol (LDL-C), triglycerides (TG) and total cholesterol (TC). Despite this 
basic framework it should also be noted that the exclusion of these markers and 
the inclusion of others frequently occur from study to study.  
It is well documented that patients with T1D are at an increased risk of CM risks 
for a variety of reasons. One such reason is that the weight of patients has been 
increasing over recent decades, with the Pittsburgh Epidemiology of Diabetes 
Complications Study cohort illustrating how over 18 years the prevalence of 
overweight patients has almost doubled and obesity has increased seven fold 
(Conway, 2010). This high prevalence of weight gain has also been shown in the 
UK with over 62% of patients with T1D now being either overweight or obese 
(Diabetes UK, 2015). Furthermore, the subsequent insulin resistance associated 
with this increased weight and/or a family history of T2D may predispose patients 
with existing T1D to also succumb to T2D. This condition has been recently coined 
‘double diabetes’ and although the long-term effects are currently under-studied, 
patients are likely to be at a greater risk of diabetes-related complications (Cesur, 
2008; Cleland, 2012).  
Even in the absence of excessive weight and the so-called ‘double diabetes’, 
patients with T1D remain at an increased risk of macrovascular complications 
concerning the larger blood vessels such as the aorta, coronary arteries and the 
wider arteries in the limbs. These frequently result in strokes, coronary artery 
disease and peripheral arterial disease and are typically referred to using the 
collective term ‘cardiovascular disease’ (CVD) (Fowler, 2008). Despite great 
improvements over recent years the risks of these CVD complications remain high 
and patients residing in the UK are no exception to this. A Diabetes UK funded 
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cohort study of 23,751 patients by Laing et al. (2003) highlighted both high 
mortality rates and a gender disparity regarding CVD, with standardised mortality 
ratios of 8.8 for females compared to 4.5 for males (Laing, 2003). Similar findings 
were also found in a study by Soedamah-Muthu (2006) who interrogated data 
concerning 7475 individuals with T1D derived from the UK General Practitioners 
Database. This study also highlighted both the high risk of CVD which those with 
T1D face as well as the predisposition towards females compared to males, with 
hazard ratios for major CVD events being 7.7 and 3.6 respectively. It is difficult to 
find more recent data offering an accurate breakdown of the current state of CVD 
in UK patients with T1D; however, the last published National Diabetes Audit 
(2012 – 2013) (which included 71.1% of all patients with diabetes in England and 
69.3% of those in Wales) reported that despite cardiovascular complications 
largely remaining stable over the last 3 audit periods (2009 – 2012), the risk of 
patients with T1D being admitted to the hospital with heart failure is still 322% 
greater than those without the disease (HSCIC, 2015).  
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Despite these concerning figures the pathogenesis of cardiovascular disease in 
those with T1D has not yet been fully elucidated; however, it is clear that its 
progression is the result of various insults to the macrovascular system. These 
have been broadly illustrated in Figure 7.1.  
 
 
 
 
 
Figure 7.1 – Associated issues which may catalyse macrovascular disease (Adapted from: 
Retnakaran, 2008) 
 
 
 
 
 
 
 
The image originally presented here cannot be made freely available via LJMU Digital Collections 
because of copyright. The image was sourced at 
http://www.sciencedirect.com/science/article/pii/S0140673608607679.  
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Atherosclerosis is one of these principle components. It is characterised by the 
accumulation of ‘fibrofatty’ deposits in elastic and medium to large arteries which 
over time build up causing the vasculature to become stiffened and blocked as 
illustrated in Figure 7.2 (Wang, 2012).  
 
 
 
 
The progression of atherosclerosis is very much dependent on the presence of 
lipoproteins. These particles are a biochemical assemblage consisting of both a 
hydrophilic, polar outer shell comprised of phospholipids, apolipoproteins and free 
cholesterol and a hydrophobic, non-polar inner core of triglycerides and 
cholesterol esters (Figure 7.3). This arrangement allows the lipids to be ‘packaged’ 
and transported through the aqueous blood stream to their destination.  
Figure 7.2 –Progression of atherosclerosis (Adapted from: HeartandHealthMedical, 2015) 
 
 
 
 
 
The image originally presented here cannot be made freely available via LJMU Digital Collections 
because of copyright. The image was sourced at http://nyheartfailure.com/heart-failure. 
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Figure 7.3 – The nomenclature of a lipoprotein particle (Antisense, 2010). 
Figure 7.4 – Lipoprotein classes and subclasses categorised by density and size (Adapted from: 
Wood, 2006). 
 
 
 
 
 
 
The image originally presented here cannot be made freely available via LJMU Digital Collections 
because of copyright. The image was sourced at 
http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4263s1_03_Wood-FDA.pdf. 
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Residing under the general term ‘lipoprotein’ there are a number of classes and 
subclasses which can be categorised according to both their density and size 
(Figure 7.4). These particles also differ in terms of the proportions of lipids 
contained in their core and the apolipoproteins which contribute towards their 
structural integrity (see Table 1).  
 
These important compositional differences have various functional implications 
which complement the distinct role each particle plays in the complex metabolism 
of lipids and the pathogenesis of lipid-based disease. A basic explanation of these 
processes is shown in Figure 7.5.  
This process, although greatly simplified, is complicated by various subclasses 
which exist within the individual lipoprotein classes as shown in Table 7.2. These 
are also categorised by density and size and are composed of differing amounts of 
lipids which also impact upon their function. For example, LDL may be stratified 
Table 7.1 – The composition of lipoprotein particles categorised by class (adapted from Feingold, 
2015 and AOCS, 2015). 
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into four main subfractions:- LDL-I (density = 1.019 – 1.023), LDL-II (density = 
1.023 – 1.034),  
 
 
Figure 7.5 – Human lipid metabolism (Adapted from: Daniels, 2009). 
 
 
 
 
 
 
 
 
 
 
The image originally presented here cannot be made freely available via LJMU Digital Collections 
because of copyright. The image was sourced at 
http://www.ncbi.nlm.nih.gov/pubmed/19584955.  
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LDL-III (density = 1.034 – 1.044) and LDL-IV (density = 1.044 – 1.060) (Berneis, 
2002). Although the existence of these subfractions has been known for some 
time their role in lipid metabolism and disease risk is an emerging and frequently 
debated subject; however, the existing literature suggests that some may be more 
injurious than others. Specifically, it has been acknowledged that the small, dense 
LDL subfractions (LDL III and IV) may be more atherogenic than their larger, more 
buoyant counterparts due to an increased susceptibility to oxidation, decreased 
rates of degradation and a greater affinity for the arterial wall (Lamarche, 1999). 
Furthermore, it is also important to note that the prevalence of these particles is 
rarely seen in isolation, as LDL particle size and buoyancy has been shown to be 
inversely related to plasma triglycerides and VLDL levels (Krauss, 1980; 
McNamara, 1987).  
Similar categories of subfractions also exist within the individual HDL classes 
(Table 7.2). These are distinguishable by their density and size and can be 
categorised as follows:- HDL2 (density = 1.063 – 1.110) and HDL3 (density = 1.110 
– 1.170) (Rosenson, 2011). The question of which particular fraction is more 
atheroprotective is a contentious one. Some studies have shown that in patients 
with dyslipidaemia a reduction in the larger HDL2 particles and an increase in the 
Table 7.2 – The composition of lipoprotein particles categorised by subclass (adapted from 
Berneis (2002) and Rosenson (2011)). 
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denser, smaller HDL3 particles occur and that this trend is also present in those 
with coronary artery disease (Pirillo, 2013). However, a number of other studies 
suggest that HDL2 actually may be a better predictor of coronary artery disease 
than either HDL3 or total HDL (Drexel, 1992; Lamarche, 1997; Johansson, 1991). 
These contradictory findings are further confounded by the sparse number of 
studies available in this area, along with the variety of methods used to separate 
the particles and therefore it would be premature to suggest which specific 
subfraction may be more beneficial (Superko, 2012). 
In T1D this complex system of lipid metabolism is often disrupted. The large scale 
DCCT study made clear the positive relationship between glycaemic control and 
lipids and lipoproteins, as those with poorly controlled diabetes typically have 
raised total cholesterol, LDL and triglycerides and are in turn associated with an 
increased risk of CVD (The DCCT Research Group, 1992). This has been 
replicated elsewhere and is now generally accepted as the conventional wisdom 
(Feitosa, 2013; Guy, 2009). Conversely, when patients maintain good glycaemic 
control they often display improved lipid profiles similar to healthy individuals 
without the disease (Dullaart, 1995). Specifically, triglycerides and LDL-C are often 
found to be normal or decreased, which are thought to result from 
hyperinsulinemia originating from the subcutaneous methods of injection generally 
favoured by patients that in turn may cause a downregulation of VLDL production 
and an increase in the activity of lipoprotein lipase (Vergès, 2009). Furthermore, 
HDL levels are often seen to be normal or slightly increased (Mattock, 1982). 
Although this overall lipid profile may appear at first glance to confer cardio-
protection it is important to remember that even patients with favourable glycaemic 
control remain at an increased risk of CVD. This may in part be explained by 
various qualitative abnormalities which are often found to exist, even in patients 
with good control, which are likely to promote the progression of atherosclerosis. 
These abnormalities are typified by a predominance of small, dense LDL fractions 
(LDL III and IV) that are abundant in triglycerides (Vergès, 2009). Whilst a higher 
number of these particles are directly related to an increased risk of CVD, they are 
also more prone to oxidation and decreased uptake by the LDL receptor 
(Wadhera, 2016). Indeed, small dense LDL has also been shown to be more 
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predisposed to glycation in those with diabetes than their buoyant counterparts, 
thus further increasing their atherogenic potential (Younis, 2013).  
Despite normal or slightly raised HDL in those with well managed T1D it is not 
conclusive which particular subfraction of HDL is raised; with some studies 
suggesting HDL2 and others suggesting HDL3 (Eckel, 1981; Winocour, 1996). 
Also, the function of HDL itself is often found to be compromised due to its 
enrichment with triglycerides, impaired antioxidant properties and increased 
glycation, which has in turn been shown to decrease the particles’ ability to 
perform reverse cholesterol transport (Dullaart, 1995; Perségol, 2007; Hoang, 
2007; Brindisi, 2013; Fievet, 1992). These qualitative abnormalities are no 
exception in those with T1D, with altered HDL function, even in spite of normal or 
elevated levels, likely to contribute towards the increased CVD risk experienced by 
patients (Manjunatha, 2016).  
These lipoprotein abnormalities are of interest to the authors of the present study 
as CSII therapy is well-known to improve glycaemic control and therefore one 
might expect the standard lipid profile of patients using this treatment to improve; 
as has been demonstrated previously (Pickup, 2002; Vergès, 2009). Despite this 
little is known about potential co-existing abnormalities which may occur in relation 
to lipoprotein quality in those engaging with treatments known to significantly 
improve glycaemic control, such as CSII (Vergès, 2009). The evidence 
surrounding this has been discussed in detail previously in the Literature Review 
chapter (see page 30) and forms the rationale for the focus of the present study on 
lipoprotein quality in those using CSII, with a particular focus on LDL and HDL 
subfractions. Additionally, it is also important to remember that typical diagnostic 
tests used by physicians to observe lipid levels only measure the standard lipid 
panel (i.e. total cholesterol, HDH-C, LDL-C and triglycerides). Thus, qualitative 
abnormalities, such as those described previously, are likely to exist ‘unseen’. This 
further emphasises the need for a study of this type to gain a comprehensive 
overview of this understudied yet important area and how it may be relevant to 
those using CSII therapy.  
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7.2 Aims and objectives 
Aims 
To determine the cardiometabolic risks of adult patients with T1D using CSII 
compared to those using MDI using a cross-sectional study design.  
Objectives 
 To inspect participant’s medical records with respect to CM risk markers. 
 
 To analyse the quality of lipoproteins. 
 
7.3 Methods 
 
Medical Record Assessment 
As previously mentioned in the General Methods section (see page 45) the 
medical records of participants were interrogated for basic clinical details. All 
measurements were originally taken by either a Consultant Endocrinologist or 
Diabetes Specialist Nurse and all laboratory analysis was conducted by a 
Biomedical Scientist in concordance with standard hospital procedures. The only 
exception to this was LDL-C concentration, which was calculated using the 
Friedewald formula (Friedewald, 1972). The most recent measurements were 
recorded by the author and were all within the previous three months of the study 
commencement date. The measures which were documented consisted of date of 
birth, gender, BMI, HbA1c, insulin dose, basal rate, blood pressure, total 
cholesterol, HDL cholesterol, LDL cholesterol and triglycerides (derived from 
plasma). A record was also taken if patients were using any kind of medication, 
whether or not they were a smoker and their length of time using either CSII or 
MDI.  
Plasma Preparation 
A venous blood sample of 20 ml was taken from each participant by a trained 
phlebotomist using a lithium heparin BD vacutainer. The blood was immediately 
centrifuged at room temperature for 15 minutes at 2000 rpm using a Woodley 
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Clinispin 2000 centrifuge (no brake was used). The resulting plasma was then 
aliquoted using a Pasteur pipette equally into 1.8 ml cryovial tubes. Plasma was 
frozen at -80 °C until further analysis (described below) was performed. 
Analysis of Whole Plasma  
Half of the plasma was thawed and analysed using an Alfa Wassermann spACE 
Clinical Chemistry System for total cholesterol, plasma triglycerides, Apo-A1 and 
Apo-B content. All methods were based upon enzymatic or immunoturbidimetric 
principles, whereby the reaction between the reagent and sample either resulted in 
a coloured pigment or an insoluble complex. The absorption of these pigments 
and complexes at a specified wavelength was directly proportional to the 
concentration of the biochemical compounds of interest. Quality controls of a 
known concentration were used in all assays to ensure precision and reveal any 
deviations in sensitivity from acceptable ranges of absorbance. The specific 
methods for the assays used during the study are described below:- 
 Total Cholesterol 
Total cholesterol was determined following the method of Trinder (1969). The 
cholesterol was measured after performing enzymatic hydrolysis and oxidation. 
This resulted in the indicator quinoneimine being formed from hydrogen peroxide 
and 4-aminoantipyrine in the presence of phenol and peroxidase. The assay is 
estimated at having a within-run precision of 3.73% at 1.71 mmol/L and 3.84% at 
7.70 mmol/L and a between-run precision of 1.33% at 1.67 mmol/L and 1.39% at 
7.52 mmol/L. The chemical equation for the process is shown in Figure 7.6.  
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 Triglycerides 
Triglycerides were measured by using a colorimetric method, based upon their 
enzymatic hydrolysis with lipases. The indicator quinoneimine was formed from 
hydrogen-peroxide, 4-aminophenazone and 4-chlorophenol under the catalytic 
influence of peroxidase. The assay is estimated to have a within-run precision of 
3.29% at 0.308 mmol/L and 1.77% at 5.61 mmol/L and a between-run precison of 
3.51% at 0.642 mmol/L and 1.33% at 3.03 mmol/L. The chemical equation for the 
process is shown in Figure 7.7. 
 
  
 
 
Figure 7.6 – Enzymatic reaction for the determination of total cholesterol 
Figure 7.7 – Enzymatic reaction for the determination of triglycerides 
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 Apo-A1 and Apo-B 
For the determination of Apo-A1 and Apo-B immunoturbidimetric assays were 
used. These methods are based upon the reaction of sample containing human 
Apo-A1 or Apo-B and an antiserum which forms an insoluble complex from which 
turbidity can then be measured at 340 nm. The results can then be compared to a 
standard curve to determine the content of either Apo-A1 or Apo-B.  
For Apo-A1 the manufacturers estimate that the assay has a within-run precision 
of 2.67% at 76.0 mg/dl and 4.10% at 221.0 mg/dl and has a between-run precision 
of 3.1% 70.0 mg/dl and 3.22% at 222.0 mg/dl. 
For Apo-B the manufacturers estimate the assay has a within-run precision of 
3.86% at 52.7 mg/dl and 4.13% at 154.0 mg/dl and has a between-run precision of 
1.79% at 49.4 mg/dl and 2.57% at 127.0 mg/dl.  
Separation and Analysis of Lipoprotein Subclasses 
The remaining half of frozen plasma was thawed and rapidly separated into LDL 
and HDL subclasses using ultracentrifugation. The separation of lipoprotein 
particles in this manner was first performed by John W. Gofman who discovered in 
the late 1940s that the extremely high speeds which could be achieved using the 
newly designed analytical ultracentrifuge could also be used to separate 
lipoproteins into categories (Steinberg, 2007). Over the subsequent years and with 
the advent of vertical and near-vertical rotors this pioneering work was continued 
by others and refined to allow the separation of the particles into discreet 
subclasses in drastically shorter time periods (Havel, 1955; Chung, 1986; Griffin, 
1990; Krauss, 1994; Swinkels, 1987). Due to the speed, relative simplicity and 
ability to easily manipulate gradients ultracentrifugation quickly become an 
established and frequently used methodology. Work by Graham (1996) 
revolutionised these techniques by substituting the traditionally used KBr or NaBr 
salts for iodixanol; a non-toxic, non-ionic and iso-osmotic solution, to create the 
continuous density gradient required for the successful separation of the principle 
lipoprotein classes. This method was further developed by Davies (2003) to allow 
the rapid separation of LDL subclasses and then by Harman (2013) for HDL 
subclasses. These methods are briefly described below:- 
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 Separation of LDL Subclasses 
 Materials 
Beckman Coulter Optima XPN-90 Ultracentrifuge 
Beckman Coulter NVT-65 rotor (capacity for 8 tubes) 
Labconco Auto Densi-Flow 115V 
Gilson FC203B Fraction Collector 
Beckman Coulter rotor accessories (i.e. tube rack, spacers, screw caps, spacer 
removal tool, torque wrench and adapter). 
Beckman Coulter OptisealTM Tubes (11.2 ml) (and supplied caps) 
Axis Shield OptiprepTM solution (60 w/v) 
5 ml disposable syringes 
Stainless steel cannula 
Phosphate buffer solution (PBS) 
Methanol 
Distilled water 
Bijou tubes 
Pipettes and tips 
 
 Method 
A 9% (v/v) solution was prepared using OptiprepTM and PBS as a diluent and 7.9 
ml was dispensed into each OptisealTM tube (1 tube per patient). Iodixanol at 60% 
(w/v) (0.7 ml) was combined with plasma (2.8 ml) to create a 12% (v/v) iodixanol 
solution. Next 3.0 ml of this solution was underlayered beneath the 9% solution 
using a syringe and steel cannula, forming a two-step gradient. The tubes were 
placed in the rotor and left to stand for 20 minutes. The ultracentrifuge was then 
programmed to spin for 3 hours at 65,000 rpm at 16°C, with acceleration and 
deceleration speeds both set to 5.  
Each tube was then fractionated using a Labconco auto densi-flow together with a 
Gilson FC-203B fraction collector. Each 500 µl fraction (consisting of 21 droplets) 
was collected into 1.5 ml Eppendorf microcentrifuge tubes. The refractive index of 
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each fraction was then determined using a Bellingham & Stanley Abbe60 
refractometer. This was converted into density using the following formula:-  
ρ = ηa – b  
(ρ = density, η = refractive index, a = 3.4172 and b = 3.5637) 
All samples were then frozen at -80°C until further subfraction analysis was 
required.  
The further analysis which followed utilised an Alfa Wassermann spACE Clinical 
Chemistry System to determine the total cholesterol content (method already 
previously described) of each fraction. These findings, together with the density of 
each fraction, were used to deduce the presence of different LDL subclasses in 
each participant and hence determine atherogenic phenotypes. The density 
ranges pertaining to the different LDL subclasses can be seen in Table 7.3 
(Davies, 2003).  
 
  
 Separation of HDL Subclasses 
 Materials 
The materials used were the same previously described for the separation of LDL 
subclasses. 
 Method 
The method used to separate HDL subclasses was largely the same as that used 
to separate LDL subclasses; however, a 3-step gradient was employed. To 
generate the top layer a 15% (v/v) iodixanol solution was produced by adding 
Table 7.3 – LDL subclass densities (adapted from Davies, 2003) 
 
The image originally presented here cannot be made freely available via LJMU Digital Collections 
because of copyright. The image was sourced at 
http://www.clinchem.org/content/49/11/1865.abstract.  
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PBS. This solution (3.9 ml) was added to an 11.2 ml OptisealTM tube. Iodixanol 
was then added to thawed whole plasma to produce a 17.6% (v/v) solution of 
which 3.4 ml was carefully underlayered beneath the 15% (top layer) solution 
using a syringe and steel cannula. Finally, a 23% (v/v) iodixanol solution was 
made by diluting with PBS. This solution was then underlayed beneath the 
previous solutions again using a syringe and steel cannula, thus producing a 
three-step gradient.  
The same procedure was then followed which was used to separate and analyse 
the LDL subfractions. The fraction densities used to determine the presence of 
specific HDL subfractions are denoted in Table 7.4. 
 
It should be noted that the original protocol by Harman (2013) for the separation of 
HDL subfractions was intended to be used in conjunction with smaller 4.9ml 
OptisealTM tubes and the author had to scale the method up to account for  the 
NVT-65 rotor which only accommodates larger 11.2 ml OptisealTM tubes. Although 
no experiments were performed to compare these methods it was hypothesised 
that the larger tube length would actually facilitate the separation, therefore 
providing superior resolution.  
 Quality Control 
Before any analysis was carried out a number of quality controls for each assay 
were run to determine intra-assay variability. Each quality control was run in sets 
of 15 duplicates. The findings were recorded and a coefficient of variation (CV) 
was calculated for each quality control. All findings revealed % CV <10, thus 
indicating low levels of dispersion between each assay and this variability was 
therefore deemed acceptable. The findings are shown in Table 7.5. 
Table 7.4 – HDL subclass densities (adapted from Harman, 2013) 
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 Statistical Analysis 
All data were analysed using Statistical Package for Social Sciences (SPSS) 
(v.21). Initially the data was subjected to descriptive statistics after which normality 
was determined by using the Shapiro-Wilk test. Any data which could be 
normalised using a log10 transformation was then analysed using Student’s t-test 
(the assumption of homogeneity of variance was also tested in this instance). Any 
data which could not be normalised was subjected to non-parametric Mann-
Whitney U tests. Spearman correlation coefficients were used to determine 
relationships between variables of interest. The strength of a relationship between 
variables was determined according to categories devised by Evans (1996) which 
are described in Table 7.6. All findings with a p-value <0.05 were deemed to be 
statistically significant. 
 
 Lipoprotein Recovery Rates 
During the calculations for the lipoprotein subclasses recovery rates were 
determined for both LDL and HDL separation methods. It was found that when 
using the LDL separation method the percentage recovery from samples derived 
from the CSII treatment group was 76.1% (± 2.6) and from the MDI treatment 
group was 74.1% (± 8.4). When using the HDL separation method the percentage 
recovery from samples derived from the CSII treatment group was 74.8% (± 4.6) 
Table 7.6 – Correlation r-values and their corresponding levels of association (adapted from Evans, 
1996). 
Table 7.5 – Coefficient of variation results for each set of quality controls. 
The image originally presented here cannot be made freely available via LJMU Digital Collections 
because of copyright or other reason here. The image was sourced at Evans J.D. (1996) 
‘Straightforward Statistics for the Behavioral Sciences’ 1st ed. Brooks/Cole Publishing, California. 
154 
 
and from the MDI treatment group was 73.0% (± 7.1). These findings are 
illustrated in Figures 7.8 and 7.9. 
 
 
 
Figure 7.8 – Percentage lipoprotein recovery rates for CSII and MDI treatment 
groups using LDL separation method. 
Figure 7.9 – Percentage lipoprotein recovery rates for CSII and MDI treatment 
groups using HDL separation method. 
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7.5 Results 
Patient Medical Record Data 
 Basic Characteristics 
The medical records of all consenting participants (n = 60) (40 using CSII and 20 
using MDI) were assessed. The basic characteristics are summarised in Table 7.7. 
Please note that although best efforts were taken to retrieve all data some 
regarding smoking habits was not available in patients’ medical records 
 
 Clinical Characteristics 
The medical records were assessed for various clinical markers of cardiometabolic 
risk. These consisted of BMI, HbA1c, total cholesterol, LDL-C, HDL-C, triglycerides 
and systolic and diastolic blood pressure. The findings illustrated that both 
treatment groups had a BMI >25 (28.1 kg/m2 in those using CSII and 25.2 kg/m2 in 
those using MDI) and that HbA1c was lower in patients using CSII compared to 
those using MDI (7.8% vs 8.5% respectively). There was little difference between 
total cholesterol, LDL and HDL cholesterol levels in either treatment group; 
however, triglycerides were significantly higher in those using MDI compared to 
those using CSII (p = 0.021). Furthermore, both systolic and diastolic blood 
pressure was higher in those using MDI compared to patients using CSII and the 
difference in systolic pressure reached statistical significance (p = 0.023) (Table 
7.8).  
 
 
Table 7.7 – Basic sample characteristics of all consenting participants. 
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Lipoprotein Quality Analysis 
 Basic Characteristics 
Although 60 patients initially consented to take part in the study, only a subsample 
(n = 29) consented to donate a sample of blood to allow the further analysis of 
lipoprotein quality. This subsample of participants consisted of 20 patients using 
CSII and 9 patients using MDI. A breakdown of clinical characteristics for this 
subsample extracted from the medical record data are described in Table 7.9.  
Table 7.8 – Clinical characteristics of all consenting patients. All p-values derived from Student’s 
t-test1 (or Mann-Whitney U test2 if data was non-normal). 
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 Lipoprotein Subclass and Apolipoprotein Analysis 
Table 7.10 describes the findings from analysing the whole plasma for total 
cholesterol, triglycerides and apolipoproteins, together with the LDL and HDL 
subclasses which were derived through ultracentrifugation and subsequent 
analysis. There was little difference in the total cholesterol and triglyceride content 
of the participants’ whole plasma regardless of treatment. This was also true for 
the LDL I & II which were the same (1.4 mmol/L) in both groups. Furthermore, 
HDL3 was also extremely similar between groups, as was Apo-A1 and Apo-B; 
however, the participants using CSII did possess increased levels of HDL2 
compared to their MDI counterparts (1.7 mmol/L vs 1.0 mmol/L respectively). 
None of the differences between these variables were shown to be statistically 
significant. The Apo-B / Apo-A1 ratio was shown to be lower in those with using 
CSII (0.60) compared to those using MDI (0.72) and this was found to be 
statistically significant (p = 0.025). These differences are also illustrated in Figure 
7.10. When the Apo-B / Apo-A1 ratio was split by gender males using CSII were 
Table 7.9 – Basic clinical characteristics of the subsample who donated blood to allow the further 
analysis of lipoprotein quality. All p-values derived from Student’s t-test1 (or Mann-Whitney U 
test2 if data was non-normal). 
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found to have a lower ratio than males using MDI and the same was found with 
females. This breakdown is shown in Table 7.11. 
 
 
 
 
Table 7.10 – Lipid and apolipoprotein characteristics derived from the analysis of whole plasma, 
together with calculated Apo-A1 / Apo-B ratio and LDL and HDL subclass characteristics resulting 
from plasma ultracentrifugation. All p-values derived from Student’s t-test1 (or Mann-Whitney U 
test2 if data was non-normal). 
Figure 7.10 – Calculated Apo-A1 / Apo-B ratio difference between subsample using 
CSII and MDI. 
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 Correlations 
The findings from these additional lipid quality investigations were further 
interrogated by comparing them with the data extracted from the medical records 
of the subsample (previously described in Table 7.8) to determine any 
correlations. Spearman’s correlation coefficients were used throughout and all 
significant relationships have been tabulated in Table 7.12.  
In participants using CSII a very strong positive correlation was seen between total 
cholesterol and LDL-C (r = 0.829, p < 0.001) and between HDL-C and Apo-A1 (r = 
0.811, p < 0.001).  
In those using CSII strong positive correlations were shown to exist between BMI 
and insulin dose (r = 0.747, p < 0.001), basal rate (r = 0.763, p < 0.001) and 
triglycerides (r = 0.649; p = 0.003) and also between total cholesterol, Apo-A1 (r = 
0.636, p = 0.011), LDL I & II (r = 0.623, p = 0.013) and HDL3 (r = 0.655, p = 0.008) 
respectfully. Strong, negative relationships were also revealed in those using CSII 
between age and total cholesterol (r = -0.601, p = 0.018), as well as between BMI, 
HDL2 (r = -0.631, p = 0.003) and HDL3 (r = -0.639, p = 0.002). Furthermore, 
additional strong negative relationships were seen between insulin dose and HDL2 
(r = -0.635, p = 0.003) and between triglycerides and HDL2 (r = -0.687, p = 0.007). 
In the MDI group strong positive correlations were found between BMI and 
triglycerides (r = 0.738, p = 0.037) and between total cholesterol, age (r = 0.738, p 
= 0.037) and systolic blood pressure (r = 0.786, p = 0.036). There was also a 
similar positive relationship between and LDL and triglycerides (r = 0.786, p = 
0.036). Strong negative relationships were seen in those using MDI between total 
cholesterol and diastolic blood pressure (r = -0.786, p = 0.036), between LDL and 
HDL (r = -0.795, p = 0.018) and between LDL and HDL2 (r = -0.771, p = 0.025). 
Table 7.11 – Apo-B / Apo-A1 ratio split by treatment and gender. 
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Moderate, positive relationships were found in those using CSII between HbA1c 
and LDL I & II (r = 0.515, p = 0.024) and between insulin dose and LDL III & IV (r = 
0.542, p = 0.017). There were also strong, positive relationships between total 
cholesterol, HDL (r = 0.562, p = 0.037), Apo-B (r = 0.533, p = 0.041) and HDL2 (r = 
0.550, p = 0.034) respectfully. Further moderate, positive associations were also 
observed between diastolic blood pressure, systolic blood pressure (r = 0.577, p = 
0.008), triglycerides (r = 0.471, p = 0.036), LDL I & II (r = 0.490, p = 0.028) and 
LDL III & IV (r = 0.461, p = 0.041) respectfully. Moderate negative relationships 
were seen in those using CSII between age, diastolic blood pressure (r = -0.502, p 
= 0.024), total cholesterol (r = -0.493, p = 0.027) and LDL I & II (r = -0.487, p = 
0.029). Additional moderate negative relationships were shown between insulin 
dose and HDL3 (r = -0.473, p = 0.041) and between basal rate, Apo-A1 (r = -0.543, 
p = 0.013), HDL2 (r = -0.557, p = 0.011) and HDL3 (r = -0.581, p = 0.007). 
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Table 7.12 – Correlations between clinical characteristics derived from patient medical 
records and plasma lipid and lipoprotein quality analysis. Data derived from medical records 
are denoted with ‘MR’ and data derived from autoanalyser measurements are denoted 
‘Auto’. Spearman correlations used throughout and only significant (p<0.05) findings 
included. 
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7.6 Discussion 
 Medical Record Assessment 
Upon consenting to take part in the study the participants (n = 60) gave permission 
for the author to examine their medical records for standard clinical markers 
pertaining to cardiometabolic risk. It can be seen from the results in Table 7.7 that 
the majority of patients who participated were using CSII (n = 40) compared to 
using MDI (n = 20).  
On inspection of HbA1c of those using CSII it can be seen that they had 
substantially lower levels than their MDI counterparts (7.8% vs 8.5% respectively 
(p = 0.072)). This improvement in blood sugar control is a typical hallmark benefit 
of CSII and generally occurs immediately after commencing the therapy (Pickup, 
2002). Although not statistically significant this may be clinically significant, with 
previous studies such as the Diabetes Control and Complications Trial suggesting 
that a 10% reduction in HbA1c is associated with a 43% reduction in the risks of 
retinopathy (DCCT Research Group, 1995). These favourable reductions are also 
complimented by those using CSII requiring both smaller daily doses of insulin and 
a lower basal rate than those using MDI. This is not entirely unexpected as 
previous studies have demonstrated that the improved glycaemic control typically 
inferred by CSII is often accompanied by a reduction in insulin requirements 
(Melidonis, 2016). Despite this being a somewhat predictable finding it remains 
promising as the large levels of insulin required for subcutaneous methods of 
administration are generally regarded as physiologically unsound (Wang, 2013). In 
fact peripheral hyperinsulinaemia, which is common in those with T1D, is 
associated with inflammation and coronary artery disease and there is additional 
evidence to suggest that it may impact upon lipid and lipoprotein levels (Wang, 
2013; Vergès, 2009).  
With respect to the lipid panel, those using CSII generally experienced superior 
regulation than those using MDI. For example, HDL-C was shown to be slightly 
higher and total cholesterol and LDL-C was slightly lower (Table 7.8). Triglycerides 
were the only variable where a significant difference could be seen between those 
using CSII and MDI (0.8 mmol/L vs 1.8 mmol/L respectively (p = 0.021)). Despite 
these differences it is important to note that both groups displayed a lipid profile 
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either bordering upon or lower than recommendations i.e. total cholesterol <4 
mmol/L, LDL-C <2.0 mmol/L, HDL-C >1 mmol/L and triglycerides <1.7 mmol/L 
(NICE, 2015). Furthermore, those using CSII also presented significantly lower 
systolic blood pressure than those using MDI (123.5 mmHg vs 135.3 mmHg 
respectively) and diastolic blood pressure was also lower in those using CSII (73.0 
mmHg) compared to those using MDI (81.8 mmHg). These findings illustrate that 
those using MDI are actually hypertensive (when using the NICE hypertension cut-
off level of >130/80) compared to those using CSII with blood pressure within the 
normal range (NICE, 2015). 
Despite these somewhat descriptive findings largely ‘painting’ a promising picture, 
especially for those patients using CSII, they should be considered in relation to 
the rest of the results. In particular it is important to note that the mean BMI of 
participants using both treatments was >25 kg/m2 and that this predominance of 
overweight and obese patients is somewhat contradictory to the well maintained 
blood sugar, lipid and blood pressure parameters illustrated by the findings. That 
said this is not a particularly controversial finding in itself, with evidence suggesting 
that after diagnosis BMI typically increases in both children and adults and that the 
inclusion criteria for the study stipulated all participants must have been diagnosed 
for a year or longer so weight gain is likely to be expected (de Vries, 2014, 
Rosenfalck, 2002). The implications of this are far reaching and have been 
outlined in the introduction, with the incidence of ‘double diabetes’ becoming more 
prominent over recent years. Despite these concerns about BMI the other markers 
of cardiometabolic risk derived from medical records appear at first glance to 
suggest a population enjoying an absence of wider metabolic abnormalities. 
However, a closer look at Table 7.7 reveals that this interesting ‘alignment of 
control’ may be no coincidence as it is clear there are a relatively high number of 
patients using both lipid lowering and anti-hypertensive medications, with patients 
using CSII tending to gravitate more strongly towards these drugs. This may 
explain the normotensive blood pressure levels, specifically occurring in those 
using CSII, as well as normalised LDL-C. Furthermore, some evidence suggests 
that statins may also infer beneficial effects on plasma HDL-C concentrations; with 
a systematic review of 103 studies by McTaggard (2008) demonstrating that 
modest increases in both HDL-C and Apo-A1 may occur, likely mediated by 
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reduced cholesteryl ester transfer protein (CETP) activity. It is unknown why 
exactly the group using CSII are more highly medicated; however, a reason for 
this may be that patients using insulin pumps are likely to have more frequent 
appointments with the same Healthcare Professional, therefore medication 
requirements may become more ‘tailored’, as opposed to those using MDI who 
may only have an annual check-up if their diabetes is well-controlled (as anecdotal 
evidence suggests is often the case). It should also be remembered that the 
majority of patients are only offered CSII if difficulties achieving glycaemic control 
remain despite best efforts; therefore, it is reasonable to suggest that co-existing 
and related issues may also have been present prior to the commencement of 
CSII, thus leading to early initiation with these medications. Irrelevant of the 
reason, medication with these lipid lowering and anti-hypertensive therapies is 
likely to significantly contribute towards the well-controlled lipid and blood pressure 
levels described in Tables 7.8 and 7.9 and may explain why they can co-exist 
concurrently with a raised BMI (which incidentally may be more difficult to control 
than with medication alone).  
 Lipoprotein Subclass and Apolipoprotein Analysis 
In addition to secondary data derived from patients’ medical records, further 
analysis was also carried out on a sample of blood donated by a subsample. Table 
7.9 describes the medical records of the subsample and it is clear to see the 
findings reflect those illustrated from the larger pool of medical record data 
pertaining to the general sample. There were only two dissimilarities of note; firstly 
that the triglycerides in the MDI group appear to be lower than that of the larger 
sample and display a slight and insignificant difference between those using CSII, 
with both being below the cut-off value of 1.7 mmol/L (p = 0.942) (NICE, 2015). 
Secondly, the mean HbA1c of those using CSII was slightly, but non-significantly 
higher than those using MDI (p = 0.910). This is an unexpected finding and 
suggests that the patients, who consented to take part in the subsample, whilst 
possessing an acceptable level of control, may be inferior to that of the general 
sample as a whole.  
After separating the lipoproteins using ultracentrifugation each individual fraction 
was analysed along with the whole plasma. The results are summarised in Table 
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7.10 and illustrate that the findings for total cholesterol and triglycerides derived 
from the analysis of whole plasma are in good agreement with data derived from 
the assessment of patients’ medical records and similarly show little difference 
between treatments. Furthermore, when looking at the LDL subclasses between 
treatments it can be seen that both are identical and that there is a predominance 
of the larger, more buoyant LDL I and II (forming a so-called ‘Pattern A’) as 
opposed to the smaller, denser LDL III and IV particles (which contribute toward 
the more atherogenic Pattern B) (Krauss, 1992). When looking at the literature this 
is a somewhat unusual finding, with previous research showing how those with 
T1D, even with good glycaemic control, frequently present a high proportion of 
small, dense LDL particles (Vergès, 2009).  
Although the findings from the present study may be contradictory to this it is 
important to note that many of the original studies which reported these findings 
are dated and therefore investigated patients using now antiquated methods of 
insulin administration (James, 1990; Lahderperä, 1994). Furthermore, many 
focused on patients with concurrent complications such as kidney disease, which 
in turn are highly likely to impact upon reported levels of small, dense LDL (Ibid). It 
is therefore hypothesised that the combination of improved glycaemic control 
inferred by both intensive forms of treatment may have contributed toward this 
favourable finding. Indeed, this has been shown more recently by Zhang (2016) 
who used nuclear magnetic resonance (NMR) to measure the lipoprotein 
subclasses of 1294 patients either randomised to conventional or intensive insulin 
therapies. The findings demonstrated that although quantitative lipid profiles were 
similar regardless of therapy, those using intensive treatments presented 
significantly lower levels of small, dense LDL. When considering that both 
treatment groups in the present study had not only analogous LDL subclasses but 
also similar HbA1c levels may indicate that the two groups are similarly controlled 
and may in turn explain the lack of difference which one might expect considering 
CSII is typically regarded as a superior method of achieving euglycaemia (Pickup, 
2002).  
In addition to this another influencing factor may be the proportions of patients 
using lipid lowering therapies. It can be seen from Table 7.9 that 35% of those 
using CSII and 33.3% of those using MDI were using statins (with a very small 
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number using alternative lipid lowering substances). It is well known that the 
principle mechanisms used by these compounds is to target LDL-C is through both 
the reduced synthesis of endogenous cholesterol via the inhibition of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase and by increasing the 
clearance of LDL particles (Stancu, 2001). Furthermore, this group of substances 
has not only been shown to reduce the risks of CVD by approximately 20% for 
every 1 mmol/L reduction in LDL-C, but also reduce the concentration of the small, 
dense fraction of LDL, thus further lowering risks (Ng, 2013). It is therefore 
reasonable to propose that the engagement by approximately a third of all 
participants with these drugs is likely to have contributed towards the generally 
favourable LDL subclass measurements demonstrated in the present study. 
Additionally it is equally likely that these substances will also have influenced the 
HDL subclass profile shown in Table 7.10. It has already been mentioned earlier in 
this chapter how statins may exert a beneficial effect upon HDL and Apo-A1 and 
how it is probable that their use may have influenced the lipid profile of the group 
as a whole. However, when focussing closer on the HDL subclass profiles 
belonging to the subsample using MDI it can be seen that HDL2 and HDL3 were 
equal and totalled 2 mmol/L. This is again suggestive of a well-protected sample, 
especially considering that current recommendations advocate obtaining plasma 
HDL levels above 1 mmol/L (NICE, 2015). Furthermore, it can be seen that those 
using CSII possessed substantially more of the HDL2 fractions (1.7 mmol/L) as 
opposed to HDL3 (1.1 mmol/L) which totals 2.8 mmol/L and is far greater than 
recommendations. As mentioned in the introduction it is unknown exactly which 
particular subfraction infers the most benefit as the number of studies in this area 
are small with mixed results; however, regardless of this the substantial total HDL-
C may initially suggest a high level of cardio-protection. Unfortunately the literature 
implies that this may not be the case, as despite high quantities of HDL-C very 
little is known about the functionality of the actual particles. This ‘functionality’ was 
first considered in the 1990s and it is now accepted that some HDL particles may 
lose their ability to carry out important functions such as reverse cholesterol 
transport, as well as the impairment of anti-oxidant and anti-inflammatory 
properties (Eren, 2012). Interestingly, the findings from recent studies into 
pharmacological substances designed to increase circulating HDL have proved to 
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be disappointing. The most recent being a trial on evacetrapib, the latest in a class 
of failed CETP inhibitors, which reduced LDL and more than doubled HDL, yet the 
trial was aborted due to no effect on heart disease or stroke (Kolata, 2016). This 
surprising finding possibly suggests that with regards to HDL perhaps quality may 
be more important that quantity and in a population at a high risk of CVD, such as 
those with T1D, further future research investigating this HDL functionality could 
be useful. 
So the question remains; what is an appropriate lipid measure of CVD risk 
protection in those with T1D? Some evidence suggests that using a ratio of Apo-B 
/ Apo-A1 may be superior. As LDL together with intermediate density lipoproteins 
(IDL) and very low density lipoproteins (VLDL) all contain an Apo-B molecule in 
their structure and are regarded as potentially atherogenic particles and Apo-A1 is 
strongly associated with HDL, a ratio of the two offers a representation of the 
balance between atherogenic and anti-atherogenic particles (Lima, 2007). There is 
also evidence that it is a suitable predictor of retinopathy in those with T2D (Hu, 
2012). Furthermore, work by Walldius (2004) documented cut-off values to 
determine risk factors based upon this Apo-B / Apo-A1 ratio. These focussed on 
cut-off values of 0.69 for low risk to moderate risk and 0.90 from moderate risk to 
high risk in males. Similar values for females were also defined, with 0.59 being 
the cut-off from low risk to moderate risk and 0.80 from moderate risk to high risk 
(Walldius, 2004). When looking at the findings shown in Figure 7.10 and Tables 
7.10 and 7.11 it can be seen that regardless of gender patients using MDI were 
shown to be at a moderate risk of CVD, yet those using CSII appeared to be at a 
low risk. Although a promising finding, it should be noted that the use of the Apo-B 
/ Apo-A1 ratio has not yet been fully established in the literature as a robust 
method of determining CVD risk. Also, the small sample size of the present study, 
which was further reduced when separated by sex, should be observed with 
speculation and whilst providing interesting findings care should be taken not to 
over-interpret. 
In addition to direct measures various relationships were found between variables 
derived from patients’ medical records and those resulting from the laboratory 
analysis of plasma which became apparent after performing correlation tests. 
Among the most striking were the relationships between BMI, insulin dose and 
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basal rate in those using CSII. Although the associations between this triad of 
variables were both strong and highly significant they are not entirely unexpected. 
The literature demonstrates that the higher the BMI the more insulin is required to 
metabolise circulating glucose as a result of decreased insulin sensitivity 
(Ferrannini, 1997). Furthermore, in those using CSII specifically it has also been 
shown that although bolus amounts typically decrease after glycaemic control has 
been established with the device basal rates actually increase (Chico, 2014). 
Indeed, this was also shown in the present study, with both basal rates and BMI 
either being equal to or higher than those presented by participants using MDI, 
despite lower overall insulin requirements.  
In addition to this, a very strong and significant relationship was also seen 
between total cholesterol and LDL-C in those using CSII. Again, despite being a 
highly significant finding it is not particularly unexpected, as clear positive 
correlations have been shown previously between total plasma cholesterol and 
LDL (Lam, 1990). Furthermore, mechanistic insights reveal that the endogenous 
synthesis of cholesterol by the liver is a precursor to the production of VLDL 
particles, which are subsequently stripped of triglycerides, thus forming the LDL 
used to transport cholesterol to cells (Nguyen, 2007). Interestingly, this 
endogenous production of cholesterol in those with well controlled T1D is typically 
undisrupted, unlike those with T2D, hence likely explaining the favourable total 
cholesterol levels revealed by the results (Gylling, 2004). Despite this, qualitative 
metabolic disturbances such as increased dietary cholesterol absorption have 
been reported to exist which may pose risks regardless of favourable quantitative 
levels, again suggestive of more complex abnormalities which could have had a 
profound influence, yet were out of the remit of the study (Ibid).  
Further strong and significant positive relationships were also revealed which have 
been previously documented by others, such as between age and total cholesterol 
in those using MDI. It is well known that total cholesterol typically increases from 
puberty until around age 55 in males and 65 in females, after which time levels 
diminish. Plasma cholesterol levels originate from three sources; namely the 
reabsorption of bile salts, the absorption of dietary cholesterol and cellular 
synthesis and it a reduction in this endogenous synthesis of cholesterol which is 
predominantly responsible for the decrease in total cholesterol observed in older 
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individuals (Félix-Redondo, 2013). Additionally, these improvements are often 
accompanied by a reduction in LDL-C and little change in HDL-C (Ferrara, 1997). 
Unfortunately, individuals older than 50 years are at an increased risk of CVD and 
these paradoxical lipid ‘improvements’ may ultimately offer little atheroprotection 
(NICE, 2015). Furthermore, in those with obesity, metabolic syndrome or T2D 
these lipid changes often occur in conjunction with an increase in triglycerides and 
VLDL and although overall LDL-C may decrease there is typically a predominance 
of small, dense LDL particles (Strandberg, 2006). Those with T1D are no 
exception and it is for this reason that NICE recommend patients over 40 years of 
age with T1D be prescribed statin therapy and is likely to be a principle reason 
why a high proportion of participants recruited to the present study are using lipid 
lowering agents (NICE, 2015). 
In addition to these relationships, positive associations were also shown in 
patients using CSII between HDL-C, HDL2, HDL3 and Apo-A1, which has again 
been previously documented (Srivastava, 2000). This, although expected, 
confirms the symbiotic relationship between HDL-C and it’s subclasses and that 
those with well managed T1D typically experience an increase in Apo-A1 
containing HDL particles (Vergès, 2009). This has been shown to be facilitated by 
an increase in lipoprotein lipase activity resulting from the subcutaneous 
administration of insulin (Kahri, 1993). Although this may initially appear 
favourable, those with T1D remain at an increased risk of CVD and these insulin 
mediated changes may in fact be another mechanism of influence on the Apo-B / 
Apo-A1 ratio described previously. It may therefore be likely that the reduced 
insulin dose associated with CSII contributed towards the lower Apo-B / Apo-A1 
ratio enjoyed by participants using the therapy, as shown in Tables 7.10 and 7.11 
and Figure 7.10 (Pickup, 2002). 
Despite these somewhat predictable yet important relationships there were others 
which were more perplexing. An example is the strong and significant negative 
association between diastolic blood pressure and total cholesterol in those using 
MDI therapy. This is unusual because one would not expect levels of cholesterol 
to decrease with a rise in blood pressure. The evidence also does not support this 
view, with numerous epidemiological studies highlighting that these CVD risk 
markers typically develop in tandem rather than inversely (Ferrara, 2002). 
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Furthermore, there were also negative correlations between age, diastolic blood 
pressure, total cholesterol and LDL I & II respectfully in those using CSII. As 
previously mentioned, it is well known that age is often accompanied by 
detrimental changes in risk markers, even in a healthy population, and in those 
with T1D these changes are often more pronounced, especially in those with poor 
glycaemic control; thus further increasing the risks in this already vulnerable 
population (Vergès, 2009; ADA, 2004). This finding is therefore somewhat difficult 
to explain. 
 Limitations 
It should be noted that these unexplained relationships were all associated with 
those using MDI and that the sample size, particularly in this group, was extremely 
low (n = 9). For correlations to be effective it is useful to use a larger sample as a 
small number of participants are very susceptible to easily skewed results. 
Although the data was checked for outliers and none were excluded the standard 
deviations shown in the results often describe high levels of dispersion from the 
mean. This is unfortunate; however, the study only had access to one clinic and 
every possible CSII patient and a matched number of MDI patients were contacted 
during the recruitment process and so the sample size for this pilot study was 
saturated within the target area. Needless to say the findings cannot be 
extrapolated to patients with T1D in general. Additionally, it should also be noted 
that the quality of data derived from patients’ medical records is unknown. 
Although all measurements were taken / analysed by an appropriate member of 
hospital staff the conditions under which they were originally derived is 
unspecified. Furthermore, the method used by the hospital staff to calculate LDL-C 
(Freidwald equation), despite being cheap and easy to implement also has 
limitations, with some studies showing the calculation routinely underestimates 
LDL-C when compared to homogenous assays (Tighe, 2006, Esteban-salán, 
2000). These are limitations of this study and although it is acknowledged that 
some measurements are simple to take (such as blood pressure) and that the 
author could have made the findings more robust by taking these himself under 
controlled conditions, the financial cost of others (such as HbA1c and additional 
lipid analysis) was out of the remit of the study. Despite offering useful insights into 
the cardiometabolic risks of patients using both CSII and MDI it should also be 
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remembered that the study was a cross-sectional design. The data therefore only 
offer a ‘snapshot’ of patients at a single time point with no opportunity to see 
longitudinal progress. This is unfortunate as the eligibility criteria requested 
patients to have been using their particular treatment for a year or longer, so all 
were well-established; however, it would be interesting to see changes 
immediately after commencement of the therapy where principle improvements in 
glycaemic control have been shown to take place (Pickup, 2002).  
In addition to these study design and medical record assessment issues, there 
were also various pragmatic problems with the laboratory analysis of plasma 
which may have influenced the findings. Firstly, as mentioned in the Methods 
section of this chapter, the HDL method was scaled up from an original protocol 
devised by Harman (2013). This required the use of 4.9 ml ultracentrifuge tubes 
whereas the rotor available to the author could only house larger 11.2 ml tubes. 
Although the method was adapted and it was hypothesised that the larger tube 
would facilitate a superior separation, without performing a comparative study with 
the Harman (2013) method it is unknown for sure if this is the case. Hopefully this 
will be addressed in future work. Secondly, there were also issues with some of 
the fractionation equipment throughout the process. When fractionating the 
plasma there were problems with the reliability of the auto-densi flow and it is 
difficult to assess the damage done. For future studies a more reliable method 
would be useful, or at the very least an alternative auto-densi flow. It must be 
stressed that this occurred sporadically and the author immediately intervened 
where possible to minimise disturbances to the gradient. That said, the recovery 
rates shown in Figures 7.8 and 7.9 for both LDL and HDL separation methods 
show disappointing mean percentages, with other published work using iodixanol 
separation methods recovering up to 100.1% (±4.0) of cholesterol (Kulanuwat, 
2015). It is therefore recommended that for future research using these 
procedures reliability testing is performed.  
Conclusion 
Despite limitations, the findings from this pilot study show that patients using MDI 
therapy are generally well-managed and that the same could be said to a slightly 
greater degree for their CSII counterparts. As expected, glycaemic control overall 
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was shown to be superior in those using CSII, as was blood pressure; however, 
very little difference could be seen regarding both quantitative and qualitative lipids 
and lipoproteins and surprisingly the two groups were remarkably similar. Overall 
these are promising findings for patients with T1D regardless of which intensive 
form of insulin therapy is used.  
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Quality of Life 
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8 - Quality of Life 
 
8.1 Abstract 
Continuous subcutaneous insulin infusion (CSII) therapy has been shown in the 
literature to offer improvements in quality of life; however, much of this evidence 
has been derived through quantitative methods. Qualitative approaches focussing 
on diabetes-related quality of life and CSII in particular are scarce, yet have the 
potential to offer unique insights into patients’ lived experiences. As such, the 
author recruited a sample of patients using CSII (n = 40) and MDI (n = 20) to firstly 
complete a brief quality of life questionnaire. These findings were then used to 
triangulate responses given by a subsample of patients using CSII (n = 12) and 
MDI (n = 10) during semi-structured interviews pertaining to quality of life. After the 
interview data was transcribed verbatim and analysed using thematic analysis the 
principle findings revealed that diabetes had severely impacted upon patients. The 
main themes indicated that after diagnosis there was typically an attempt to 
rationalise the disease and explain why it had developed; together with a fear of 
the future which sometimes resulted in rebellious behaviour. This was often 
followed by patients learning to accept and live with the disease; a challenge 
which for many became an obsession, frequently leading to mental health issues. 
For those using MDI the concept of CSII seemed pointless; however, for patients 
with poor control who were recommended the therapy the hope of improved 
glycaemia was welcome. Despite this many were initially concerned about the 
physicality of the therapy along with worries about changing their insulin regimen, 
which had often become an embedded routine. Although many were worried about 
commencing CSII, after becoming initiated many expressed positive regard for the 
pump and mentioned that the lifestyle flexibility it inferred greatly improved their 
quality of life. Aside from emphasising the benefits of CSII and highlighting the 
improvements in quality of life which can be enjoyed by using an insulin pump this 
study also revealed important areas of diabetes management which prove difficult 
for patients and provide areas of focus for future research in this area.  
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8.2 Introduction 
As has been previously discussed, Type 1 diabetes (T1D) is a complex, 
multifaceted disorder and although daily exogenous insulin administration 
facilitates the physiological management of the disease, a constellation of 
additional aspects may lead to detrimental health outcomes, including a decline in 
quality of life (Rubin, 2000). The term ‘quality of life’ is itself rather ambiguous and 
associated with numerous definitions depending on the source consulted; 
however, one in particular, coined by the Quality of Life Research Unit at the 
University of Toronto, describes the concept as ‘the degree to which a person 
enjoys the important possibilities of his or her life’ (Quality of Life Research Unit, 
2015). The authors then proceed to break this statement down into a number of 
conceptual categories which in turn are dissected into further subcategories 
pertaining to their practical ‘real-world’ components. A more detailed explanation 
of this is offered in the General Methods section (see page 45). Although this 
proposed framework refers to the general population, the level of detail is also 
particularly apt for describing the factors influencing quality of life in those with 
T1D. This is because the overall well-being experienced by patients is often 
compromised for a wide variety of reasons which other models often do not 
account for with more generalised statements.  
This plethora of influencing factors has been highlighted in a longitudinal study by 
Imayama (2011), which revealed that increased health-related quality of life was 
related to a diverse range of elements, such as being a non-smoker, partaking in 
physical activity, possessing an ideal body mass index (BMI) and having little co-
morbidity. Also, relationships have been shown to exist between quality of life and 
level of social support, emotional burdens and glycaemic control (Joensen, 2015).  
Furthermore, due to the issues associated with transitioning from childhood 
through to adulthood and the increased prevalence of T1D in youngsters, a 
substantial body of evidence investigating the quality of life of this population 
exists. This also reveals a variety of factors which impinge on quality of life, 
ranging from the level of psychological well-being, peer-support and the school 
environment (Cassarino-Perez, 2014). Additionally, qualitative work by Lowes 
(2015) shows further relationships between the impact of attending clinics, the 
communication (or sometimes miscommunication) between patients and 
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Healthcare Professionals and emotional responses to the disease, which may all 
impact upon quality of life.  
It is important to appreciate that this brief selection of influencing factors is 
uncomprehensive and serves primarily to demonstrate the complexity of the issue; 
however, it is also important to recognise that the impact of declining quality of life 
can be catastrophic for both the individual patient as well as society as a whole. 
Recent evidence from the Vital Signs report, commissioned by the Richmond 
Group of charities, described how those with long-term illness are suffering from 
severely compromised quality of life, with 60% mentioning how their condition 
impacts upon their daily life (The Richmond Group, 2015). When focussing 
specifically on diabetes it is estimated that 80% of amputations could be prevented 
and that the level of access to psychological support is highly lacking, with the UK 
‘Minding the Gap’ survey highlighting how of 85% of patients with diabetes have 
either no access to psychological support, or at best generic local mental health 
services (The Richmond Group, 2015; Trigwell, 2008). Furthermore, these 
disappointing statistics, combined with increased NHS waiting times due to 
underfunding as demonstrated by a recent report, further compound the issue 
(NHS, 2016).  
Despite this, advances in other areas have improved patient outcomes to an 
unprecedented level, with the Pittsburgh Epidemiology of Diabetes Complications 
study showing how the lifespan of those with diabetes has been increasing at 
rates which far exceed those demonstrated by the general population (Miller, 
2012). The UK is no exception to this, with an epidemiological study of 24,000 
patients’ medical records by Livingstone (2012) illustrating that life expectancy has 
also increased in those with T1D and whilst patients on average still live 11 years 
less than the general population, this is a significant improvement on previous 
research citing a reduced lifespan of between 15 and 27 years.  
One factor which is likely to have contributed towards these improvements is the 
advent of continuous subcutaneous insulin infusion therapy (CSII) in the 1970s. 
Although initial reports of cannula site infections and incidents of diabetic 
ketoacidosis briefly tempered enthusiasm for the therapy this was short-lived and 
as technology and education improved, so too did outcomes and CSII is now 
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regarded as a safe and effective form of insulin therapy (Pietri, 1981; Pickup, 
1982). Consequently, CSII is now associated with improvements in glycaemic 
control, which in turn may contribute towards reductions in micro and 
macrovascular disease risk; however, this is not the only benefit of the device, as 
the very nature of the treatment also infers a level of flexibility above and beyond 
that offered by its predecessors (Pickup, 2002). For example, the ability of the 
device to allow the administration of rapid acting insulin in small, regular 
increments potentially allows patients the opportunity to liberalise their eating 
behaviours. This has been discussed in detail in the Eating Behaviours chapter 
(see page 95). Furthermore, the ability to either suspend the insulin basal rate or 
temporarily detach the device facilitates uncompromised participation in physical 
activity (Franc, 2015). Additionally, the reduction in hypoglycaemic episodes 
associated with the therapy is another ‘mechanism of encouragement’ which may 
motivate patients with T1D to take part in exercise, which is particularly promising 
when considering that the main barrier preventing engagement is often cited as 
being a fear of hypoglycaemia (Brazeau, 2008). Also, the reasonably small 
inconspicuous size of the device, along with the ability to administer boluses with 
minimal button presses and with fewer injections is often promoted by 
manufacturers as providing an extremely quick and unobtrusive method of 
treatment compared to other therapies (Animas, 2016).   
Despite the clear documented advantages and potential benefits of CSII there is 
very little evidence which examines the therapy in terms of quality of life, not least 
in terms of patients’ thoughts and feelings. This dearth of data has been discussed 
in detail in the Literature Review chapter (see page 30) where a clear case for 
further investigation has been proposed. This chapter will therefore describe an 
investigation, through the utilisation of qualitative and quantitative methods, to 
determine the influence CSII may have upon the quality of life of adult patients 
with T1D.  
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8.3 Aims and objectives 
Aim 
The aim of this study is to investigate the impact CSII has upon quality of life 
compared to patients using multiple daily injections (MDI). 
Objectives 
 To determine patient quality of life using a brief questionnaire. 
 
 To investigate patients lived experiences of T1D with regards to quality of 
life by using semi-structured interviews.  
 
 
8.4 Methods 
A synopsis of the overall methodology and specific methods used to determine the 
quality of life of participants are in explained in the General Methods section (see 
page 45). To summarise, all consenting participants were asked to complete one 
brief quality of life questionnaire (EQ-5D) as a minimum requirement (Euroqol, 
2016). This questionnaire had previously been validated and extensively used in 
varied populations, including those with T1D (Solli, 2010). A subsample of 
consenting participants was then asked to take part in one interview. These 
processes can be visualised through flow diagrams which can be found in the 
General Methods section on pages 60, 61 & 62. 
The interviews were audio recorded and the first interview acted as a pilot. After 
confirming the data collection method was acceptable (by asking patients if they 
understood each question during and after the interview) the results were then 
used as the first data set. The interviews were semi-structured in nature and 
consisted of open-ended questions grouped around themes designed to 
investigate participants’ ‘lived experiences’. The aim of this was to access the 
thoughts, feelings and subjective understandings of the participants influenced 
how they experienced quality of life and the manner in which this varied in different 
contexts (Sparkes, 2014). A detailed explanation of how the structure was 
determined can be found in the General Methods chapter (see page 45) and 
examples of the interview structure can be found in appendix 12.6. 
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 Data Analysis 
The qualitative data resulting from the semi-structured interviews was analysed 
using a grounded theory approach. This analytical framework was originally 
derived from the writings of Glaser and Strauss (1967) which outlines the 
production of theories and hypotheses generated from systematically collected 
and analysed data. This process is often recursive, with data collection and 
analysis often operating in tandem with one another (Bryman, 2004). Since little is 
known of the quality of life of those using CSII it was agreed by the research team 
that grounded theory would therefore be an appropriate method to determine the 
lived experience and thoughts and feelings of participants. 
The audio recorded data was transcribed verbatim into separate Microsoft Word 
documents (1 file per participant). These were then imported into QSR NVivo 10 
where the transcripts were coded into themes pertaining to quality of life. This was 
achieved by following the system outlined by Corbin and Strauss (1990), who 
suggest three main methods of coding which can be used in grounded theory 
studies: open coding (where data is broken down and conceptualised and later 
combined into categories and subcategories), axial coding (where data from open 
coding is pieced back together in new ways to form relationships based upon their 
interaction) and selective coding (where coding systematically takes place around 
a specific framework or central issue). Given that the qualitative aspect of the 
study is exploratory, combined with a sparse existence of previous evidence and 
an absence of theories pertaining to the quality of life of those using CSII, the 
author decided that open coding would be the most appropriate practice to follow 
due to its propensity to stimulate ‘generative and comparative questions to guide 
the researcher upon return to the field’ (Corbin, 1990, p.12).  
The quantitative EQ-5D questionnaire was analysed by inputting the responses 
into a Microsoft Excel spreadsheet, which was then transferred to Statistical 
Package for Social Sciences (SPSS) (v.21). The data was then subjected to 
descriptive statistics. Due to the ordinal nature of the Likert Scale it would be 
inappropriate to further compare variables using parametric tests. Additionally, as 
there are only two independent variables to be compared (i.e. the treatment 
variable which consists of those using CSII and those using MDI) non-parametric 
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Mann-Whitney U Tests were instead deemed more suitable. It should also be 
mentioned that at the end of the questionnaire participants are asked to complete 
a visual analogue scale (VAS) to determine present health state. As this is a 
continuous variable the responses to this were also analysed using descriptive 
statistics and then examined for normality using the Shapiro-Wilks test. The data 
was found to be non-normal and attempts were made to correct this by applying a 
log10 transformation; however, this was not successful and so non-parametric 
Mann-Whitney U tests were again used to compare differences between treatment 
groups. An example of the questionnaire can be seen in appendix 12.4. 
The ‘quality’ of qualitative data is an important aspect which was considered by the 
author. In quantitative research this is of key importance, with principle indicators 
including objectivity, reliability, generalisability and validity and although it would 
be inappropriate to apply the same principles directly to qualitative findings, the 
issue of data quality is no less important (Sparkes, 2014). It is therefore 
unsurprising that this has been the source of much deliberation which has resulted 
in the development of various strategies to ensure quality; a thorough review of 
which is out of the scope of this thesis. Despite the attention this has received 
most approaches are ultimately founded upon work by Guba and Lincoln (1989), 
in which key criteria more appropriate to qualitative research was produced, which 
consisted of confirmability, credibility, dependability and transferability.  
The issue of confirmability refers to the level of objectivity presented in the 
findings. It is important that outcomes are not derived from the researcher’s own 
beliefs or pre-conceived ideas and must be free from bias. One suggestion to 
tackle this issue is to recruit a ‘critical friend’ to encourage reflection and appraise 
the findings (Sparkes, 2014). In the present study two members of the supervisory 
team who had no part in the data collection process evaluated the findings in 
detail. This allowed any findings which were potentially biased to be discussed and 
evaluated. 
Credibility is another important issue which applies specifically to the validity of the 
data. Traditionally in quantitative data analysis this is typically concerned with the 
level of confidence concerning the ‘trustworthiness’ of the data. Although not 
based around measurements these principles are still relevant in qualitative 
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analysis to determine that the conclusions made by a researcher reflect reality. 
Guba and Lincoln (1989) suggest a variety of methods to achieve this, many of 
which were not suitable for the present study; however, one technique which was 
incorporated involved the concept of triangulation. This method of observing the 
research from two or more vantage points required the findings from the interviews 
and questionnaires to be combined and considered together with a view to 
validating the outcomes (Denzin, 1989).  
Another issue pertaining to the ‘quality’ of qualitative research is that of 
dependability. In quantitative research this typically describes the reliability of an 
experiment which the researcher strives to achieve through the manipulation of 
conditions; however, it would be inappropriate to apply this strategy to qualitative 
research as the researcher should not try to ‘force’ something to happen (Wolcott, 
1995). Therefore some authors, such as Wolcott (1995), suggest rather than trying 
to address reliability in qualitative studies, efforts should instead be made to 
explain to audiences why it is not appropriate. After considering this the author 
decided that reliability is not an issue which needs not be discussed further. 
The final potential issue related to the ‘quality’ of qualitative data involves the 
generalisation of findings to the larger population. This is commonly addressed in 
quantitative research through the use of sample size calculations and other 
methods founded in probability theory to ensure that study outcomes can be 
extrapolated to the general population with a degree of confidence (Flick, 2015). 
This is not a concern of the present study, firstly because it is already 
acknowledged by the research team that the study was pilot in nature and 
secondly, because the sample was derived from only one clinic it would be 
premature to suppose that any findings are representative of a larger population of 
patients with T1D. Furthermore, some authors such as Chenail (2010) suggest 
that whereas quantitative research demands that the responsibility must lie with 
the researcher to ensure generalisability, qualitative research instead requires a 
large portion of the responsibility to sit with the reader when assessing the value of 
a piece of research. Therefore, although it is recognised by the author that there 
may be issues when attempting to relate the findings from the present study to the 
wider population, the reader may also have to accept this too.  
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8.5 Results and Discussion 
As the study utilised both quantitative and qualitative methodologies this section 
will firstly describe the findings from the quantitative questionnaire and will then 
move on to present and discuss the qualitative findings whilst referring back to 
those obtained from the questionnaire for triangulation purposes. It is hoped that 
this will not only provide a suitable level of data quality, but that it will also provide 
a logical ‘flow’ and allow a story to develop, thus allowing the reader to develop an 
understanding of the lived experiences and quality of life of patients using both 
CSII and MDI. 
EQ-5D Quantitative Results 
The EQ-5D questionnaire was given to every consenting participant of the cross-
sectional study to complete (n = 60). A brief summary of the sample characteristics 
can be seen in Table 8.1.  
 
It can be seen in Table 8.1 that the majority of participants were using CSII 
therapy (n = 40) compared to those using MDI (n = 20). Furthermore, in the CSII 
group there were also fewer males compares to females (32.5% and 67.5% 
respectively). Similar proportions of males compared to females were also seen 
the MDI group (35.0% and 65.0% respectively). The ages of the participants were 
also similar between those using CSII and those using MDI (46.6% and 46.3% 
respectively).  
The outcomes from the main questionnaire are summarised in Table 8.2. When 
looking at these findings one can see that both treatment groups have nearly 
identical responses referring to participants’ ‘mobility’; however, despite these 
similarities between groups nearly a quarter of participants using both CSII and 
MDI reported problems (25.0% and 20.0% respectively). Also, one participant 
using MDI failed to provide a response for this question.  
Table 8.1 – Summary of participant characteristics 
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The levels of ‘self-care’ between groups were identical, with 90.0% of those using 
both CSII and MDI reporting no problems with self-care and only 10.0% of those 
using either treatment reporting issues. 
When looking at the levels of ‘activity’ it can be seen that those using CSII 
reported slightly less issues (70.0%) compared to those using MDI (75.0%); 
however, there were still approximately a quarter of participants using both CSII 
and MDI who reported some problems engaging in activity (25.0% and 20.0% 
respectively). A small proportion of participants using both treatments (5.0%) 
reported extreme problems engaging in activity. 
Participants using both treatments (55.0%) reported no problems regarding ‘pain’; 
however, a large amount using both CSII and MDI reported some problems 
(35.0% and 40.0% respectively) and a smaller amount in those using both CSII 
and MDI reported extreme problems (10.0% and 5.0% respectively).  
When looking at the responses given to the ‘anxiety’ question it can be seen that 
the majority of participants using CSII (72.5%). The majority of those using MDI 
(65.0%) also reported no issues. Despite this, over a quarter of those using both 
CSII and MDI reported some problems (27.5% and 30.0% respectively) and a 
small amount of those using MDI reported extreme problems (5.0%). 
After performing Mann-Whitney U tests on each variable it can be seen in Table 
8.2 that none of the differences were statistically significant. 
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Table 8.2 – Findings from the EQ-5D questionnaire quality of life categories and p-values derived 
from Mann-Whitney U tests investigating the difference between treatment groups 
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The findings for the EQ-5D VAS question showed that those using CSII on 
average reported a mean health score of 69.9 ± 20.6 (with 0 denoting worst 
possible health and 100 denoting best possible health). Those using MDI reported 
a higher score of 77.3 ± 13.9; however, after performing a Mann-Whitney U test it 
can be seen that the difference between these findings was not statistically 
significant (p = 0.307).  
Semi-Structured Interview Results and Discussion 
Interview Summary 
In total 22 semi-structured interviews were carried out (12 with participants using 
CSII and 10 with participants using MDI). The overall group consisted of 31.8% 
males and 68.2% females. As mentioned in the General Methods (see page 45) 
and earlier in this chapter a number of definitions pertaining to quality of life exist 
and the author thought it appropriate to utilise one definition in particular to 
underpin the structure of the interviews. This definition was derived from the 
University of Toronto and although it has been previously discussed in more detail 
it is important to point out that despite many of the points bring covered during the 
interviews the aim was not to use it as a rigid ‘checklist’, but rather a general guide 
to inform the direction of the research (Quality of Life Research Unit, 2016). 
Copies of the interview guides which were used can be found in appendices 12.6. 
Also, the real names of participants have been anonymised to protect their 
identities and each was instead assigned a code, which are referred to herein. 
Each interview lasted between 1 – 1½ hours. 
During the analysis of the interviews various themes emerged. It became apparent 
that these could be grouped into three broad categories concerning ‘the impact of 
T1D on the sense of ‘self’, ‘the principles and realities of CSII and MDI’ and ‘the 
future of living with T1D’. These then contained various principle subthemes. This 
structure is summarised in Table 8.3 and discussed in detail thereafter. 
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The impact of T1D on the sense of ‘self’ 
 Desire to ‘rationalise’ diagnosis 
It is well known that T1D is a progressive autoimmune disorder which may develop 
asymptomatically for a number of years; however, by the time noticeable onset 
occurs the patient is likely approaching a ‘critical mass’, typically leading to an 
onslaught of rapid and serious metabolic disturbances, which if left untreated can 
quickly become fatal (Atkinson, 2000). During the interviews participants were 
asked to describe themselves before T1D and most emphasised how their lives 
previously were ‘typical’ or ‘normal’; however, a common theme which surfaced 
was desire to unpick and rationalise the onset of the disease. For instance, many 
believed that the diabetes was triggered by a traumatic experience. An example of 
this was given by patient C006 (a female, CSII user, aged 30) who suggested it 
was …  
‘really strange because there was no family history or nothing, but when I 
was seven I fell asleep on top of a twelve foot fence. I fell off … the shock of 
that caused my pancreas then to stop working’  
Patient C055 (a male, MDI user, aged 55) also explained how after being 
unexpectedly punched after intervening in a street fight …  
Table 8.3 – Specific principle themes which emerged from semi-structured interviews 
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‘I actually felt this shudder inside me and I don’t know what it was but I went 
back home to my wife and my wife said I was really reacting funny saying 
“oh I feel really strange”, you know and then 10 days later I was diagnosed 
as a Type 1 diabetic … so I’m convinced that the shock of it kicked it off’.  
These imagined links are often seen in those with chronic illness, with work by 
Williams (1984) revealing how patients with arthritis also revealed a strong desire 
to determine an exact reason for their condition, which is likely the result of the 
medical profession unable to explain the cause. When bringing the focus back to 
diabetes this appears to be no exception, with current knowledge unable to 
determine the exact aetiology of the disease and interview findings suggestive of a 
strong desire to determine the cause. Unfortunately, the scientific evidence placing 
trauma as a cause of T1D is not quite as enthusiastic, with controversies 
surrounding the topic being decades old. Dr Elliott Joslin discussed this 
phenomenon in a review over 70 years ago and concluded that the concept had 
lost favour in the medical profession, yet more recent evidence has shown 
correlations between traumatic experiences in early life and the onset T1D (Joslin, 
1943; Nygren, 2014). Despite this, existing studies are few in number and it would 
be premature to infer causation as it highly likely that those who experience a 
traumatic situation may consequently acquire the disease by chance alone and 
many reports fail to account for the time where the disease develops ‘covertly’ 
prior to symptoms (Atkinson, 2014). Healthcare Professionals may do well to note 
this desire of patients to rationalise their disease and whilst supporting them 
through diagnosis also ensure that an evidence-based approach is utilised to 
ensure any conclusions based upon reflections aren’t unfounded.  
 Difficulties during diagnosis 
Aside from the traumatic pre-diabetes experiences which many patients reported, 
it was also common for the actual onset and diagnosis of T1D to be described in 
detail. This was almost universally regarded, for a multitude of reasons, as a 
powerful and life-changing experience. Initially participants generally offered 
descriptive, longitudinal accounts of the symptoms which typically consisted of 
increased weight loss, tiredness and urination as well as an unquenchable thirst 
(Diabetes UK, 2015). Many patients remarked about how they initially mistook or 
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downplayed their symptoms with Patient C008 (a female, CSII user, aged 38) 
remarking that … 
‘I put it down to completely different things … I was up in the middle of the 
night [to go to the toilet] … but then I’m not a medic so I didn’t put it 
together, but thinking about it now I think it all fitted in’.  
Despite attempting to ignore the warning signs they often became unbearable and 
providing the patient hadn’t already collapsed they would usually make an 
appointment to see their family doctor. It was at this point an assortment of themes 
emerged. A principle theme which became quickly obvious was that this 
misdiagnosis all too often extended from the patient to the medical profession. 
Patient C020 (a female, MDI user, aged 69) illustrated this when she mentioned 
how … 
‘I went to my G.P. and she took a specimen of my urine and she tested it 
and it was blue and she berated me for wasting her time and she said that I 
shouldn’t try and self-diagnose by reading books and a lot of other stuff and 
the thirst she said must have been due to eating too many spicy foods that I 
didn’t eat’.  
She later explained how she was rushed to hospital after collapsing and falling into 
a coma and that the G.P. should have in fact performed a blood test to check 
blood sugar levels. These stories in addition to being common also highlighted a 
frequent mistrust of the medical profession, even in the early stages of T1D.  
In a society where consumers typically rule and medical information is easy to 
obtain patients often feel like they no longer have to obediently follow Healthcare 
Professionals and erosion of trust can have profound implications (Rowe, 2006). 
The healthcare system has recognised this and responded by adopting so-called 
‘patient-centred’ care which was revealed by the interviews to frequently play a 
key role during and immediately after diagnosis where many patients explained 
how their knowledge of the disease was generally poor and many were initially 
shocked and worried about their health and future. Patient C049 (a female, using 
MDI, aged 23) illustrated her high regard for this by stating that … 
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‘I started coming to the Diabetes Centre at the hospital and the nurses 
would talk you through things here and they would have presentations and 
they would talk you through all the treatments and any complications and I 
felt that having these things explained and why you have to do this certain 
type of treatment in this way really helped me to understand it and I think 
that that really helped to make it a lot easier’.  
In contrast, participants diagnosed with the disease some time ago described a 
distinct lack of information and communication from doctors and nurses, with 
Patient C026 (a female, using MDI, aged 68) explaining how …  
‘you weren’t told anything in them days and you didn’t have the internet to 
read things up so it was just what a nurse or a doctor told you really and I 
mean you never knew about your own condition and the complications that 
came with it’.  
Admittedly, diabetes knowledge in the healthcare profession is now greater, which 
may in part have contributed towards the level of disseminated information; 
however, it has been known for some time that these positive patient-Healthcare 
Professional relationships may in themselves improve metabolic control 
(Viinamäki, 1993). Therefore, this trend towards patient-centred healthcare can 
potentially result in swiftly broken relationships if poorly managed, can also be built 
upon to empower patients and ultimately improve outcomes.  
 Adaptation to life with T1D 
After the initial shock of diagnosis and the subsequent discovery of information 
about T1D, the participants then typically reported a number of lifestyle 
adaptations which took place to accommodate T1D into their lives, aside from the 
daily administration of insulin alone. One such lifestyle change was that patients 
had to give extra consideration to physical activity, with Patient C009 (a male, 
using CSII, aged 39) explaining how … 
‘post-diabetes you have to know what your blood sugar levels are, how 
much insulin you’re taking and you have to plan everything, everything has 
to be planned. You know you can’t just get up and think right I’m going to go 
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out and play football. You’ve got to get up, you’ve got to test, you’ve got to 
eat, so it makes you a lot more structured’.  
In addition to this alterations to diet were required to ‘feed’ excess insulin and were 
also referred to as being challenging. Patient C059 (a male, using MDI, aged 33) 
emphasised this by mentioning how … 
‘I would have to make sure I have breakfast, make sure I have lunch and 
make sure I have an evening meal throughout the day and it was something 
I struggled with for a number of years really, just making sure I had 
arranged all those meals and just making sure they were all balanced and 
everything and it caused me problems with my blood sugars and stuff’.  
Lifestyle changes regarding diet and physical activity in general are notoriously 
difficult to achieve in both the normal population and in other populations where 
changes are essential to improve outcomes, such as the obese. The literature is 
awash with records of poor attainment, such as the NDNS showing frequent 
failures by the public to meet dietary recommendations and the Active People 
Survey highlighting how 57% of adults in the UK do not take part in any form of 
sport (NDNS, 2014; Sport England, 2014). When focussing on diabetes, the 
Eating Behaviour chapter revealed failures by the participants’ to meet some 
dietary recommendations and Diabetes UK data illustrated how only 39% males 
and 29% females with the disease fail to meet recommended physical activity 
levels (Diabetes UK, 2014). Furthermore, it is also important to reiterate salient 
findings shown by the EQ-5D questionnaire which revealed how despite the 
majority of participants reporting no problems with their levels of activity or 
mobility, there remained approximately a quarter who mentioned either some 
problems or extreme problems regardless of treatment type. It is therefore easy to 
understand why these required changes may pose such a challenge to patients 
and these findings should emphasise that consideration and support is required by 
Healthcare Professionals (Young, 2014).  
 Barriers associated with T1D and divorce from a ‘normal life’ 
These practical aspects, whilst providing their own individual challenges, 
contributed to the wider theme of ‘barriers’ which were associated with the 
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disease. For example, career opportunities were viewed as restricted, with Patient 
C010 (a male, using CSII, aged 58) remarking how his aspirations were dented 
when …  
‘the doctor said to me “the army’s out for you”, which was a bit of a shock 
really as I sort of thought I had my life laid out’.  
There were also various authoritative restrictions imposed, with Patient C059 
describing how …  
‘you still want to live a normal life and you can't….it’s stuff like the DVLA 
saying that you need to take your blood sugar before you go out driving and 
stuff’.  
Interestingly, some of the barriers, aside from those imposed by the disease itself 
or societal requirements were also imposed by those who cared about the 
participants the most, with Patient C013 (a female, using MDI, aged 60) 
remembering how …  
‘my Mum was very protective and I remember … it was a big impact. You 
couldn’t do anything. You couldn’t go out with your friends. You know it just 
impacted such a lot’.  
The specific descriptions of barriers to the ‘normal life’ mentioned by Patient C059 
were reoccurring themes throughout the interviews and have been previously 
recognised by others and it is for this reason that charities such as Diabetes UK 
offer support through the organisation of holidays and information weekends for 
newly diagnosed patients and their carers (Diabetes UK, 2016). Unfortunately, 
despite support, this idyllic notion of a ‘normal life’ remains impossible to define 
and equally as unfeasible to achieve, yet it remained an aspiration which was 
often expressed as the participants took the author through the journey of their 
lives. 
 Stigma and T1D 
Unfortunately, this mirage of a hallowed ‘normal life’ was frequently juxtaposed 
against a backdrop of stigma, with participants opening up about unjustified 
vindications resulting from the disease, thus further compounding the perception 
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that their lives were in some way distinctly different to those without. An example 
was when Patient C001 (a male, using CSII, aged 45) mentioned that on a night 
out …  
‘I’ve had a bouncer come up to me and ask me what I was doing cause he 
thought I was doing drugs but I just said “no I’m just checking my bloods to 
see if I could have another drink … I could always do it in the toilet and 
make it look even more dodgy” and he said “well fair enough, but if anyone 
complains we are going to have to ask you to leave”’.  
This public shaming even occurred in places where individuals should be better 
protected, such as in the workplace, with Patient C048 (a female, using MDI, aged 
62) mentioning how when sat in the staff canteen at her supermarket job …  
‘I used to say to the girls sitting round the table “if you don’t like needles 
look away now” and I just used to stick it [insulin pen] in and one of the 
managers, a section manager, said “it’s enough to put yourself off your food 
isn’t it”, so I said to her “it doesn’t look like anything puts you off your food 
love!” because she was so overweight and everyone on the table started to 
laugh ... I was surprised, I was shocked, but I thought “you’re not getting the 
better of me love!”.  
These remarks, although shocking and discriminatory, are not unusual, with the 
literature also confirming how the scope of this stigma is widespread and how 
derogatory comments made through either a lack of knowledge, misconceptions or 
prejudice serve only to isolate and are likely to further catalyse the feelings of 
‘abnormality’ referred to above (Browne, 2014). 
 Resentment of T1D 
Maintaining control of T1D on a daily basis is a large obligation to shoulder, 
requiring high levels of patient motivation and responsibility. Unfortunately, these 
were shown to often suffer under the pressures of directly managing the disease 
combined with additional factors such as those previously described and stories of 
participants deviating from the required disciplined approach were common. 
Patient C026 aptly described this by mentioning how …  
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‘I used to feel really sorry for myself….”why me?, Why do I have to do this? 
Why can’t I eat this? Why can’t I have what I want?”, you know I really really 
resented it as a teenager and I really went off the rails and I freely admit 
that … in terms of my food. I just ate everything, I couldn’t have cared. I 
really rebelled against it. I can remember drinking bottles of Vimto. I liked it 
and I thought “well I’m gonna drink it”. I used to forge my blood urine test 
results. Oh I can remember doing it yes. Really really resented it. Hated 
every minute of it’.  
This strongly voiced denial of the disease and the neglect of responsibility is not 
restricted to Patient C026 alone, but is a common trait in newly diagnosed patients 
and particularly in those passing through adolescence and this rebellious 
behaviour is often regarded as a coping strategy (Graue, 2004). The implications 
of this behaviour are profound, as non-adherence to insulin regimens has been 
associated with declines in glycaemic control, which are in turn associated with 
increased risks of complications (Hood, 2009; The DCCT Research Group, 1998). 
Fortunately, with support from Healthcare Professionals many patients may refrain 
from this behaviour as they emerge from adolescence or the shock of diagnosis 
fades; with Patient C026 herself embodying this by describing how when she got 
married she started to think … ‘hang on, I’m only doing harm to myself here’ 
(Taddeo, 2008). Despite this it is unknown quite how much damage is caused 
during these periods of deviation; however, it is known that metabolic disturbances 
begin at an early age, with adolescents with T1D frequently presenting disrupted 
lipid profiles and reduced insulin sensitivity in those with poor control, indicating a 
potential area of risk in which Healthcare Professionals should pay close attention 
to (Bjornstad, 2015).  
 Fear and T1D 
Despite the grave implications of these disturbances it is not to say that patients 
are oblivious. In fact the opposite may be true, with ‘fear’ being a common theme 
interwoven throughout the interviews and with regards to long-term health 
implications patients understandably expressed unease. Patient C049 explained 
this by mentioning how …  
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‘I was quite concerned when I first got it [diabetes] and it was quite a lot to 
take on board that all of these horrible things might happen to you’.  
However, despite the long-term complications it appeared to be the more 
immediate, short-term issues which seemed to cause the most distress. In 
particular a fear of hypoglycaemia was often referred to as being an important 
aspect of the disease which when uncontrolled had a crippling effect on patients’ 
lives. Due to the unpredictability of the events and the severity of their nature 
many recovered and were left feeling embarrassed, ashamed and lacking 
confidence, which in turn often manifested in patients withdrawing from activities. 
Furthermore, in some cases the participants also explained how their warning 
signs had disappeared making the experiences even more alarming. Although the 
examples are too numerous to describe individually a particularly vivid insight was 
expressed by Patient C030 (a female, using CSII, aged 59), who mentioned how 
when working alone at work … 
‘I was passed out under the table and it wasn’t until somebody else came 
up and they walked around the table and they found me … yes, it’s 
embarrassing being carted through the office on a chair!’.  
Also Patient C059 proceeded to describe how when in Spain …  
‘I had a really scary hypo when I was on the train back to Barcelona and 
everyone was asleep on the train and I woke everybody up screaming and 
banging my head against the window and stuff’.  
He then explained how this subsequently developed into …  
‘a fear about blood sugars because you aren’t aware [of the onset due to 
diminished awareness] and you are worried that you are going to have a 
hypo so you will … change your food and lifestyle and the first thing that is 
easiest to change is to not do much exercise’.  
These characteristics are common in those with T1D and the evidence suggests 
the intensity of the fear grows with the severity and frequency of the episodes and 
that in some cases the apprehension of patients may even exceed anxieties 
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regarding long-term issues such as vascular diseases (Anderbro, 2010; 
Pramming, 1991).  
 Decline in mental health after diagnosis 
The complex interactions previously described unfortunately often culminate in a 
decline in mental health. This has been extensively investigated in the literature, 
with estimations suggesting that up to a third of patients with diabetes experience 
depression or anxiety or both (Anderson, 2001; Grigsby, 2002). The participants in 
the present study appeared to be no exception to this, with some describing how 
the permanency of the disease caused a perceived loss of control and a perpetual 
feeling that diabetes is ‘always on the mind’. This it turn frequently resulted in 
certain obsessive behaviours, with Patient C006 illustrating this by explaining how 
…  
‘I’d get an A4 sheet of paper and I’d highlight my highs, this is how crazy I 
am, highlight my highs in red, highlight my lows in yellow and do the green 
for the normal bloods and I’d say like “I’ve had say four highs in one day”, 
so that’s like fifty percent … I became obsessed and diabetes was my life 
and it didn't work!’.  
These disorders were typically accompanied by other numerous issues such 
feelings of guilt and hopelessness which in turn often manifested themselves as 
depression and anxiety. Interestingly the findings from the EQ-5D questionnaire 
shown in Table 8.2 also describe that over a quarter of those using both CSII and 
MDI reported suffering from anxiety, corroborating comments made both in the 
interviews and the literature about these common mental health disorders in this 
population. 
The principles and reality of CSII and MDI 
When patients were asked about living with T1D the comments were invariably 
negative; however, in contrast the commencement of CSII was held with generally 
positive regard considering the steep learning curve of the therapy and the 
requirement to adopt a completely new way of managing the disease. Perhaps the 
most obvious benefit which was initially expressed was the ability of the device to 
improve glycaemic control and hypoglycaemia. Furthermore, the EQ-5D 
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questionnaire also showed how patients reported no problems in their self-care, 
further indicating that participants were generally pleased with the therapy overall. 
Although these are positive attributes they were not unexpected as improvements 
in glycaemic control upon the commencement of CSII have been reported 
extensively in the literature (Pickup, 2002). Interestingly, although it is likely that 
these positive findings may have had an impact upon quality of life when 
considering the anxiety and fear poor glycaemic control can instigate, it was 
surprising that the participants were somewhat reluctant to spend time discussing 
this and were more eager to explain how the benefits from other areas of the 
therapy had more of an impact upon their quality of life.  
 Potential of CSII to allow lifestyle flexibility 
A principle reoccurring theme was the opportunity provided by CSII for patients to 
escape the rigid structure imposed when using other regimes such as MDI. A 
specific example of this was the ability to relax the diet. Participants mentioned 
specifically how the relatively structured diet associated with MDI was partly 
responsible for the obsessional behaviours mentioned earlier and how this in turn 
frequently resulted in food and drink items becoming ‘medicalised’. An example of 
this was highlighted by Patient C009 who stated that …  
‘I did start to see biscuits as a sort of medicine on the basal bolus regime, it 
was sort of “you’ve got to take your snack before bed” and emotionally 
there is a loss of control and feelings’.  
This relaxation of dietary habits is a currently under-researched area, with a 
thorough review of the topic in the Literature Review and Eating Behaviour 
chapters (see page 30 & 95); however, it was clear from the interview data that the 
participants regarded CSII as a vehicle to break free from this imposed structure. 
Interestingly, patients using MDI who had recently completed a carbohydrate 
(CHO) counting course also reported this opportunity for dietary liberalisation and 
couldn’t see how CSII could offer any benefit in this regard. The literature 
surrounding the physiological benefits of this are somewhat controversial, with a 
meta-analysis by Bell (2014) showing that weak, non-significant improvements in 
HbA1c are typically seen after completing a CHO counting course. Furthermore, 
there was only one study included in the analysis which lasted over 12 months and 
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so the long-term impact is disputable (Ibid). Despite this, research by the DAFNE 
Study Group (2002) does indeed suggest the courses are associated with quality 
of life benefits, with significant self-reported improvements when compared to 
controls which substantiate the participants’ comments. Unfortunately, it is 
unknown if these changes are the result of the course per se or from spending 5 
days focussing on T1D with enthusiastic facilitators (The DAFNE Study Group, 
2002). Furthermore, it should be noted that all CSII patients have to complete a 
CHO counting course before commencing the therapy; however, no such 
requirement exists for those using MDI (who typically perform the course 
voluntarily). Also, when considering that only 1.1% of patients in 2012 - 2013 
attended a structured education programme illustrates that the participants using 
MDI may therefore be indicative of a particularly well disciplined group of patients 
(Diabetes UK, 2015).   
This increased flexibility was not limited to dietary practices alone, with some 
patients also describing how other practical aspects of CSII helped to improve 
their quality of life. In particular the convenience of the therapy and its relative 
inconspicuousness was held in high regard. Patient C019 (a male, using CSII, 
aged 54) described how his experience in social situations had changed for the 
better upon commencing the therapy by saying how …  
‘when I was first diagnosed I would go to things like formal dinners with 
round tables and things like that and you would have to get up and you 
would have to go out to the toilets or … and you were carrying boxes round 
with you and you walk into an evening do and there you are walking in with 
a little box of stuff with you and it wasn’t socially acceptable … socially it 
became a lot easier on the pump and now when we go out with friends with 
4 or 6 of us all I do is sit at the table and do my bloods under the table and 
check what it is and we are sitting chatting and then my pump goes away 
and I’m dealt with’.  
Furthermore, aspiring triathlete Patient C010 also explained how …  
‘when you are on the bike you can actually do it [inject insulin]. It doesn’t 
happen very often but you can actually do it so again one of the advantages 
198 
 
of the pump is that. You can give yourself a jab very quickly … it’s very very 
convenient’.  
This allowed patients unprecedented opportunities to keep the disease private and 
for their lives to continue uninterrupted by the necessity of insulin administration 
which would have been impossible when using MDI. 
 Practical challenges of CSII 
Despite these favourable comments it would be wrong to think that CSII is a 
panacea for T1D. The participants also mentioned various negative aspects to the 
therapy. Some of the most prominent were somewhat in contrast with previous 
comments regarding the convenience of the device, with various participants 
describing issues with the physical dimensions of the pump, such as Patient C030 
who mentioned how …  
‘the hardest part is….men they just put it on their belt or trousers so it is 
probably not as noticeable, but you know if you are wearing a dress you 
haven’t a belt to put it on and even if I did have a belt it would probably be 
on the outside and it would be a bit obvious ... but now I’ve found out what 
my bra is for so I can shove it down that [Laughs]’.  
These issues are well known, with Barnard (2007) also finding that patients often 
had problems with the physical size of the pump; however, there is unfortunately 
nothing that can be done about this at present, although manufacturers are 
making efforts to minimise the profile of the devices and developing more friendly 
alternatives, such as patch pumps.  
Furthermore, participants frequently reported finding the process of commencing 
the therapy initially overwhelming due to the substantial information to take in as 
operating the pump and the regimen in general is considerably different to MDI. 
This was summarised by Patient C009 (a female, using CSII, aged 42) who 
mentioned how …  
‘it took a while to ‘get’….I remember sitting and going through the manual 
thinking “how on earth am I going to remember all this”, so it obviously took 
time’.  
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Patient C004 (a female, using CSII, aged 63) also explained how she was initially 
concerned about the level of technology involved and the thought of handing over 
control of their diabetes to the hospital staff. She described how …  
‘it’s very nerve racking really, going from when you’ve sort of got control. To 
have that taken off you and then to go on something entirely different. I was 
thinking “would at my age would I be able to control and programme myself 
in to do this and do that”.  
Despite these concerns the rigorous week-long education course provided by the 
hospital, although challenging, was regarded as an excellent induction process 
which prepared patients well for independently managing their diabetes using 
CSII. Patient C008 explained how …  
‘it was over 2 weeks virtually and intensive. So yeah every other day for 2 
weeks seeing (DSN) and with the presentations and stuff and having a 
practice and learning how to draw up a vial and stuff and talking about it 
and you know the consequences and stuff like that and why it’s important to 
monitor and check and kind of getting it drummed into you’.  
Patient C007 (a female, using CSII, aged 42) emphasised how the nurse who 
facilitated the session was … 
‘absolutely brilliant’.  
The importance of appropriate, structured education cannot be understated, with 
Morrison (2013) describing how it is a critical factor for success with the therapy. It 
should be noted that not all of the participants were inducted to CSII at the Royal 
Liverpool Hospital and that a recent audit revealed education sessions vary 
considerably over the UK, with some Trusts allowing pump manufacturers to 
commandeer the sessions (White, 2014). In sharp contrast to the positive 
comments regarding the educations sessions attended in Liverpool some 
participants complained about being referred to the hospital from other Trusts, 
often arriving with poor glycaemic control and stories of disappointing education 
sessions. Patient C030 emphasised this by mentioning how …  
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‘it was basic, “you do this and you do that”, a bit like when I first got 
diabetes and they said “you take your insulin at 5 o’clock and you eat at half 
past 5 and never the two shall meet” … even my own doctors had never 
seen one [insulin pump] before so they weren’t supportive and they couldn't 
tell you how to use it or anything and it was all a bit “do it yourself” if you 
like. Do you know what I’m saying? It all relied on me reading the book and 
being really interested in it’.  
It is important at this point to note that the Royal Liverpool Hospital Diabetes 
Centre is an NHS Centre of Excellence and that these tales from other Trusts are 
likely not due to negligence, but rather the result of funding and staffing 
constraints, as was illustrated in the insulin pump audit (White, 2014). 
Nonetheless, this evidence reveals the impact both good and bad education may 
have upon patients’ quality of life with CSII, as well as the influence positive 
relationships with Healthcare Professionals may infer; the importance of which has 
previously been discussed. 
Although issues exist, CSII was generally held in high regard with participants 
welcoming the opportunity to regain control of the disease. Patient C004 
summarised this by saying how …  
‘it’s always hard work. A lot of self-discipline … but the pump has definitely 
made life easier because I feel more in control than I did before’ and that 
‘the diabetes was controlling me….it still controls me, but I can control it 
now’.  
This in turn often resulted in patients developing a more relaxed attitude towards 
T1D and enabled their focus to shift towards looking ahead instead of having to 
continually deal with the present, which Patient C006 highlighting by saying how 
…  
‘I can look ahead now on the pump, I never could with the injections which 
is one big difference as well’. 
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Perceptions of CSII 
This is not to say that the patients who used MDI felt like their treatment was 
inferior. In fact many participants were quick to point out how happy they were with 
MDI, with many patients having graduated from conventional insulin therapy as 
their control deteriorated and found that MDI offered a method of superior 
management compared to once or twice daily injections. As such, this increased 
flexibility was perhaps the main positive theme which patients attributed to the 
therapy. Patient C055 described this by explaining how he … 
‘was on 2 injections a day, one in the morning and one in the evening so 
you had to make sure you ate at certain times through the morning or you 
would go low or whatever, whereas now if I inject in the morning I have a 
piece of toast, and if I’m busy all morning I don’t go low it doesn’t matter if I 
don’t have something to eat, so I can be in meetings all morning and 
everything else and I don’t have to have a bottle of Lucozade or a chocolate 
bar with me’.  
Despite this praise it was interesting to note that these patients generally could 
see no obvious benefit which CSII could give with regards to flexibility, with Patient 
C009 mentioning how …  
‘unless I’m missing something I can’t really see how that [CSII] would help 
because it would still be up to me to eat at the right times and eat the right 
amount and make sure I had enough or used the right amount of insulin’.  
Furthermore, those using MDI also had an extremely negative perception of being 
permanently connected to the device (although it can be removed for up to an 
hour maximum). Patient C020 highlighted this by saying … 
‘I just don’t particularly want anything on me the whole time and it probably 
is psychological because when you have your injection you put your pen 
away and here you are without any physical signs of diabetes and you can 
carry on living and it is possibly this idea that I have that I want to cling onto 
for as long as possible. That if I have something on me or attached to me it 
is a constant reminder of the diabetes’.  
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This desire by patients to ‘escape’ their T1D is not unique and work by Saarinen 
also highlighted how patients commencing the therapy found wearing the device 
made their diabetes ‘visible’, both to themselves and others. This contrasts with 
the absence of comments from established users of CSII which may potentially be 
a result of becoming accustomed to the device over time.  
This therefore poses an interesting divergence between those using CSII, the 
majority of whom previously used MDI and who deplored the treatment’s rigid 
structure and those currently using MDI who praise it and are sceptical of CSII. It 
is likely that the participants using CSII may have the benefit of hindsight and have 
only realised the true benefits after commencing the therapy. It should also be 
remembered that to be offered CSII strict criteria must be met and therefore it is 
likely that glycaemic control could not be reached in these patients using MDI and 
their time using the injections may have been torrid. Furthermore, as mentioned 
previously, given that many of those using MDI had attended carbohydrate 
counting workshops and had kindly volunteered to take part in the study it could 
also be speculated that may be a particularly disciplined group. That said, those 
using CSII made it clear that they were very happy with the device with Patient 
C001 mentioning how … 
‘I’d recommend the pump to any diabetic I know. I say “try and get on the 
pump, not injections, get on the pump and you’ll notice the difference” … 
the worst thing that can happen is it doesn’t work for you and that’s that. 
The best thing is that it does work for you and gets everything in your life 
sorted. It gets your sugar levels down. It gets you feeling better’. 
The future living with T1D 
 Health aspirations 
Although the participants were engaging with very different insulin therapies, it 
became apparent that when looking to the future both sets of participants had 
similar aspirations, which were typically focussed around health outcomes. Nearly 
all patients reported fears about their future health, with Patient C004 highlighting 
these concerns by stating how … 
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‘I worry because I haven’t got perfect control … you do worry, but there’s no 
point. You know, if you see something on the television and someone loses 
their sight, but I think it just makes you more determined that you’ve got to 
keep on the ball with it’.  
Some also had optimism for future developments which may assist with the 
management of T1D. Patient C060 (a female, using MDI, aged 57) explained this 
by mentioning how … 
‘there have been big changes and changes are coming all the time and 
more and more, I wouldn’t say cures have been found for things, but they 
have developed things for high blood pressure and high cholesterol and 
things and they can be controlled now whereas they couldn’t be controlled 
.... 40 odd years ago they wouldn’t be able to be as well controlled … It 
makes me feel reasonably optimistic you know. I mean, not that I want to 
live to be 120 because I certainly don’t, but I want to live a normal lifespan 
and be able to do things’. 
These universal health concerns appeared to be at the fore of the majority of the 
participants’ minds, regardless of treatment and that living a life free from 
complications with an acceptable quality of life was their priority. This is 
understandable considering the increase risks posed by T1D and despite often 
unfavourable circumstances the patients should be commended for their 
commitment and overall attitude to their self-care.  
Limitations and recommendations 
Despite this research producing some novel findings there are various limitations 
which should be acknowledged. Firstly, the participants all belonged to one 
hospital and although some may have been referred from other areas it would not 
be appropriate to extrapolate the findings to the wider population with T1D. 
Furthermore, it has been stated various times throughout this discussion that the 
participants using both CSII and MDI may have been particularly well disciplined. 
As such they may even not be truly representative of patients belonging to the 
clinic itself, which should be considered by the reader when judging the 
generalisability of the data. Also, despite best efforts to build rapport and the 
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utilisation of active listening techniques it is difficult to gauge how honest the 
participants were when talking about their experiences with T1D. Although no 
particularly sensitive questions were asked the topic in itself was still very personal 
and it is hoped that all participants felt comfortable enough to be open; however, 
this cannot be confirmed for sure. The cross-sectional design of the study also 
hindered this as it meant that the author only met each participant once, which 
made building rapport in a relatively short space of time a challenge.  
For future similar studies, although it is difficult to gather a truly representative 
sample due to the relative rareness of CSII, perhaps considering a multi-site 
design may ensure more generalisable results. Furthermore, it may also be useful 
in future to ensure adequate rapport is built before the interviews and perhaps pre-
study briefing sessions may help to ensure this. 
 
8.6 Conclusions 
To summarise, although this study revealed interesting findings regarding the 
quality of life of those with T1D using both CSII and MDI it is important to 
recognise that both sets of participants generally held their therapies in high 
regard and that both treatments appeared to assist with their principle function of 
attaining glycaemic control, which in turn was a catalyst for improved quality of life. 
Furthermore, it also became apparent that many participants conveyed great 
optimism in the face of harsh realities. It is an unfortunate truth that those with T1D 
experience shorter lifespans and greater risks of complications than the general 
population; however, once control of the disease had been regained using either 
method of treatment the participants often began to focus on the future rather than 
the present and to look further afield than the sometimes all-consuming 
management of diabetes. It also became clear through the interviews that a ‘if its’ 
working don’t fix it’ mentality often prevailed. An example of this was that many 
patients on MDI couldn’t see any direct benefit of using CSII when their current 
regimen is already working and that if anything it would be more of a hindrance. 
This was an unexpected discovery and whilst the author would not want to 
suggest that well-controlled, happy patients would be better off using CSII, it would 
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surely be better to at least ensure they are aware of the benefits of other therapies 
to allow more informed choices to be made. That said, it could also be 
hypothesised that those using MDI, if well-controlled, may realise that they may 
not be eligible for CSII funding and become resigned to MDI, hence the praise for 
the therapy.  
Overall, although more robust research would be welcomed in this area, this study 
has produced novel findings which the author hopes may be of use to those 
working in this currently under-researched area of diabetes. In particular, it is 
hoped that these findings illustrate the positive regard for effective education and 
services and given the currently poor provision for patients serve to highlight their 
importance. On the other hand they have also clearly shown the detrimental effect 
poor services may have and upon the lives of patients and it is hoped that 
evidence such as this will allow Healthcare Professionals to gain a deeper insight 
into the patient experience which can then be used to forge stronger relationships 
between the two parties.  
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9 - Case Studies 
 
9.1 Abstract 
There is a dearth of data which focuses on the longitudinal transition of patients 
from multiple daily injections (MDI) onto continuous subcutaneous insulin infusion 
(CSII) therapy, with a specific focus on eating behaviours, quality of life and 
cardiometabolic risks. It is important that this is elucidated as it is currently 
unknown if these aspects change over time after commencing the therapy. In the 
light of this the author carried out a number of case-studies (n = 5). Patients were 
asked to complete a number of food diaries to investigate their eating behaviours, 
take part in semi-structured interviews pertaining to quality of life and donate 
samples of blood, as well as allowing the author to access to their medical records 
for the determination of cardiometabolic state. These aspects were each carried 
out every three months over a one year period. The findings, although not 
statistically meaningful, offered a deep insight into patients’ transition onto the 
therapy. Initial concerns about the physicality of the device were revealed, but also 
excitement about the ability of CSII to potentially improve glycaemic control. 
Funding inequalities were also demonstrated with some patients having 
advantages over others. When commencing the therapy the consistency of care 
and improved level of support received was highlighted as being a highly 
favourable attribute of the therapy. Overall, the case studies revealed the 
complexity of patients which diabetologists regularly encounter; an issue which 
can complicate matters. These challenges mean that effective management of the 
disease can only be achieved through an individualised approach when adequate 
support networks are in place. Further research using a larger sample 
investigating the implications of CSII over time would be beneficial.  
9.2 Introduction 
Despite offering improvements in glycaemic control and the potential for additional 
lifestyle benefits, CSII is not a panacea for those with T1D and commencing the 
therapy can be extremely challenging for a number of reasons (Pickup, 2002; 
NICE, 2008). For example, the device itself is based upon sophisticated 
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technology and although the complex workings are hidden beneath a relatively 
simple user interface the thought of managing such a complicated piece of 
equipment may intimidate some patients (Jones, 2008). Others have also 
previously reported that the idea of being connected to a pump can be a constant 
reminder of the disease (Saariner, 2014). Furthermore, for initiation of the therapy 
to be a success, a high degree of education and support is required, which the 
patient must be open and receptive to (Morrison, 2013). These examples and 
others have been highlighted in the present study during the cross-sectional 
interviews described in the Quality of Life chapter (see page 173). Data derived 
from food surveys and blood samples also illustrated subtle behavioural and 
metabolic differences between patients using CSII and their counterparts engaging 
with MDI. Unfortunately, despite offering an insight into under-researched areas of 
CSII therapy the cross-sectional design of the study did not lend itself well to 
illustrating how these differences may change over time. The study inclusion 
criteria also required that all participants must have been using their specific 
treatment for a year or longer. Therefore all participants using CSII were well 
acquainted with the therapy and any opinions of the challenges they faced during 
its commencement were described retrospectively and as such the findings may 
not truly represent their experiences at the time.  
This therefore provides an opportunity for further research investigating CSII over 
time, both during and after its inauguration. A longitudinal study was initially 
proposed to examine this, but as described in the ‘Recruitment Feasibility’ chapter 
(see page 65), issues beyond the control of the research team prevented this from 
occurring to the extent originally planned. Despite this a small number of patients 
did consent to take part and the research team agreed that the resulting data 
would instead be better presented as a series of brief case studies.  
Case-studies were deemed to be an appropriate method for presenting the 
findings primarily for pragmatic reasons as any quantitative measures would be 
statistically redundant with such a small sample size. Despite this limitation the 
descriptive analysis of data derived from an individual can still offer valuable 
insights, upon which questions can be posed to inform subsequent, more robust 
studies (Budgell, 2008). Furthermore, it was also clear that any qualitative data 
derived from interviews, if described ‘per participant’, may also allow a deeper 
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understanding into the complexity of a particular individual’s specific lived 
experience, as opposed to discussing data in the context of a group of 
participants, as is typical of other qualitative methods. The intension of these case 
studies is therefore to utilise these advantages to offer a ‘flavour’ of the transition 
from MDI to CSII through a combination of quantitative and qualitative data 
pertaining to the lived experiences, physiological changes and lifestyle habits of a 
small number of individuals. This will allow the reader to understand the 
transitionary process from MDI to CSII at an individual level and appreciate the 
challenges and complexities involved. 
9.3 Aims and Objectives 
Aim 
The aim of these case studies is to investigate the eating behaviours, quality of life 
and cardiometabolic risks of adult patients with T1D commencing CSII therapy.  
Objectives 
 To determine the eating behaviours of patients commencing CSII therapy 
using food diaries. 
 To assess the quality of life of patients commencing CSII using a brief 
questionnaire and semi-structured interviews. 
 To evaluate the cardiometabolic risks of patients commencing CSII therapy 
through the assessment of medical records and the laboratory analysis of 
plasma. 
 
9.4 Methods 
As the originally designed longitudinal study did not occur due to recruitment 
issues and a series of case studies were instead proposed this inferred an 
important methodological shift. Rather than adhering to the planned ‘concurrent 
embedded’ strategy (meaning data is collected together and that the qualitative 
element would be smaller and hypothesis forming), the methodology changed to a 
‘concurrent integrated’ strategy (where all data would be equally combined to tell a 
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story) (Creswell, 2009). As such, the quantitative and qualitative data were treated 
with equal weight and used together throughout the case studies.  
The actual data collection methods used for each case study remained the same 
as described for the original longitudinal study and are outlined in the General 
Methods chapter (see page 45). To summarise, each participant was asked to 
attend an appointment to collect baseline measurements shortly before they 
received their insulin pump and prior to the commencement of CSII education. The 
participants were then asked to attend a further four appointments every three 
months for one year. During each appointment every participant was asked to 
complete a 5 day weighed food diary, an EQ-5D quality of life questionnaire, 
donate a small sample of blood (20 ml) and to take part in a semi-structured 
interview to determine quality of life. Standard markers of risk were retrieved from 
patients’ medical records after consent from the participants. These consisted of 
age, BMI, HbA1c, insulin dose, total cholesterol, triglycerides, LDL-C, HDL-C and 
systolic and diastolic blood pressure. A note was also taken if the patient was 
taking any lipid lowering medication.  
All quantitative data was analysed using Microsoft Excel 2010 to determine basic 
mean averages and standard deviations where appropriate. As each case study 
only consisted of one participant, often with single measurements for each 
variable, no further statistical analysis was performed.   
All semi-structures interviews were audio recorded and transcribed verbatim. The 
resulting transcripts were then exported to NVivo (version 10) where coding took 
place. All qualitative data was analysed using a grounded theory approach. The 
interview and analysis process has been previously explained in detail in the 
General Methods and Quality of Life chapters (see pages 45 and 173).  
It should be noted that the quantitative and qualitative findings were combined 
using triangulation. This is a concept outlined by Guba and Lincoln (1989) and 
involves using two or more other forms of data to support and offer different 
viewpoints and in the present study involved the data collected from patients’ 
medical records, food diaries, quality of life questionnaires and the laboratory 
analysis of plasma samples to be combined with qualitative semi-structured 
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interviews concerning quality of life. It is hoped that this will offer the reader an 
intimate insight and allow the validation of the outcomes (Denzin, 1989).   
All findings have been presented following the method of Budgell (2008). This 
method requires the author to firstly describe the patients’ perspective using an 
efficient narrative style and draw from all relevant sources of information with a 
clear emphasis. In the case of the present study this involved focussing 
specifically on the transition onto CSII and patients’ subsequent engagement with 
the therapy for one year. Each case study then finishes by briefly discussing the 
outcome of CSII and the overall salient points regarding the process of transition 
(Budgell, 2008). A final section then concludes the case studies by briefly 
summarising all findings and outlining any limitations and recommendations.  
 
9.5 Results and Discussion 
These case studies describe specifically the process of transition from MDI to CSII 
for five individual patients from the Royal Liverpool Hospital Diabetes Centre. The 
patients all consented and began the study just before they were due to be issued 
CSII and before the education sessions were scheduled to begin. The results are 
presented as brief individual, anonymised case studies and alphanumeric codes 
have been assigned to each participant to retain this anonymity. These codes and 
the basic characteristics for each participant are shown in Table 9.1 Each case 
focuses specifically on the immediate transitionary process from MDI to CSII and 
where possible reports their engagement with the therapy for the following year. 
All patients were previously using MDI and none had any prior experience with 
CSII. It should also be noted that not all participants completed all parts of the 
study. The reasons for these discrepancies are varied and will be described within 
each individual case study.  
 Table 9.1 – Anonymised patient codes and basic characteristics 
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 Patient L001 
As mentioned in Table 9.1, Patient L001 was a white, British 41 year old male 
factory worker from Liverpool with long-standing T1D. The patient commenced 
CSII in December 2013. When consenting to the study he stipulated that he did 
not want to take part in semi-structured interviews. This was agreed by the author; 
however, after attending the second scheduled study appointment the patient’s 
personal life had become difficult with abnormal shift work and family 
commitments. He decided that whilst he would still be prepared to donate a 
sample of blood (as the short phlebotomy appointment could be easily fitted 
around work and combined with other clinic appointments to minimise the burden), 
he would no longer have the time or inclination to complete any more surveys or 
food diaries. The author accepted this and mentioned that the blood sample would 
still be very much appreciated. This therefore explains the missing data, 
particularly for visits 3, 4 and 5 and the lack of qualitative data. 
Although CSII is often noted for its inherent ability to improve glycaemic control 
and offer reductions in insulin requirements (Pickup, 2002), it can be seen in Table 
9.2 that neither of these occurred in the case of Patient L001. In fact his HbA1c 
actually increased from 8.6% to 8.9% and insulin dose remained circa 32 IU per 
day. This was an unexpected finding; however, the patient made it clear that after 
commencing CSII his personal life had become more stressful and it is well known 
that stress can mediate HbA1c through activation of the corticoid and epinephrine 
systems (Pickup, 2004). For example, work by Kawakami (2000) revealed that 
occupational stress, even in healthy individuals, may have an adverse impact. 
Furthermore, the impact of stress upon blood sugars in those with diabetes has 
been well documented, with chronic and acute stressors, both directly and 
indirectly related to diabetes being associated with higher HbA1c (Hillard, 2011). 
Therefore, perhaps it could be said that the patient’s challenging lifestyle issues 
may be partly responsible for these glycaemic anomalies; although with the 
absence of definitive evidence it is difficult to say with certainty. That said, the 
findings shown in Table 9.3 contradict this by indicating that at baseline the patient 
felt he was in good health with no perceived problems, thus further confusing 
matters.  
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The increases in HbA1c were also accompanied by increases in blood pressure to 
borderline hypertension (NICE, 2008). Although little literature exists to suggest 
that CSII can influence blood pressure it is well known that stress is associated 
with hypertension, thus further bolstering the hypothesis that the lifestyle of Patient 
L001 may be mediating some of these metabolic changes. Although Table 9.3 
illustrates no perceived problems in terms of quality of life and overall health, this 
is perhaps an indication that whilst Patient L001 may consider himself to be 
Table 9.2 – Basic clinical measurements and lipoprotein subfraction findings. All data derived 
from patient medical records apart from total cholesterol, triglycerides, apolipoprotein and 
lipoprotein subfraction data (which were derived from auto-analyser measurements). 
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dealing well with stress, aspects of his physiology suggest otherwise. It is 
unfortunate that there is a lack of qualitative data to further elaborate upon this 
hypothesis. 
Despite a lack of glycaemic improvements and increases in blood pressure Patient 
L001 appeared to have a relatively stable lipid profile, which although not changing 
greatly throughout the course of the therapy remained protective. His LDL-C levels 
were below recommendations of 2 mmol/L and his HDL-C was consistently above 
1 mmol/L (NICE, 2015). Furthermore, subfraction analysis demonstrated a 
predominance of the less atherogenic LDL-I and LDL-II subclasses and the patient 
was found to possess a favourable Apo-B / Apo-A1 ratio (consistently around 0.40 
– 0.50), suggestive of low cardiovascular disease risk according to the criteria of 
Walldius (2004). Although these are promising findings it is important to note that 
Patient L001 was also using statins which may account for this well-managed 
lipoprotein profile and in the light of his challenging lifestyle and poor glycaemic 
control may also be an indicator of the benefit of regular appointments with 
Healthcare Professionals ensuring his medication is well ‘tailored’ to his needs. 
 
 
When focussing attention on Tables 9.4 and 9.5 it can be seen that Patient L001 
consumed considerably less than the EAR of energy per day (although this 
increased after commencing CSII), which contrasts against his BMI measurements 
indicating he was slightly overweight.  
Table 9.3 – Findings from the EQ-5D questionnaire. (A finding of 0 on the EQ-5D Health Scale 
denotes worst possible health, whereas 100 denotes best possible health). 
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This paradox could be the product of under-reporting, which is particularly 
common in those who are overweight or obese (Black, 2000). Furthermore, the 
patient’s consumption of CHO, although being close to recommendations, 
consisted of an increased intake of total sugars. Despite being below 
recommendations of 90 g/day it is unlikely that this increase in total sugars is the 
result of an increased consumption of fruits and vegetables as vitamin C and NSP 
levels remained static after the commencement of the therapy and may be 
perhaps suggestive of an increased consumption of sugary foods and drinks 
(European Food Safety Authority, 2009). Furthermore, this patient also appeared 
Table 9.4 – Average daily macronutrient findings from 5 day weighed food diary. 
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to be consuming substantially more sodium than recommendations of 1600 
mg/day which is again concerning given his increased blood pressure. It has been 
proposed in the literature that CSII may allow patients the opportunity to liberalise 
their diet and these findings reiterate that Healthcare Professionals should 
encourage any relaxation to take place with healthful food choices. 
 
Despite these concerns it is striking that the amount of calcium consumed by 
Patient L001 doubled after the commencement of CSII and he was virtually 
meeting recommendations. When considering this with the increased consumption 
of saturated fats and MUFA may perhaps be suggestive of a higher intake of dairy 
products. Therefore it could be argued that as some of these foods, in particular 
cheese, has been shown to infer neutral effects and in some cases improve the 
lipid profile, offer a potential mechanism which may be working in tandem with 
pharmacological lipid lowering treatments resulting in the patient’s positive lipid 
profile (Nilsen, 2015). Despite these favourable findings they reveal very little 
about other qualitative lipid abnormalities which may be present, such as glycation 
Table 9.5 – Average daily micronutrient findings from 5 day weighed food diary. 
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and oxidation which have been shown to exist even in those with well controlled 
T1D and which may infer an increased level of CVD risk (Vergès, 2009).  
These findings, whilst offering interesting perspectives on an individual patient’s 
progress from commencing CSII are not without limitations. A lack of qualitative 
data makes it difficult to further investigate questions regarding some of the 
quantitative changes demonstrated. Also, as Patient L001 completed the food 
diaries at home it is impossible to say with certainty the accuracy of the data. In a 
similar respect, some of the data was derived from his medical records and it is 
impossible to know the conditions they were measured under, although that said 
the LDL-C and HDL-C results are largely similar to the combined sum of their 
respective subclass measures determined by the author, which is suggestive of a 
degree of accuracy. Despite these issues the data still offers a useful, if 
incomplete, view of a patient’s 3 month journey through the commencement of 
CSII.  
 Patient L002 
Patient L002 was a white, British, 24 year old unemployed female from Liverpool 
with long-standing T1D who commenced CSII therapy in December 2013. Prior to 
being a patient at the Royal Liverpool Hospital this patient mentioned how she had 
experienced poor service at another hospital which interfered with her regular 
appointment schedule. She described how… 
‘I got lost in the records … and I was supposed to be going to [names 
hospital], but then I ended up coming into A & E [at the Royal Liverpool 
Hospital] with ketoacidosis and I saw a diabetic nurse and she took us to be 
referred. I hadn’t seen anybody for two years.’ 
Unfortunately, this temporary hiatus allowed the development of a host of diabetes 
related issues including insulin insensitivity, retinopathy and liver problems. This 
medley of complex issues was further complicated by uncontrolled diabetes and it 
was the onset of severe gastroparesis which finally persuaded her Consultant 
Diabetologist to suggest that she may achieve better management through the use 
of CSII; a strategy which has been shown to offer significant improvements in 
glycaemic control in patients with the condition (Sharma, 2011).  
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The patient expressed concerns about commencing the therapy, mainly related 
to…  
‘the change, cause it’s like starting all over again. Having to do everything 
different … It’s just remembering everything isn’t it. The way you’ve got to 
do things is a lot different.’  
However, despite these anxieties Patient L002 explained in detail her 
complications, the impact they have had upon her quality of life and how she was 
very much looking forward to commencing CSII to improve not only her blood 
sugars, but also reduce her retinopathy risks and improve her gastroparesis 
symptoms. It was this condition in particular which appeared to cause much 
distress and is typified by the delayed gastric emptying due to damaged autonomic 
nerves, leading to nausea, vomiting and bloating which has additional nutritional 
implications as the patient may be unable to eat (Abrahammson, 2007). 
When considering these issues the data presented in Tables 9.6, 9.8 and 9.9 
begin to form meanings. Firstly, when looking at BMI it can be seen that the 
patient was approaching obesity. It is well-known that having a raised BMI 
perpetuates insulin insensitivity and it is therefore likely to be a contributory factor 
for this patient’s own insulin sensitivity problems; a suspicion further substantiated 
with the high subcutaneous doses of insulin shown in Table 9.6 (Pickup, 2004). 
Furthermore, despite her raised BMI the patient’s energy intake was markedly 
below recommendations. Although an element of under-reporting may be 
occurring (as is typical in those who are overweight or obese) Patient L002 was 
also suffering from severe gastroparesis (Black, 2000). In fact during the brief 
interviews which the author conducted to ensure the quality of the food diary data 
the patient made it clear that she was eating very little. Furthermore, this did not 
appear to improve even after the commencement of CSII and after 3 months she 
stated that… 
‘It’s the same at the moment. I’ve had a bit of a flare up of my gastroparesis 
over the last couple of weeks and not feeling very well.’ 
This will also likely explain the very poor consumption of a number of 
micronutrients such as calcium, iron and vitamins A and C which actually 
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decreased after using CSII and as the symptoms of her gastroparesis increased. 
These vitamins and minerals are individually extremely important for a number of 
key biological processes and if prolonged these sub-optimal intakes may place the 
patient at risk of additional issues such as poor immune function (Wardlaw, 2002). 
 
 
  
 
Table 9.6 – Basic clinical measurements and lipoprotein subfraction findings. All data derived 
from patient medical records apart from total cholesterol, triglycerides, apolipoprotein and 
lipoprotein subfraction data (which were derived from auto-analyser measurements). 
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The difficult time that Patient L002 was experiencing was also reflected in her 
responses to the EQ-5D questionnaire presented in Table 9.7. She described no 
problems with her activity levels; however, for every other category there were 
‘some problems’ and none of these improved after commencing the therapy. This 
was further compounded by the patient rating her overall health at a score of 50 
both before and after the commencement of the therapy, thus showing no 
improvement at all. 
Despite Patient L002 initially appearing at risk, some positive aspects were 
revealed after the commencement of CSII. Although there was a slight decrease in 
both HDL-C and LDL-C, there were also reductions of 0.49 mmol/L of total 
cholesterol and 0.50 mmol/L of triglycerides. These are promising findings given 
her initial poor glycaemic control and complications, although it is likely that they 
may also be the result of a decreased consumption of food as a result of 
gastroparesis. Furthermore, despite her initial reluctance, the patient also highly 
praised the transition onto CSII, by mentioning that… 
‘it has been brilliant really cause [says DSN’s name] is on hand if you need 
to speak to her and she always phones you back and stuff like that so there 
is no worry there … and I do think that [says DSN’s name] and [says 
doctors name] are a lot better than the doctor and nurses I had before. 
They [previous doctors] just left me to get on with things.’ 
Table 9.7 – Findings from the EQ-5D questionnaire. (A finding of 0 on the EQ-5D Health Scale 
denotes worst possible health, whereas 100 denotes best possible health). 
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Additionally, it was also mentioned how despite issues out of her control the 
patient still managed well to control her blood sugars… 
‘At first I found it a bit difficult to control my blood sugars, but now it’s stable. 
it’s still a bit up and down now because I’ve had a constant water infection 
for 3 months so my blood sugars have been a bit up and down but they’ve 
levelled out now.’  
Despite this there were two main issues specifically with the pump itself which 
were emphasised. Firstly, the patient mentioned how the cannulas often fell out, 
leaving her at high risk of diabetic ketoacidosis (DKA), but was impressed with the 
service she received. She described this by remembering how… 
‘I panicked a bit a few weeks ago when my cannulas were messing up 
because I had ketones and my blood sugars were through the roof so I 
came into hospital and they were all sorted out within a few hours. So it’s 
just better.’ 
Secondly, the alarm system on the pump device which sounds after insulin 
administration has taken place to remind the patient to check their blood proved to 
be disruptive, particularly for the patient’s partner… 
‘It’s like a song. It’s the only song on the pump. It’s just a bit of a nightmare. 
You can switch it off, but I don’t in case I don’t remember to check my blood 
sugars … half the time I sleep through it and my partner has to switch it off 
… it keeps him awake!’ 
This is not an isolated issue and has been previously reported with insulin pump 
devices and is a major disruption to sleep, not only for the patient, but also their 
significant others (Barnard, 2016). This is out of the remit of the patient or 
physician to solve; however, the device manufactures may do well to take 
comments such as these on board and amend their products to better deal with 
this issue. 
Although presenting some interesting findings the reader has no doubt been 
drawn to the fact that there is a significant amount of missing data, particularly 
pertaining to visits 3, 4 and 5. After visit 2 Patient L002 informed the author that 
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she was pregnant and whilst she wanted to remain part of the study this 
development combined with her concurrent complications would prevent her from 
doing so. 
 
The author accepted this and the patient therefore unfortunately withdrew from the 
study. Despite this the findings gathered from the short time she did participate 
gave an interesting insight into a highly complex case. It is this complexity which 
illustrates exactly why data should perhaps be considered more holistically instead 
of compartmentalising findings. For example, the dietary data pertaining to Patient 
L002 reveals very little alone, but when considered in the context of her 
Table 9.8 – Average daily macronutrient findings from 5 day weighed food diary. 
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complications helps to partly explain some of the abnormal findings. It is this 
benefit of case-studies which the author would like to exploit to hopefully give a 
deeper insight into the world of individuals; a trait which often gets missed in 
studies where participants are grouped into categories and assessed ‘on-mass’ 
using probability theory. 
 
 
 Patient L003 
Patient L003 was a white, British, 23 year old male, living in Liverpool who, upon 
commencing the study had just completing his third year of a degree and was due 
to begin a placement as a Healthcare Professional. The patient had only been 
diagnosed with T1D four years ago and had found coming to terms with the 
disease initially challenging with regards to the habitual routine of an insulin 
regimen; however, he quickly adapted to using MDI and found the therapy 
adequate for his needs. He commenced CSII therapy in April 2014. 
Table 9.9 – Average daily micronutrient findings from 5 day weighed food diary. 
224 
 
Patient L003’s route to being offered CSII was somewhat different than most other 
patients and was in part attributable to his profession. He described this by 
explaining how when working … 
‘I got talking to one of the specialist nurses who specialises in sport and 
managing diabetes and she asked me if I was on injections or a pump. I 
said I was on injections and she asked me if I had ever thought about a 
pump and I was under the impression that you could only get a pump if your 
diabetes was badly controlled and that there was a certain threshold for 
your HbA1c and mine was below that. She said “no, email [says doctors 
name] and see what he says”, so I emailed him and he emailed me back in 
November or December 2013 and that just got it all going really.’ 
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This exposure to the medical ‘establishment’ afforded to this through this patient’s 
profession is atypical and it could be said that the expert advice he received 
regarding who to contact and the steps required to obtain CSII approval are tools 
which are out of reach for the majority of patients and certainly not documented in 
NICE guidelines. Furthermore, after then researching the benefits of CSII the 
patient became convinced that the therapy could improve his lifestyle. He 
explained how… 
Table 9.10 - Basic clinical measurements and lipoprotein subfraction findings. All data derived 
from patient medical records apart from total cholesterol, triglycerides, apolipoprotein and 
lipoprotein subfraction data (which were derived from auto-analyser measurements). 
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‘when I looked into it and realised that you can improve your control and 
have much more freedom in what you eat and she [colleague] did say to me 
that you get more freedom with regards to sport because I obviously like 
sport quite a lot so I thought I’d give it a go.’ 
This newfound conviction combined with a clear understanding of the process 
involved in obtaining an insulin pump were then used by Patient L003 to build a 
case of why CSII would be the best solution for him, even in the absence of any 
glycaemic control issues which NICE states as being essential criteria. The patient 
did this by using flexibility as a principle reason and explained that he was 
currently going through a stressful time with university examinations and how he 
would be eventually going to start working chaotic shift patterns, which would in 
turn make managing his diabetes difficult. He also mentioned how since 
developing the disease his participation in sports and eating patterns had suffered 
due to the structure of MDI; both of which he would like to regain.  
Despite these clearly thought out benefits he also had various hesitations 
regarding the device… 
‘I’d always disliked the idea of them because I’ve always disliked the idea of 
having something attached to me, constantly reminding me that I’m a 
diabetic sitting in my pocket.’ 
Comments such as these are not exclusive to Patient L003, with other authors 
demonstrating that these concerns of ‘diabetes made visible’ are typical of 
patients’ initial worries; however, it is common that these issues disappear after 
the commencement of the therapy (Saarinen, 2014; Todres, 2010).  
 
227 
 
 
 
After the first visit and upon completing his university examinations the patient 
decided to go travelling for three months. This explains the absence of data when 
visit 2 should have taken place. Upon his return Patient L003 mentioned how this 
trip truly tested the device and overall had been a positive experience; however, 
his diet in particular had become somewhat chaotic… 
‘I couldn’t carb count at all really because the nature of what I was eating … 
I just kind of accepted the fact that I would not have great BMs [blood 
sugar].’ 
and that his diet typically consisted of… 
‘a lot of bread and a lot of cakes and things. Not the best kind of food for me 
to be eating but yeah, it wasn’t really representative of what my diet is 
normally like because I never usually eat things like that.’ 
Interestingly, when looking at Table 9.10 it can be seen that during visit 3 although 
LDL-C had decreased, unfortunately so had his HDL-C and there was an increase 
in total cholesterol and triglycerides. Furthermore, the patient’s Apo-B / Apo-A1 
ratio also increased to 0.74, thus changing his risk status from low risk to 
moderate risk, according to the criteria of Walldius (2004). Despite these 
detrimental changes when looking at the patient’s diet in Tables 9.12 and 9.13 it 
can be seen that his energy intake on visit 3 was actually lower than visit 1 and all 
Table 9.11 – Findings from the EQ-5D questionnaire. (A finding of 0 on the EQ-5D Health Scale 
denotes worst possible health, whereas 100 denotes best possible health). 
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macronutrients as well as total sugar, saturated fat and sodium were lower than 
his baseline measurements.  
 
 
After speaking with the patient it quickly became apparent that these paradoxical 
metabolic changes were likely to be remnants from his trip and he emphasised 
how the relatively uncontroversial food diary findings shown in visit 3 illustrate his 
attempts to improve his diet upon his return … 
Table 9.12 – Average daily macronutrient findings from 5 day weighed food diary. 
229 
 
‘now I am back I am a lot more strict [with diet] because I need to be but out 
there I didn’t care really.’ 
 
Despite this uncharacteristic deviation in diet, Patient L003’s eating behaviours 
appeared to generally stabilise over the following two visits; however, what 
became particularly apparent was his praise for the flexibility inferred by the device 
and the ability to better manage blood sugars on occasions when unusual dietary 
behaviours may occur. A typical example of this was his experience with tackling a 
large Christmas dinner which in previous years had been an issue. He mentioned 
how… 
‘having the extended boluses on the pump has made it easier. If you are 
eating a big meal you need a large extension on the boluses and you can’t 
do that on the injections.’ 
This flexibility was the principle reason for the patient wanting to use CSII in the 
first place and as time went on he mentioned really enjoying the convenience and 
how this flexibility also allowed him to take part in physical activity again… 
Table 9.13 – Average daily micronutrient findings from 5 day weighed food diary. 
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‘I wouldn’t say that it has helped with my performance, but it usually means 
that my blood glucose is normal for exercise and that it stays normal. If I 
was running high I would never perform quite as well because I would be 
dehydrated and it makes you feel a bit crap, but it just means it is more 
predictable what my blood glucose is going to be.’ 
Furthermore, CSII also has a large impact during Patient L003’s final exam period; 
a time which he noted as being notoriously stressful and which he summarised by 
saying how… 
‘it is really good for if you are getting stressed. During the exams it always 
sent my blood sugars absolutely sky high, but you can just ‘up’ the basal 
rate and have normal BMs so it make it a hell of a lot easier.’ 
The patient also made clear as the interviews progressed that his life was not 
particularly bad before engaging with CSII; however, the therapy has simply 
improved it and made tasks easier which he would have attempted to engage with 
anyway. It is also interesting to remember the patient’s unique position as both a 
patient and Healthcare Professional and how his view of both sides of the 
healthcare industry shaped his views and how he has still benefitted greatly, even 
in the absence of any glycaemic control issues. This case study therefore poses 
questions of whether other patients who may be ‘metabolically healthy’ may too 
benefit from other aspects of the therapy, in addition to its principle ability to 
improve glycaemic control. 
 Patient L004 
Patient L004 was a white, 28 year old female from Northern Ireland residing in 
Liverpool. She worked as teacher at the time of the study and commenced CSII 
therapy in April 2014. It should be mentioned before proceeding that the patient 
initially agreed to participate in all parts of the study; however, after the second 
visit it became impossible to contact her. Furthermore, during her second 
appointment she also mentioned that she had forgotten her second food diary and 
quality of life survey and would forward them on later. After numerous failed 
attempts to retrieve these documents and arrange another appointment the author 
had no choice but to presume the patient no longer wished to be part of the study 
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and she was regretfully withdrawn, thus explaining the dearth of data for some 
sections of this case (particularly visits 3, 4 and 5). Despite this the interviews 
were extremely enlightening and provided a comprehensive insight into the 
transition onto CSII from MDI.  
Patient L004 had long-standing T1D which developed during her childhood and 
after diagnosis she devised and habitually adhered to a strict routine for the 
successful management of her blood sugars. Unfortunately, when the patient 
attended university in Liverpool for three years this routine was lost. This was in 
part due to not wanting to bring attention to her disease. She explained this by 
saying how… 
‘I think that when I went to Halls [of residence] I didn't do myself any favours 
in the sense that I hated bringing attention to it [T1D]. Not the way that I am 
embarrassed by it, but that I would hate anyone to think I was being an 
attention seeker from it, you know? I would never say I need to go and have 
something to eat now, like I would wait until everybody was ready to eat 
and then eat.’ 
This fear of what others think, need for approval and lack of self-confidence were 
to be important reoccurring themes in the interviews which ultimately led to the 
patient’s referral for CSII as the management of her blood sugars began to spiral 
out of control. Interestingly, when looking at Table 9.14 it can be seen that 
although her metabolic control may seem reasonable on average, it was the day to 
day challenges of managing chaotic blood glucose levels which proved to be the 
biggest challenge. She also described how upon leaving university and 
commencing her job as a newly qualified teacher was when the situation got 
worse, particularly as… 
‘I find myself running slightly high [blood sugars] at work because I don’t 
want to go low and leave the classroom to go and have to sort it out. You 
know I can't leave the job if that makes sense … I just don’t want someone 
to think that I can't do it [the job] properly.’ 
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This constant, self-imposed high blood glucose not only made the patient feel 
physically ill, but it also began to affect her mental health and the constant 
balancing act and consequent failure to achieve suitable glycaemic control began 
to manifest in anxiety, obsessive behaviours and depression. This can be seen 
from the results of the EQ-5D survey in Table 9.15, in which the patient describes 
how her anxiety causes her ‘some problems’ and that her overall self-perceived 
health is only 60 out of a possible 100. After a number of unsuccessful attempts to 
Table 9.14 - Basic clinical measurements and lipoprotein subfraction findings. All data derived 
from patient medical records apart from total cholesterol, triglycerides, apolipoprotein and 
lipoprotein subfraction data (which were derived from auto-analyser measurements). 
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explain her predicament to dismissive Healthcare Professionals and her glycaemic 
control becoming progressively worse her struggle culminated with a breakdown 
during a routine appointment. 
She described the situation…  
‘I just kind of broke down and begged for help basically and then they got 
the head guy [Consultant Diabetologist] in and he said straight away “you 
are the ideal candidate for a pump”, just like that. So it was kind of 
something that I’ve been asking for the last couple of years and then all of a 
sudden one breakdown and “oh you can have it”’. 
 
 
Upon hearing this news Patient L004 mentioned how she was excited about the 
prospect of not only improving her glycaemic control, but also allowing her to enjoy 
a more relaxed diet and participate in sports; both of which had become difficult. In 
fact the findings shown in Tables 9.16 and 9.17 illustrate this and show how her 
self-imposed restrictive diet resulted in her consuming less than the EAR of 
energy, as well as being deficient in key nutrients such as NSP, calcium and 
vitamin A. Also, the potential to reduce the risks of retinopathy were appealing as 
the patient had recently been diagnosed with small haemorrhages which were the 
source of great anxiety (Zabeen, 2016). Furthermore, the patient also mentioned 
how she was looking forward to hopefully being part of a consistent medical team 
which she had previously lacked and which she hoped may offer her a ‘guiding 
Table 9.15 – Findings from the EQ-5D questionnaire. (A finding of 0 on the EQ-5D Health Scale 
denotes worst possible health, whereas 100 denotes best possible health). 
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hand’. Despite these aspirations she also had apprehensions, with concerns 
ranging from the complexities of the device itself to the physical dimensions of the 
pump and where to put it. The patient also mentioned how she was initially worried 
about the idea of being actually connected to a device and how… 
‘one of the reasons I didn’t want to go on the pump is because I didn’t want 
something permanently attached to me. I always thought that would bring 
attention to me and that it would make me feel like have a disability if that 
makes sense?’ 
 Table 9.16 – Average daily macronutrient findings from 5 day weighed food diary. 
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After meeting with Patient L004 for a second time after she had commenced CSII 
it was apparent that these concerns had dissipated and that she was extremely 
pleased with the therapy. Her initial reluctance to be connected to a machine was 
now seen as a small price to pay for the flexibility it offered. This is not unusual 
and has been previously documented in the literature, with work by Saarinen 
(2014) showing how despite initial hesitations, the device often becomes seen as 
a natural ‘part of the body’.  
Furthermore, the flexibility offered by the pump also allowed the patient to 
participate in sporting activities with minimal disruption; an activity she very much 
enjoyed. This is known in the literature and was to be expected, but nonetheless 
the implications this freedom and control had were profound (Yardley, 2013). She 
mentioned how… 
‘I can’t really explain it because I don’t know how it has made such a big 
difference … with a [netball] match if my blood sugars were wrong I just 
couldn’t play in the match and I was being stubborn [previously] by playing 
Table 9.17 – Average daily micronutrient findings from 5 day weighed food diary. 
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on when I shouldn’t have, but now I feel in control of that and I can play and 
I know roughly what it’s [blood sugars] going to do and roughly with it will be 
and if it’s at a certain level I know how to rectify and manage.’ 
The patient also offered some interesting and unexpected comments regarding 
dietary freedom. In particular she explained how although the pump offers the 
potential for dietary liberalisation this never transpired due to a continued mentality 
that snacking and administering bolus insulin before meals will lead to an excess 
of ‘insulin on board’ and therefore she chose to shun the opportunity of dietary 
flexibility. Furthermore, these concerns were also extended to sugar-containing 
alcoholic beverages and soft drinks; despite comments prior to commencing the 
therapy that she was very much looking forward to having the option to indulge. 
Unfortunately, no food diaries were collected from Patient L004’s second visit and 
so it is impossible to quantitatively confirm these comments in relation to data 
collected at baseline (shown in Tables 9.16 and 9.17) and is a concept little 
discussed in the literature. Also, this habitual, ‘better the devil you know’ mentality 
may offer a potential explanation why previous studies have found little evidence 
of metabolic disturbance, even after patients had the opportunity to consume a 
liberalised diet upon the commencement of CSII (Chantelau, 1983). 
In addition to this flexibility Patient L004 also mentioned the commencement of the 
therapy almost immediately improved her mood, whether that was through 
physiological or psychological methods is unknown; however, she reported that 
her partner had also commented that she appeared ‘brighter’. It is highly likely that 
improvements in quality of life may be mediating this and indeed this has been 
shown in the literature, with a systematic review by Barnard (2007) showing 
improvements in not only general health, but mental health in particular after the 
commencement of the therapy. The patient expands on this by describing how… 
‘I feel as though I’ve got control over it [T1D] again so it’s a brilliant feeling 
because that was what was leading me feel the anxiety and I think I put in 
the first [EQ-5D] questionnaire that I was feeling extremely anxious and 
moderately depressed and I think that it was because it [T1D] was taking 
over everything.’ 
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Despite these benefits there were some negative sides to the commencement of 
CSII which the patient explained. These included the physical aspect of the pump 
and how on occasion it is difficult to ‘wear’. She also mentioned how she 
sometimes finds it difficult to distinguish when she is actually tired or experiencing 
the symptoms of hyperglycaemia and although this is not an issue with the pump 
per se, poor judgement can cause her to force through situations which she would 
perhaps be better off abandoning, such as strenuous sporting activities. Although 
these issues had a small impact on the patient’s life it must be stressed that she 
emphasised they were minor compared to the benefits that the pump infers and in 
her own words she described the joy of… 
‘having something that’s going to work for me because it got to the point 
where I thought “I can’t do it any more” and not to sound dramatic, I got to 
the point where I just didn’t want to do it anymore and nothing seemed to be 
working so I think that having that positivity back and knowing that this isn’t 
something that is going to control me and I’m able to control it again … and 
in hindsight you look back and you don’t realise how bad things had got 
until you are so much happier with it … I can’t believe the difference both 
mentally and emotionally’ 
Although many of these aspects are attributable directly to the device itself; Patient 
L004 also mentioned how the support from the Healthcare Professionals was a 
key element in the process. She emphasised how the consistent nature of the 
service and seeing the same doctors and nurses made her feel she was getting 
the ‘guiding hand’ she previously desired… 
‘[says DSN’s name] and [says doctors name] are experts in their field and 
it’s lovely knowing they are there and that’s the thing with the pump, you 
almost are getting that bit of special treatment and their numbers are 
available and if you ever need a question answering they are there to call, 
whereas before if I had any questions I didn’t know who to speak to or even 
how to go about getting in contact with someone … now [says DSN’s name] 
knows me, or knows my name if not anything else, whereas before I would 
have thought “oh I can’t ring you”, so it’s almost like a comfort knowing that 
there is a lot more support being on the pump.’ 
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This support is discussed in the literature and is an important part for the 
successful transition onto CSII and this patient’s experience is a testament when 
the fine line between patient autonomy and appropriate support is met (Morrison, 
2013).   
These findings in their totality show how for Patient L004, despite initial 
hesitations, the commencement of CSII principally improved her glycaemic control, 
which in turn allowed her to regain control of her life. For example she was once 
again able to take part in sporting activities and this level of freedom consequently 
improved the patient’s mental state, thus highlighting how the benefits of CSII can 
often transcend the physiological. Despite these benefits it would be unfair to say 
they are solely the result of the device, as the support service offered by the 
hospital was also held in high regard and gave the patient the ability to 
successfully manage her T1D independently, yet was always there when she most 
needed it.  
 Patient L005 
Patient L005 was a white, British 18 year old female residing in Liverpool and 
about to embark on a college course with aspirations of becoming a Heathcare 
Professional. The patient was diagnosed with diabetes when she was 16 and had 
only been living with the disease for two years and commenced CSII in April 2014. 
She completed all parts of the study. 
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As Patient L005 had only been living with T1D for two years she had little 
experience of growing up with the disease; however, after diagnosis she found her 
life drastically change and in addition to the task of learning to manage daily 
insulin injections she also found that upon returning to school to complete her A-
level studies she was faced with another challenge from a very unexpected 
source… 
Table 9.18 - Basic clinical measurements and lipoprotein subfraction findings. All data derived 
from patient medical records apart from total cholesterol, triglycerides, apolipoprotein and 
lipoprotein subfraction data (which were derived from auto-analyser measurements). 
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‘my friends weren’t very supportive of it and were just quite harsh really … 
they didn't want their friend to inject because it was a kind of like freak thing 
to do so that was kind of like weird, so I left school and got an 
apprenticeship thinking that it will be fine, you know the people I was 
working with were in their sixties and that it would be cool.’ 
Unfortunately, the patient was not to know that these more mature individuals 
working at a well-respected charitable organisation would also hold prejudiced 
views towards those with diabetes. In her own words the patient describes how… 
‘because I was going to the hospital quite a bit because I was doing the 
carbohydrate counting course … I was getting told that I wasn’t committed 
enough because I was going to the hospital and then I wasn’t allowed to 
check my blood sugars and I wasn’t allowed to inject at my desk and then I 
got told that I wasn’t allowed to leave my desk, even in the lunch hour.’ 
The stigma which Patient L005 encountered was not only an illegal breach of the 
Equality Act (2010), but was also clearly upsetting and she described making the 
decision to leave rather than pursue a legal battle against a charity which she held 
in high regard for the good work it did. Unfortunately, despite leaving the 
organisation the scars remained and she mentioned how… 
‘I didn’t expect people to be like that, especially when it’s your first job and 
you’ve only just been diagnosed … so every time I meet someone new this 
is what they are going to do?’ 
In addition to having to manage the psychological aspects stemming from other 
peoples’ stigma of T1D the patient also had to deal with blood sugar levels which 
were rapidly becoming uncontrollable. The hospital she was under at the time in 
Liverpool was, from her point of view, not particularly supportive. She explained 
how because her HbA1c was generally fair and her other metabolic markers were 
acceptable (as can be seen in Table 9.18) she was told that she would not be 
eligible for CSII. This frustrated the patient because despite possessing a 
reasonable HbA1c, her daily blood sugars were extremely chaotic and interspersed 
with uncontrollable hypoglycaemic episodes. After speaking with various friends 
she decided to transfer her care to the Royal Liverpool Hospital where she had 
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been told she may be better listened to. Immediately after being referred she was 
informed she would be an excellent candidate for CSII and the process began to 
commence the therapy.  
The patient was excited about this for a number of reasons. In addition to the 
obvious benefit of offering superior control of blood sugars, the prospect of being 
able to keep the disease hidden also appealed after seeing another female of a 
similar age using the device to great success. The patient described how… 
‘she was a volunteer at the hospice that I worked at and I seen the way she 
was getting treated compared to me and they [other staff] didn’t know she 
was diabetic because she was on the pump and it was like amazing. I was 
like “so your life’s completely changed?” She was like “oh, yeah yeah I don't 
even have to tell people anymore that I’m diabetic because I don't get this 
needle out and everything”.  
This inspired the patient, especially seeing the contrasting treatment this other 
person received. In addition to this she was also excited about the prospect of 
being able to better manage her blood sugar during sports; an area of her life 
which she was passionate about and which had been made difficult as a result of 
her chaotic blood sugar levels.  
After meeting up with Patient L005 during the subsequent appointments after she 
had commenced CSII it could be seen that definitive changes had occurred. 
Firstly, she remarked that her glycaemic control had been drastically improved and 
hypoglycaemic episodes were now rare. These albeit predictable findings were 
highly favourable, particularly as improving glycaemic control was the principle 
reason the patient had initially desired CSII (Pickup, 2002). These improvements 
can be seen in Table 9.18, where reductions from 8.3% to 7.3% occurred, which 
are particularly favourable when considering that a 10% decrease in HbA1c is 
associated with a 43% reduction in retinopathy risk (DCCT Research Group, 
1995).  
Despite this obvious benefit the patient was keener to discuss other aspects of her 
life which had been improved as a result of the therapy. For example, she 
expressed that participating in physical activity was now far easier and although no 
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change was observed in the responses given to the EQ-5D questionnaire (see 
Table 9.19), the interviews highlighted how important this ability to take part in 
physical activity was.  
 
She mentioned how… 
‘my blood sugars have been really really good. They have been a lot better 
than on injections because I have learned how to manipulate it a little bit 
because I know that if I turn the pump down to 30% then I can eat 
something as well before and I can have stable blood sugars whereas 
before the adrenaline would make them go really high.’ 
This benefit of CSII with regards to taking part in physical activity is well 
documented and the ability to precisely adjust basal and bolus rates and the 
option to easily remove the device for a limited time are features which were 
utilised extensively by Patient L005 (Hammond, 2008).  
In addition offering newfound flexibility in terms of physical activity the patient also 
mentioned flexibility with regards to dietary behaviours. During the second 
interview she described how after losing a significant amount of weight since 
diagnosis she now wanted to regain this mass along with muscle. 
 
Table 9.19 – Findings from the EQ-5D questionnaire. (A finding of 0 on the EQ-5D Health Scale 
denotes worst possible health, whereas 100 denotes best possible health). 
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She explained her reasons for this by describing how… 
‘Yes, I’ve put weight on. Because I’ve got a little goal I set myself and 
before the pump I was struggling to get up to 8 stone and so I had a little 
goal that on the pump I wanted to reach 8 stone and I’ve managed 8 stone 
so it’s quite good … I definitely want to be a little bit heavier, just for college 
as well. Just after seeing all the people at college. They are all massive, 
with muscle and it’s quite scary and they’ve all got these protein shakes and 
stuff. They’re arms are just massive.’ 
Table 9.20 – Average daily macronutrient findings from 5 day weighed food diary. 
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These aspirations, although seemingly harmless given that at the time of study the 
patient was underweight (18 – 19 kg/m2), should also perhaps be treated with a 
small degree of caution. When looking at Tables 9.20 and 9.21 it can be seen that 
after visit 1 the patient’s energy intake does indeed go up, along with her protein 
intake; however, her micronutrient intake is often still far below recommendations, 
particularly regarding iron and vitamin A. This is concerning as it may potentially 
signal issues pertaining to the quality of food being consumed. Furthermore, it is 
important to remember that during the study Patient L005 was passing through an 
important adolescent transition period known for the development of disordered 
eating habits and in this search for weight gain and a muscular physique care 
should be taken to ensure this behaviour does not become obsessive (Young-
Hyman, 2016). This has been described in previous work as ‘muscle dysmorphia’ 
and although more prevalent in males is not unheard of in females, especially in 
those with an interest in bodybuilding exercise (Hale, 2013). Healthcare 
Professionals should perhaps heed stories such as these and be receptive to 
ensure patients are adequately supported to make healthful dietary choices and 
pursue their goals in a non-destructive manner.  
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A final benefit associated with CSII which Patient L005 was keen to exploit was its 
discreetness. After being previously inspired by the female pump user at her 
previous job the patient hoped that the therapy may offer her a degree of ‘privacy’ 
and reduce the future occurrences of stigma associated with T1D. Interestingly, as 
the interviews progressed she explained that whilst the device did indeed allow the 
discreet administration of insulin, she found that rather than others rebuffing the 
device they were actually interested in it. The patient explained how… 
‘I’ve been asked why I wear my Walkman on my trousers so I’ve explained 
and they kind of wanted to know about it a bit more and then somebody 
else asked me and I told them and she started asking loads of questions … 
I quite like it because the ‘Types’ of diabetes get mixed up and sometimes I 
do get asked questions like “you’ve done well to lose the weight then”, and 
I’m like “no it’s not like that”, so I quite like getting the awareness out 
because we didn’t expect for me to get diabetes because my lifestyle is 
quite healthy.’ 
Table 9.21 – Average daily macronutrient findings from 5 day weighed food diary. 
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This was a sharp contrast prior to the commencement of the therapy where she 
wanted to avoid confrontation about her diabetes at all costs and was looking 
forward to CSII making the disease less conspicuous, whereas now her 
confidence has grown to a point where she would actively seek to engage with 
interested parties to inform them about the disease. This is a remarkable 
transformation and one which has been previously documented in work by 
Saarinen (2014) who described how patients often receive positive interest 
regarding the device from the public and that many then felt compelled to talk 
more about their diabetes than when they were using MDI. 
9.6 Conclusions 
Although these case studies are brief they highlight the transition from MDI to CSII 
in a longitudinal manner and by describing a selection of the principle issues that 
the participants faced, the changes they made and the benefits they received 
serve to provide an intimate insight into this particular period of patients’ lives. 
Although far more attention could be given to the data collected to offer a deep 
understanding of the lives of each case, the aim was more to provide a succinct 
flavour of the transitionary process which is lacking in previous literature.  
Furthermore, the equal weighting which was given to qualitative and quantitative 
data during the triangulation process allowed each participant’s story to be 
described and supported with data from the other methods where appropriate. 
This technique has also been used in previous studies, for example, a multiple 
methods longitudinal study by Huxley (2015) that investigated potential improved 
outcomes following diabetes education found that the combination of equally 
weighted qualitative and quantitative elements offered unique insights into how 
baseline variables are associated with specific outcomes. The present case 
studies were no exception to this and also offered unique understandings which 
would not have been possible using either quantitative or qualitative methods 
alone. For example, the dietary habits of Patient L003 upon his return from 
travelling could not have been explained using only food diaries. Similarly, Patient 
L005’s aspirations to become more muscular, which she described in her 
interviews, were further substantiated using quantitative findings derived from food 
diaries. This mutual relationship resulting from the combination of methods in 
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these circumstances has therefore been successful in allowing a brief, yet highly 
informing overview of each of the cases to be formed.  
In addition to focussing on how the differing methods complement each other, 
when considering the findings as a whole specific insights regarding the transition 
from MDI to CSII can be found. In particular the results showed how patients often 
experienced some initial negative aspects associated with CSII, typically regarding 
the physical size of the pump and hesitations about being connected to a machine; 
however, these issues were quickly dispelled as patients became more familiar 
with the device. In fact the majority of comments made after commencement of 
CSII were highly positive and the therapy was praised for a variety of elements, 
typically pertaining to its overall flexibility and ability to improve glycaemic control. 
These aspects frequently resulted in patients’ regaining control of the disease and 
consequently their lives, which in turn often had profound implications on both their 
confidence and mental state. Furthermore, in addition to the device itself the case 
studies brought to the fore important external issues regarding CSII as a service. 
For example, the cases revealed funding inequalities and demonstrated how not 
only are hospitals different in their willingness to apply for funding, but also that 
successful applications can also depend on a patient’s knowledge of the system 
and how to maximise their chances accordingly. These inequalities are not unique 
to Liverpool, with a recent audit of CSII practices revealing nationwide disparities 
of CSII use, resulting principally from staffing issues (White, 2014). Also, the level 
of care was revealed as being an important aspect which became more consistent 
upon the commencement of the therapy as the same member of staff was typically 
seen and informal contact could easily be made through email or phone call 
without having to make an appointment. Although little has been discussed in the 
literature regarding this aspect its impact appeared profound and the additional 
support was highly regarded.   
The findings from these case studies, although illuminating, are also highly likely to 
be of interest to Healthcare Professionals from a practical viewpoint. As mentioned 
in the Quality of Life chapter (see page 173), there is a dearth of data regarding 
the lived experience of patients with T1D who are using CSII and it is important 
that specialists working in this field understand the therapy from a patient 
perspective. Furthermore, these findings will also be useful for non-specialist 
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Healthcare Professionals with an interest in CSII to realise how transition onto the 
therapy can be complicated in those with complex concurrent conditions, yet how 
fulfilling the treatment can be when implemented correctly.   
Despite enlightening insights and potential practical uses for those in the field 
these case studies are certainly not perfect. There are a number of fundamental 
limitations which may unfortunately dilute the quality of the findings. In particular 
there is a substantial amount of missing data as patients dropped out of the study 
for various reasons. There were also issues when assessing patients’ medical 
records as measurements were supposed to be taken by the medical team at the 
hospital but this sometimes did not occur and therefore various data points are 
missing. These issues could be resolved in future studies by ensuring that all 
measurements are taken directly by the research team. It may also be useful to 
consider that some of the patients may have varied and complex conditions and 
as such may be unfit to participate. Therefore care should be taken at the study 
design and recruitment stages to ensure that only the most appropriate patients 
are targeted and that the participant burden is minimised as much as possible. 
Once recruited perhaps the use of incentives may also be a further strategy which 
could be considered to improve attrition. Furthermore, the reader should also 
appreciate that the case studies only investigate individual patients who were all 
recruited from a single clinic and as such the findings cannot be extrapolated to a 
larger population. 
This, of course, is not the point of case studies though, and it is hoped that rather 
than offering outcomes which may be statistically meaningful or representative of a 
larger group, they will instead offer the reader some ‘food for thought’ regarding 
the patient experience at a more intimate level and provoke further questions. This 
is of principle importance, because, as has been demonstrated in these five short 
cases, when focussing on the individual it becomes apparent that there are 
invariably underlying factors driving a patient’s results, which in turn reveal lives 
that are generally more complex than quantitative and qualitative data combined to 
represent a group can ever suggest. 
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10 – Synthesis 
 
10.1 Introduction 
The diagnosis of Type 1 diabetes (T1D) is a life-changing event induced by the 
autoimmune destruction of pancreatic ß cells and the current best practice for the 
management of the condition is the daily exogenous administration of insulin 
(Pickup, 2004). Unfortunately, it is naïve to consider this a remedy which is either 
simple to adopt, or a panacea yielding results comparable to the endogenous 
production of insulin. Both physiologically and psychologically this treatment 
places a considerable burden upon patients; the impact of which can result in a 
constellation of additional issues directly and indirectly related to the management 
of the disease.  
This study has referred in detail to some of the issues faced by patients upon 
diagnosis and the subsequent impact the disease has had upon their lives. 
Unfortunately, these issues often culminate in patients becoming unable to 
manage their diabetes using multiple daily injection (MDI) therapy (which is now 
the ‘first line’ of treatment for those with T1D) (NICE, 2015). According to National 
Institute for Health and Care Excellence (NICE) guidelines, if a patient possesses 
HbA1c levels of 8.5% or above, or is experiencing disabling hypoglycaemic 
episodes whilst making every effort to co-operate with their physician, they may be 
offered continuous subcutaneous insulin infusion (CSII) therapy (NICE, 2015). 
This treatment has been shown to improve glycaemic control in those with poor 
management of T1D and may potentially offer a greater degree of dietary and 
lifestyle flexibility (Pickup, 2002).                                                                              
The study presented within this thesis embodies a comprehensive effort to, for the 
first time, address gaps in the evidence specifically related to the eating 
behaviours, cardiometabolic risks and quality of life of patients using CSII both 
over time and compared to MDI counterparts. These aspects were investigated 
using multiple methods, comprising of food diaries and food surveys to determine 
participants’ eating behaviours. Quality of life was explored using a brief 
questionnaire and semi-structured interviews. Finally, a sample of blood was 
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drawn and medical records were examined to elucidate the cardiometabolic risks 
and overall metabolic health state of participants.  
The data revealed a number of outcomes which confirmed existing evidence, for 
example, improvements in HbA1c and reductions in insulin dose in those using 
CSII. There were also improvements in various aspects of quality of life; some of 
which have been previously alluded to by others. Aside from findings which were 
in agreement with the existing literature, there were a number of novel and 
unexpected outcomes which cast new light on CSII therapy, such as subtle 
changes in eating behaviours, improvements in blood pressure and previously 
unknown quality of life benefits. Although each experimental chapter puts forward 
a detailed, compartmentalised discussion of these outcomes, this final synthesis 
will summarise the principle findings as a whole in relation to the literature; offering 
the reader a ‘birds-eye’ view, from which an overall formation of judgement can 
then be constructed.  
It should be noted that this study is not without limitations. These will also be 
discussed in this chapter with the benefit of hindsight and recommendations will be 
made regarding future research in this area. Despite issues, the findings from this 
study nonetheless make an original contribution to the literature in an under-
researched and important area of diabetes care. This is important to increase the 
knowledge of those belonging to the scientific community, for Healthcare 
Professionals working in the field and perhaps most importantly, for patients with 
T1D. Furthermore, it is also important to remember the economic burden T1D 
places upon the NHS, with direct costs totalling £1 billion and with predicted 
2035/36 costs projected at £1.8 billion (Hex, 2012). Therefore any studies which 
enhance understanding and improve patient care may not only improve quality of 
life for the patient, but may also reduce NHS costs. It is therefore hoped that whilst 
being limited in scope and highly focused, these findings may ultimately have an 
impact, however small, upon the lives of patients with the disease who are either 
already using or considering CSII therapy and the wider society as a whole.  
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10.2 Discussion of findings 
 Cardiometabolic risks 
The findings from this study revealed that a number of physiological changes 
occurred in those using CSII related to cardiometabolic risk. Perhaps the most 
prominent alteration was to HbA1c, which was found by the audit (n = 260) to 
significantly decrease during the first 12 months of commencing the therapy from 
8.3 to 7.6% (mean difference: -0.7%; 95%CI: 0.5-1.0; p < 0.001); a finding shown 
throughout the literature and which although positive was not unexpected (Pickup, 
2002). These reductions were maintained for the subsequent 3 years, with HbA1c 
stabilising between 7.6 and 7.9%. Long-term reductions such as these have also 
been shown in previous literature, with Melidonis (2016) highlighting a highly 
significant decrease in HbA1c after 3 years of pump use. This is favourable as the 
benefits in terms of reduced risks from complications are considerable; indeed, a 
10% decrease of HbA1c may potentially lead to a 43% reduction in retinopathy risk 
(DCCT Research Group, 1995). The reduction shown in the present study may 
therefore offer promise for patients, especially given both the fear regarding 
complications expressed during the study and the life-changing impact these 
issues can infer. 
Although the audit revealed that reductions in HbA1c occurred, on average, across 
the total population of patients using CSII at the Royal Liverpool Hospital, it is 
important to note that the case studies illustrated that these benefits were not 
experienced by everyone. For example, when focussing on Patient L001 it can be 
seen that his HbA1c after commencing the therapy actually increased from 8.6 to 
8.9% during the first 3 months, where it remained for the duration of the study. It 
should be remembered that after agreeing to take part in the study this patient’s 
personal circumstances changed as he became encumbered with additional 
commitments both at work and at home that he mentioned were very stressful. 
Although there is little evidence to determine a causal link between these lifestyle 
changes and the patient’s increase in HbA1c, it is probable that it was a 
contributing factor and it could possibly be argued that if he had remained on MDI 
the increases may have been even greater. Although an exact cause cannot be 
pinpointed and given that these comments are speculative they do serve to 
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illustrate that the beneficial aspects traditionally associated with the therapy may 
not work for everyone and that individuals often lead complex lives which 
observational research frequently gives little credit for.  
In addition to improvements in blood sugar there was also an unexpected 
reduction in blood pressure which was illustrated by the audit. This has never been 
found previously and showed a slow yet statistically significant decline in systolic 
blood pressure, from borderline hypertension to within the normal range over a 4 
year period (128.2 to 122.1 mmHg; p = 0.003). Similar significant reductions were 
also shown with diastolic blood pressure (72.5 to 72.0 mmHg; p = 0.027). 
Furthermore, when compared to patients using MDI, those using CSII were shown 
to have significantly lower systolic blood pressure (123.5 mmHg vs. 135.3 mmHg; 
p = 0.023). This is contrary to the literature which suggests that CSII has little 
impact upon blood pressure and it is unknown exactly why the findings in the 
present study occurred. A hypothesis may be enhanced, personalised medication 
resulting from a higher frequency of appointments with regular physicians; 
although one might then expect an aggressive initial reduction rather than the 
slow, steady decrease described in the findings. Furthermore, reductions in 
hypoglycaemia have been previously associated with corresponding reductions in 
blood pressure and this may also have been a potential mediating factor 
(Sommerfield, 2007). Unfortunately, neither of these theories can be substantiated 
as no data concerning the medication or frequency of hypoglycaemic episodes of 
patients were collected.  
Despite changes in some variables there were also others which remained static 
upon the commencement of CSII; with one such example being BMI. Despite 
participants remarking that CSII restored their ability to participate in physical 
activity, the majority of patients remained either overweight or obese, as shown in 
the audit where BMI persisted between 25 and 26 kg/m2 (see page 85 and Table 
5.2). The cross-sectional study again showed that those using CSII were largely 
overweight; as were their MDI counterparts (28.1 kg/m2 vs. 25.2 kg/m2 
respectively) (see page 155 and Table 7.8). Despite these issues it is useful to 
consider that 61.7% adults in the UK are also either overweight or obese and this 
finding may be a reflection of that (HSCIC, 2014). Nonetheless, this it still 
concerning when remembering that those with T1D are already at an increased 
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risk from a host of complications and being overweight serves to further 
exacerbate these risks (Redondo, 2015).  
In addition to this, other metabolic markers, such as the standard lipid profile, 
appeared at first glance to remain similar over the long-term, with the audit 
showing few changes over a 4 years period and the cross-sectional study showing 
little difference between those using CSII and those using MDI (see page 87 and 
page 156). However, a closer inspection reveals that subtle variances did exist, for 
example, there was a statistically significant difference in the Apo-A1 / Apo-B ratio 
between patients using CSII compared to those using MDI (0.60 vs. 0.72 
respectively; p = 0.025), which predisposes those using MDI to be a greater risk. 
Despite this there were attributes pertaining to both groups of patients which 
initially appeared to infer a degree of atheroprotection. In those using CSII high 
density lipoprotein cholesterol (HDL-C) remained between 1.7 and 1.9 mmol/L 
throughout the audit and an average of 2.0 mmol/L was measured in those who 
took part in the cross-sectional study. Similarly, those using MDI who took part in 
the cross-sectional study possessed levels of HDL-C measuring 1.7 mmol/L. 
These levels are far greater than the 1 mmol/L recommended for the general 
population (Heart UK, 2016). Unfortunately it is a reality that the risk of 
cardiovascular disease (CVD) is a raised in those with T1D and that the HDL-C 
may potentially be dysfunctional, despite being present in favourable quantities 
(Vergès, 2009; Manjunatha, 2016). These subtle differences in lipid parameters 
and ubiquitous levels of HDL-C combined with the high rate of CVD in those with 
T1D and a lack of understanding regarding the underpinning mechanisms pose 
questions for future research to further investigate the quality of lipids and 
lipoproteins in greater detail.  
 Eating behaviours 
Another area of focus during this study which initially revealed few changes were 
the eating behaviours of those using CSII compared to those using MDI. Many of 
the levels of nutrients consumed were similar with few significantly different 
variables. This in itself was an interesting finding as it indicated that despite having 
the opportunity adopt a liberalised diet patients failed to take advantage of this and 
chose not to consume lower quality foods high in sugar, salt and fat, which may 
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potentially be detrimental to health. This has never been previously shown in 
patients using modern insulin pump therapy and is a novel finding. Furthermore, 
as detailed in the case study of Patient L004, a relaxed diet was one of the 
benefits this individual was most looking forward to exploiting; however, this failed 
to occur and the patient’s diet actually changed very little. In fact she retained the 
habitual eating behaviours she had become familiar with due to a fear of metabolic 
disturbances caused by previous deviations from her structured diet, resulting in a 
‘better the devil you know’ mentality. This ‘retained fear’ could potentially explain 
the lack of dietary change shown upon the commencement of CSII; however, 
further research focussing on this would be required to confirm this hypothesis.  
Despite few dietary changes occurring upon the commencement of CSII, some 
elements of the diets appeared to be less than optimal regardless of treatment 
group, with some findings also suggestive of misreporting. An example of this can 
be seen when looking at the energy intakes of both treatment groups as shown in 
the cross-sectional study (see pages 112 & 119). These were shown to be below 
the EAR, regardless of treatment. A finding which clashes with the mean BMI 
findings described previously, which highlighted how the majority of patients, 
regardless of treatment, were either overweight or obese. This paradoxical finding 
points towards potential under-reporting, which the Goldberg equations suggest is 
likely to have occurred and which the literature reveals is often the case in those 
with a BMI >25 kg/m2. Furthermore, when looking closer at both the cross-
sectional study and the individual case studies it can be seen that the certain key 
nutrients such as fibre were often severely lacking and some micronutrients, such 
as iron in females, were typically consumed in amounts less than the RNI. 
Furthermore, there was an excess consumption of other nutrients such as sodium 
and total sugars, which have been associated with blood pressure and obesity 
respectively (Bray, 2014; He, 2007). Interestingly, it could also be hypothesised 
that these nutrient measures may be conservative at best, as it has been known 
for some time that individuals who underreport energy intake are also more likely 
to underreport poor quality foods high in sugar and fat and over report those 
regarded as ‘healthy’, such as fruits and vegetables (Bingham, 1995). Findings 
such as these point questions towards the overall quality of the diet regardless of 
treatment and should be an area monitored closely in this at-risk population. 
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 The route to CSII and its impact upon quality of life 
Although the practical commencement of CSII consists of a week-long education 
session, the route to this point and the time thereafter can involve many changes 
in diabetes-related quality of life. These were outlined by patients who participated 
in the present study and the prominent themes provide a chronological insight into 
the lived experiences of those with T1D from pre-approval of CSII through to the 
transition onto the therapy.   
Although there were many themes which were revealed during the course of the 
interviews, perhaps one of the most striking was that after diagnosis, aside from 
the practical difficulties of coming to terms with the disease, many participants felt 
that their life with diabetes was in some way ‘abnormal’. Furthermore, rather than 
addressing the problem participants mentioned that it was often easier to ignore it. 
This was evidenced as many revealed they had found the condition difficult to 
accept and rebelled at points in their lives; typically during adolescence. Although 
often short-lived, episodes of poor compliance have been shown to incur a cost, 
with the early development of complications being seen even in youngsters with 
poor control (Hood, 2009; The DCCT Research Group, 1998). Furthermore, many 
also encountered stigma from not only strangers, but also people closer to them, 
such as friends and work colleagues, which only served to further polarise 
patients. 
Fortunately, the majority of participants who mentioned these issues at some 
stage described taking responsibility for their condition and then making ‘sacrifices’ 
for an overall improvement in glycaemic control when using MDI in the hope of 
minimising the risks of future complications. These forfeits typically came in the 
forms of restricted physical activity (which patients often feared would result in 
short-term issues such as hyper or hypoglycaemia (Pickup, 2004)) and the 
amendment of diet. The present study focused on dietary aspects and revealed 
how the non-continuous nature of MDI was typically accommodated by patients 
though the adoption of a relatively structured diet which was frequently arbitrated 
by obsessive behaviours and the subsequent ‘medicalisation’ of certain food items 
which came to be associated with disease. These issues serve to highlight the 
need for more access to psychological support. Diabetes UK has recognised this 
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and outlined in their ‘15 Essentials’ programme that all patients should have 
access to these services, yet in reality only 25% of patients have reported 
psychological care to be in place when they needed it (Diabetes UK, 2015). 
Furthermore, ensuring timely access to alternative therapies such as CSII may 
also improve these issues due to its ability to allow patients to live a more flexible 
life, as described throughout this thesis. Interestingly, despite the discipline and 
hardship required to surrender to the structure of MDI many patients actually 
praised the flexibility of the therapy and the ability of the regimen to allow, with the 
caveat of personal investment, a relatively unhindered life. 
In the light of this it was therefore surprising to hear patients not only express 
concerns about the physical nature of CSII, but also the ability of the device to 
offer an unprecedented level of flexibility. Many using MDI perceived the pump to 
be of little benefit over injections and it was frequently suggested that learning a 
new method simply wasn’t ‘worth it’. This scepticism was usually based upon little 
knowledge of the therapy, with many admitting to having only briefly read about 
CSII in the literature or hearing about it though short discussions with friends, 
family or Healthcare Professionals. Furthermore, if they were deemed ineligible 
the therapy then typically became consigned to a realm of diabetes care thought of 
as being both unattainable and unbeneficial.  
At this point it is important to point out that those eligible for CSII were often 
characteristically bonded by the common denominators of poor glycaemic control 
and evidence of co-operating with Healthcare Professionals to manage the issue 
(NICE, 2015). Indeed this can be seen when looking at the audit (see page 87) 
and case studies (see page 206), which show that that prior to engaging with the 
treatment HbA1c is typically raised. It could therefore be argued that patients due to 
commence the therapy largely consist of unique selection of disciplined individuals 
suffering, in many cases and despite best efforts, from challenging symptoms. The 
impact of these can be profound, with many patients describing the effect they 
have had upon their lives; from stories of collapsing at work, through to losing the 
awareness of hypoglycaemia, thus further exacerbating anxieties. It is little wonder 
that those due to commence CSII often had a contrasting outlook and attitude to 
their MDI counterparts previously described. These patients spoke generally of 
excitement and optimism for the therapy, with the case studies (see page 206) in 
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particular revealing how despite minor apprehensions the broad feeling was one of 
positivity, with participants typically looking forward to the prospect of regaining 
control of their lives. For these patients the device took on a different meaning and 
was almost seen as a ‘beacon of hope’. Although these accounts are favourable it 
is difficult to imagine what the likely outcome of these patients would have been 
had they not been offered CSII at this point. Some presented highly complex 
physiological and psychological issues and although there is an absence of 
literature investigating the outcomes of poorly controlled patients who were 
specifically refused CSII, it is clear that those with uncontrolled T1D are at an 
increased risk of a number of complications (Pickup, 2004). Therefore it is 
encouraging to see not only the improvements in risk factors, but also the patients’ 
lives in general.  
Although the majority of participants due to commence CSII followed the path 
outlined above there was an important exception; notable in its singularity yet 
pronounced in its significance. This was a case study concerning Patient L003 
(see page 223) which revealed his unconventional route to instigating approval for 
CSII. The literature is flecked with reports demonstrating CSII being used to 
successfully treat those with Type 2 diabetes, Addison’s disease (by replacing 
insulin with cortisol) and pregnant women with T1D and although rare these 
examples illustrate how the therapy can be used beyond the confines of poor 
glycaemic control alone (Reznik, 2014; Gagliardi, 2014; Kallas-Koeman, 2014). 
Therefore, as a Health Professional this patient took advantage of the ability of 
CSII to offer more than just glycaemic control. After being informed by a senior 
colleague of the benefits CSII could offer and subsequently self-researching the 
device the patient decided that the therapy could improve his life. Unfortunately (or 
fortunately depending on the viewpoint) Patient L003’s glycaemic control was well 
managed, thus automatically falling short of NICE criteria meaning he was 
ineligible for NHS CSII funding. Nonetheless the colleague suggested a 
Diabetologist who may listen and the patient made the case that due to his keen 
interest in sport and that his future career would likely involve working abnormal 
shift patterns he was concerned that his glycaemic control may decline as he 
leaves university and embarks on chaotic full-time employment. This ‘preventative’ 
slant gained the approval of both the Diabetologist and the Commissioning group 
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and the patient received funding for the device. Although this is a positive result it 
poses an interesting juxtaposition with the perceptions of CSII described by other 
patients through a lack of knowledge of the therapy and it begs the question of 
whether if patients were fully informed would they too press for funding? Even if 
they were informed would they be adequately equipped to negotiate the 
commissioning process in the efficient manner Patient L003 did with the 
assistance of expert support? That said it should also be remembered that a 
recent audit of NHS Trusts offering CSII found many to be severely understaffed 
with insufficient resources to enrol and manage patients and that there exists an 
unofficial nationwide ‘postcode lottery’ for pump funding (White, 2014; Dudley, 
2014). As such, although this particular patient’s experience was positive it is 
unlikely representative of the nation, or even the hospital as a whole, where CSII 
funding can in some cases be a difficult proposition (White, 2014). Although the 
true representativeness of this particular example is unknown, and despite it likely 
to be an exception rather than a rule, still serves to illustrate some of the 
inequalities which exist regarding the approval process. 
From a clinical perspective, the decision to recommend CSII to a patient is not 
always straightforward and as shown in the present study, many patients may 
have underlying psychological issues regarding T1D as well as other complex 
conditions and CSII may be contraindicated despite documented physiological 
benefits. Physicians may therefore find themselves in difficult situations where 
they may have to use their experience to determine the optimum treatment for 
patients on a case-by-case basis as best-practice guidelines cannot address such 
issues. After a physician has considered a patient and decided that they would be 
an ideal candidate for the therapy the process of instigating CSII then starts, for all 
practical purposes, with approval from an NHS commissioning body; however, this 
study revealed that sentiments regarding the therapy typically develop in patients 
long before this day arrives. 
A principle example of this was when various patients reported their initial 
perceptions of the device upon hearing of it for the first time. Many explained how 
they recoiled in horror when discovering that the pump is a permanent commodity, 
with the only opportunity for respite being the ability to detach the device for a 
maximum of an hour to allow active sports or swimming etc. To many patients this 
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fusion between body and machine was perceived as an act of cementing their 
relationship with T1D, from which there can be no escape. Conversely, it was 
mentioned how when using injections after insulin is administered the pen can be 
placed into its case until next time, effectively shutting the patient off from the 
disease; albeit temporarily, whereas being attached to a machine would be a 
permanent reminder of T1D. Work by Saarinen (2014) also found similar concerns 
in patients and described the pump as ‘diabetes made visible’, which in the context 
of the present study refers to a ‘visibility’ observed by not only others, but by the 
patient as well. 
Some issues were also raised in addition to the physical aspect of the pump, with 
patients expressing concern that the move onto the treatment may be 
overwhelming. Furthermore, others reported anxieties about giving control of their 
diabetes, albeit temporarily, to doctors and nurses. An anxiety further exacerbated 
as some had developed a mistrust towards Healthcare Professionals as a result of 
previous negative experiences. It was therefore intriguing to see how over time, as 
the patients developed an understanding of the device and incorporated the 
therapy into their lives, these initial hesitations were often dispelled. It was 
frequently mentioned that, despite minor inconveniences, the pump came to be 
regarded by the patients almost as a part of their body in much the same way a 
wristwatch might; a concept again reiterated by Saarinen (2014). Furthermore, this 
union between body and machine went one step further than patients simply 
feeling comfortable with the device. Some mentioned how others had asked what 
the device was, confusing it for a Walkman or mobile phone and when told it was 
an insulin pump often asked for further explanation. Rather than shying away from 
this patients described their delight and took it as an opportunity to inform people 
about their diabetes and the role of the pump and it was clear that the device 
provoked a great deal of dialogue. This represents a polar shift from patients’ 
perceptions prior to the commencement of the therapy. Whereas beforehand the 
patients were wary of the device bringing unwanted interest and saw it as little 
more than an ‘aide-memoire’ of their condition, after commencing the therapy it 
came to be regarded almost as a ‘medal of honour’ to be worn with pride. This 
sharp contrast is a positive one and rather than trying to attain another life 
regarded as ‘normal’, the comments made after the commencement of CSII are 
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more suggestive of a group of individuals who have come to accept their life with 
diabetes. Furthermore, rather than the pump being a visual reminder of the 
condition which should be worn with shame and regret, it in fact became a motif of 
success over diabetes and a method of promoting awareness which should be 
outwardly presented with pride and confidence. This imagery ran throughout the 
study period and appeared to be a long-term metaphor and although being difficult 
to quantify represented a seismic shift in the quality of life of patients.  
If anything, the contradictions and paradoxes presented by both the perceptions 
and physiology of patients with T1D, whether they are planning to commence CSII 
or not, highlight the complexity of the disease in general. This is an extremely 
important factor and one which is has been highlighted in the literature as being 
imperative to consider during the transition onto CSII. In particular adequate 
education and ongoing support must be in place and facilitated by trained 
professionals; a requirement also outlined in NICE best practice guidelines (NICE, 
2015). This integral part of commencing the therapy appeared to be highly 
regarded in the present study, with participants detailed in the case studies 
reporting how the comprehensive the sessions were (Morrison, 2013). Although 
this is obviously positive feedback, there was an undercurrent running beneath 
these practical aspects; primarily embodied within the consistency they provided 
and the ability to develop a Healthcare Professional / Patient relationship. Many of 
the patients mentioned how they appreciated the regularity that they associated 
with CSII and which brought increased levels of predictability to the services 
provided by Healthcare Professionals. Examples of this were more regular 
appointments, seeing the same doctor or nurse at every session and whereas 
some felt they had been previously pushed ‘from pillar to post’ they now described 
a sense of ‘grounding’. Others detailed how they enjoyed the newfound rapport 
with someone who recognised their name, their background and who could offer a 
‘guiding hand’. This area regarding the consistency of care is under-researched in 
CSII therapy specifically; however, there is a body of literature revealing how, from 
a patient perspective, uniformity of care is highly favoured, especially in those with 
chronic conditions (aside from the important exception of mental illnesses where 
discontinuity may be more appropriate) (Freeman, 2010).   
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10.3 Limitations and recommendations for further work 
Despite revealing some interesting aspects of CSII therapy it would be unrealistic 
to suggest that this study is not without its limitations; many of which ultimately 
stem from its design. This research was observational and therefore has 
fundamental flaws which should be highlighted. Principally observational studies 
by their very nature, although being useful to elucidate the risks and benefits of a 
treatment, can be subject to bias (Jepsen, 2004). For example, when considering 
the complexities in patients’ lives revealed by the case studies it is easy to see 
how other, often unseen, aspects could have impinged upon not only the findings, 
but also the recruitment and collection of data. Unfortunately, it is very difficult to 
control for free-living subjects in the research design apart from choosing a more 
robust design such as a randomised control trial (RCT) to investigate some of the 
quantitative aspects; however, the resources and cost required to perform such an 
endeavour would be considerable. Furthermore, little previous research has been 
carried out specifically focusing on the areas of concern and therefore a pilot study 
to gather some preliminary data was considered by the research team to be more 
appropriate at this stage, rather than pursuing a full scale RCT.  
Similarly, it should also be remembered that to perform a robust study a properly 
powered sample size would be required. As CSII therapy is relatively rarely used 
this would mean having to recruit participants from multiple sites. As the Royal 
Liverpool Hospital Diabetes Centre has the largest clinic in the North West national 
recruitment would have been required. A study using multiple centres throughout 
the UK was out of scope of the available resources and is likely to be the reason 
why so little literature exists from RCTs originating from the UK investigating the 
use of CSII.  
With regards to recruitment for the present study, there were also a number of 
issues which should be raised. Unfortunately, there were unavoidable staffing 
issues described in the Recruitment Feasibility chapter (see page 65) which 
initially prevented adequate recruitment to the longitudinal study (with the 
participants ultimately being used as case studies). Despite this inconvenience it 
would be unfair to place blame for poor recruitment solely on this issue as it 
became obvious as the study went on that there was a large participation burden. 
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Although some of the patients had complicated issues unrelated to the study 
which caused them to withdraw, the author noted that completing five sets of food 
diaries and participating in five interviews in addition to the other study 
requirements was time consuming. Although no complaints were made directly to 
the author in hindsight perhaps the study could have been made less burdensome 
with fewer appointments. These compromises could also have been possibly 
supplemented with some form of incentive. Given that some of the participants, 
particularly those recruited to the longitudinal section, completed the study they 
should be thoroughly commended for their efforts. 
Furthermore, with regards to the actual sample recruited it should be 
acknowledged that to be eligible for CSII patients must typically meet NICE criteria 
and this automatically means that the sample may differ in some ways from 
patients with T1D in general. For example, they are more likely to possess a 
certain level of discipline having had to meet the strict criteria. Furthermore, by 
default they are also highly likely to have poor glycaemic control prior to the 
commencement of the therapy (which unsurprisingly was shown in the findings). 
Similarly, those using MDI who participated in the study were also likely to be 
those of an altruistic nature and therefore arguably ‘different’ than those who did 
not agree to take part, as well as being more likely to gravitate towards 
opportunities which may improve their own health (McCann, 2010). Indeed, the act 
of simply being a research participant has been shown to alter behaviour. This 
long-known phenomenon called the ‘Hawthorne effect’ has been shown in a recent 
systematic review to impact upon health studies and may well have contributed 
towards the findings of the present study unbeknown to the author (McCambridge, 
2014). In addition to this, the patients with MDI also appeared to be generally a 
well-managed group and it is difficult to say in the light of this if they are truly 
representative of MDI patients as a whole. Furthermore, it is unknown if patients 
recruited from the Royal Liverpool Hospital are truly representative of those with 
T1D in the UK as a whole.  
In addition to these issues of representability, the study also had some limitations 
with regards to the actual methods used. For example, surveys such as food 
diaries were completed by the participants at home and therefore, despite best 
efforts (such incorporating brief interviews to confirm the responses), it is difficult 
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to truly know the accuracy of results. The energy intake data and findings from the 
Goldberg equations were also indicative of bias and this is well-known when using 
assessment method such as food dairies in an overweight and obese population 
(Livingstone, 1990). Aside from amending the study design and monitoring food 
intake in more controlled surroundings (which was out of the remit of available 
resources) little can be done about this; however, food diaries are a commonly 
used assessment method and it is hoped that a reader will accept and understand 
their shortcomings and appreciate the findings in the light of this. 
In a similar way the patient medical records which were assessed both during the 
clinical audit and the cross-sectional study also had limitations. Although these 
issues have already been alluded to previously within this thesis, it is important to 
reiterate that the data was retrospective and not originally documented with 
research in mind. As such there is no record of the protocols used to collect the 
data and the environment in which the measurements were taken is unknown. 
This could pose issues with regards to the quality of the data. Furthermore, the 
author was told that after patients began CSII they would see a Healthcare 
Professional at 3 month intervals where basic clinical markers would be recorded. 
Unfortunately, as the study progressed it became apparent that this did not always 
occur and therefore explains some of the missing data which can be seen, 
especially in the case studies. In hindsight the author should have taken these 
measurements and acquired additional funding to run tests himself for markers 
such as HbA1c which would have almost certainly improved the quality of the data 
in areas. 
Furthermore, with regards to the qualitative aspects of the study it is difficult to 
determine with certainty if the data is reliable. The author made best efforts to 
ensure that all participants felt comfortable and relaxed and incorporated 
techniques such as active listening to facilitate the interview process. Despite this, 
some of the participants, especially those who took part in the cross-sectional 
study had never met the author before and were expected to answer questions 
about their life with a chronic condition. Although no particularly sensitive 
questions were asked, the conversations frequently deviated onto personal and 
emotional topics and it is unknown just how comfortable the participants were 
about opening up. The author tried to build rapport as best possible in the short 
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time prior to the interview commencing; however, in hindsight perhaps it may be 
best in future to offer pre-study briefing sessions to assist in this rapport building 
process. 
It should also be noted that there were some practical issues which the author 
encountered during the study. These particularly relate to the laboratory analysis 
of plasma samples as described in detail in chapter 7. It should be noted; 
however, that these issues had little bearing upon the results and so will not be 
discussed further, although for future studies using good quality apparatus is 
imperative to ensuring good quality results. 
With regards to future studies, a number of suggestions became apparent, mainly 
stemming from the regret of not measuring certain variables. For example it would 
be useful to determine the frequency of hypoglycaemic episodes during the 
commencement of CSII. This would have been beneficial as although HbA1c is a 
useful measure of average glycaemic control, it tells very little of the day-to-day 
variances which can impact greatly upon patients quality of life. Furthermore, the 
present study did not measure physical activity levels. This was in hindsight an 
error because although many patients explained in the interviews how the therapy 
had allowed freedom to perform physical activity the author had no way of 
quantifying this and when considering that this aspect was often described as an 
important part of many participants’ lives it would have been beneficial to have 
investigated this further. Similarly, no measures of lean mass were taken. 
Although BMI data was gathered from the medical records of patients these 
showed little change, despite those using CSII mentioning an uptake in physical 
activity and as such it could be hypothesised that changes in lean mass may 
instead be occurring. Also, the findings revealed an interesting paradox whereby 
patients who commenced CSII failed to take advantage of the dietary flexibility 
inferred by the therapy. This was surprising and the qualitative data suggested that 
patients preferred to remain attached to their old habits due to an underlying fear 
of the metabolic disruptions which previously occurred when using MDI. This is an 
under-researched area and if these behaviours are in fact occurring Healthcare 
Professionals will need to take heed and ensure that patients are adequately 
supported to not only take advantage of the flexibility of CSII, but to also make 
healthful food choices. A further aspect which should also be considered for future 
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research is that regarding the quality of care and support which patients receive. 
Numerous times throughout this thesis the profound impact that consistency and 
quality of care may infer has been hypothesised, yet little research has been 
performed in this area. Therefore, it would be useful for future studies to 
investigate this further and although potentially difficult to measure is a gap in the 
literature which requires confronting. Also, the lipid and lipoprotein analysis carried 
out in the study, although showing little quantitative differences between those 
using CSII and MDI shows subtle differences in some areas, such as the Apo-A1 / 
Apo-B ratio. This could perhaps be indicative of small but important qualitative 
differences. Indeed the literature suggests that there are qualitative benefits which 
can be enjoyed by improving glycaemic control and therefore perhaps it may be 
useful in future research to investigate other aspects of lipoprotein quality (Vergès, 
2009). Principle examples being low density lipoprotein (LDL) discordance, 
oxidation and glycation, as well as HDL functionality, which have all been shown to 
be sensitive to glycaemic control (Vergès, 2009). Finally, the audit and cross-
sectional studies both revealed, for the first time, a novel decrease in blood 
pressure in those using CSII both over time and compared to those using MDI. 
The research team are unsure why this may be occurring; however, a future study 
is planned to investigate the blood pressure of CSII patients more robustly to 
confirm this finding. 
10.4 Summary and relevance of findings 
This study shows that the impact of CSII far exceeds the device itself. It is a 
complex intervention for the treatment of T1D which comprises of a plethora of 
inter-related factors including technology, education, support, physician attitude 
and patient self-responsibility. Despite this complex convergence of indispensable 
elements, very little modern research has been performed focusing on the areas 
outside of glycaemic control. This study therefore, for the first time, offers an 
insight into the some of these currently under-researched aspects and amd has 
revealed often subtle but important differences pertaining to the eating behaviours, 
quality of life and cardiometabolic risks of adult patients with T1D who are well 
established with CSII. Furthermore, it also offers not only an albeit brief insight into 
the transitionary period through a number of case studies, but a more long-term 
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overview through an 8 year retrospective audit of patient medical records. In fact 
an audit of this length has never been previously attempted investigating patients 
residing in the UK. 
In addition to making an original contribution to the literature this study, through 
novel investigation, has also elucidated findings which may have greater value 
than simply enhancing the knowledge base alone. It is hoped that the findings, 
published through both a university repository and in a subsequent series of peer-
reviewed journal papers will allow Healthcare Professionals to make better 
judgements regarding patients using both CSII and MDI. In particular, it is hoped 
that these findings will emphasise the importance of ensuring that patients are well 
informed of all their treatment options. Using the case study of Patient L003 as an 
example, it can be seen that after being informed in more detail about CSII he 
decided it could be of benefit and with assistance of an expert colleague 
developed a strategy to successfully apply for the treatment. Other patients do not 
have this luxury and might be unaware of the device and its benefits and may only 
become mindful after a crisis has happened. In the light of this perhaps Healthcare 
Professionals should also consider not only how they educate their patients but 
also when and aim to prevent rather than treat issues.  
As well as being useful to Healthcare Professionals it is also hoped that the 
findings will be beneficial to patients alike and will hopefully encourage individuals 
to ask for the treatment they want and need. For example, the case study of 
Patient L004 illustrated how she was initially lacking in self-confidence and 
meanwhile her diabetes related issues were intensifying to the point she broke 
down in a clinic appointment. This got the attention of her consultant who 
immediately said she would be ideal for CSII. This begs the question that perhaps 
if she had previously voiced her concerns more assertively would her requests 
have been taken more seriously? This may have also prevented the culmination of 
her anxieties and it is hoped that patients in a similar predicament may be able to 
take some strength from this patient’s story and apply it to their own situation. 
Furthermore, it is also hoped that the findings from this study might also prompt 
patients to independently take responsibility and self-research their condition and 
to work in conjunction with, rather than under the control of Healthcare 
Professionals. Referring back to the case study of Patient L003, his motivated and 
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proactive approach to self-researching CSII after initially being informed about the 
therapy was the stepping stone he needed to decide that the treatment could be of 
benefit; whereas previously he hadn’t even considered CSII as a treatment option. 
In addition to assisting both Healthcare Professionals and patients, the benefit 
these findings may have upon society should also not be underestimated. It could 
initially be suggested by a ‘devil’s advocate’ that comments made in the previous 
two paragraphs may encourage more patients to ask for CSII and for more 
physicians to recommend the therapy, which may in turn have cost implications for 
an already overburdened NHS. However, in reality it is likely these additional costs 
would be counterbalanced against the money saved from treating the 
complications associated with poor glycaemic control. Indeed, a recent systematic 
review of studies investigating the cost effectiveness of CSII compared to MDI 
found that although higher direct treatment costs were associated with CSII, these 
were compensated by reductions in costs required for the treatment of 
complications (Roze, 2015). Despite this a the recent insulin pump service audit 
illustrated a lack of adequately staffed pump services to induct substantial 
quantities of new patients and those services which exist are already 
overburdened with the management of existing patients (White, 2014). 
Unfortunately, this evidence perhaps serves to highlight that an ever greater 
problem may lie not with the physicians or hospitals but rather the governing 
bodies who fund the time of Healthcare Professionals. With 39% of consultant, 
61% of diabetes specialist nurse and 60% of dietitian time unfunded it is likely to 
remain difficult to persuade governing bodies that extra Healthcare Professional 
time is needed to grow a service which will cost even more in short-term direct 
costs; despite the fact that the long-term financial benefits have been documented 
(White, 2013; Roze, 2015). The solutions to these issues are out of the remit of 
this study; however, it is hoped that the findings may contribute somewhat towards 
a larger case outlining the benefits of CSII and the positive impact that it may have 
upon patients, the NHS and society as a whole. 
Overall, to summarise, this study has, despite limitations, produced a variety of 
novel findings in currently under-researched areas, as well as positioning the 
foundations for a number of successive research studies. It has also created 
valuable information which can be used directly used by Healthcare Professionals 
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and which the author hopes may ultimately go some way toward improving the 
lives of those with T1D.  
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A Mixed Methods Investigation into the Eating Behaviours, 
Quality of Life and Cardiometabolic Risks in Adults with 
Type-1 Diabetes using Continuous Subcutaneous Insulin 
Infusion Therapy. 
 
Richard Webb – Liverpool John Moores University (Faculty of 
Education, Community and Leisure) 
 
You are being invited to take part in a research study. 
Before you decide it is important that you understand why the 
research is being done and what it involves. Please take time 
to read the following information. Ask us if there is 
anything that is not clear or if you would like more 
information. Take time to decide if you want to take part or 
not. 
 
1. What is the purpose of the study? 
 
The purpose of this study is to gain knowledge about how 
insulin pump therapy may affect your eating behaviours, 
quality of life and cardiovascular disease risks (and markers 
relating to metabolism). This information will be used to 
assess the effectiveness of pumps in relation to these 
factors and to improve the advice we give to people on CSII.   
 
2. Do I have to take part? 
 
No. It is up to you to decide whether or not to take part. If 
you do you will be given this information sheet and asked to 
sign a consent form. You are still free to withdraw at any 
time and without giving a reason. A decision to withdraw will 
not affect your rights/any future treatment/service you 
receive. (It should also be noted that permission for your 
participation in this study will also be asked from your 
health professional – if permission is not given you may be 
excluded from the study. Additionally, you may also be 
excluded if you have recently been involved in another study 
- you should make the researcher aware of this). 
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3. What will happen to me if I take part? 
 
If you agree to take part you will be asked to: 
 Be involved with the study for its duration 
(approximately 5 days max). 
 Complete 1 food intake questionnaire outlining recent 
food consumption and 1 short quality of life 
questionnaire. 
 Allow the research team to contact your GP to make them 
aware of your participation in the study.  
 Allow the research team to access your medical records 
to gather information regarding your current age, 
gender, weight, height, lipid profile, HbA1c level and 
blood pressure. 
 
You may also be asked to: 
 
 Be interviewed. This will occur once and will last for 
approximately 1-2 hours and will ask you questions 
relating to the quality of your life. 
 Complete 1 food diary for 5 consecutive days (the 
contents will be reviewed with you during a short 
interview upon completion). 
 Agree to an extra 4 teaspoons of blood being drawn after 
fasting for 12hr in addition to your regular diagnostic 
sample. 
 
 
A flow chart has been attached to this information sheet for 
you to look at. This visually outlines these activities. 
 
4. Are there any risks / benefits involved? 
 
This study may also pose various risks and burdens to you as 
a participant. These are outlined below:- 
- Inconvenience - Some aspects of this study may demand a 
small investment of your own time. Examples are the 5 
day food diaries and interviews. To help minimise the 
inconvenience caused by this, the food diaries have been 
designed to be as user friendly as possible.  
- Interviews - Additionally, to minimise any impact 
occurring from the interviews you will be offered the 
choice of participating either at your regular clinic 
location at a time of your choice, or alternatively they 
can take place in your own home.  
Although the interviews will only be concerned with the 
impact that insulin pumps have had on your quality of 
life, it should be noted that the diabetes team from the 
Royal Liverpool Hospital will be on hand, either at the 
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clinic sessions or over the phone to offer support and 
help on any issues.  
- Blood Samples - There is also a risk that you may feel a 
slight discomfort during the drawing of the additional 4 
teaspoon volume of blood needed by the study; although 
this will be no more uncomfortable than any of your 
other regular blood visits. To minimise the risks of 
this all blood will be drawn by a trained phlebotomist 
and will be only be taken in addition to your regular 
diagnostic sample if needed. 
 
 
 
 
5. Will my taking part in the study be kept confidential? 
 
All your data collected from this study will be kept 
confidential. This will be done by:- 
 
- Ensuring that your name will not be used in any of the 
data derived from food diaries, food intake 
questionnaires and quality of life surveys as well as 
any results from tests carried out on your blood 
samples.  
- Ensuring all data will be stored on a secure NHS and 
university server (apart from your contact details which 
will be stored separately). 
- Interviews will be audio recorded and transcribed and 
stored anonymously on a secure NHS computer.  
- After transcribing is complete the audio tapes will then 
be destroyed and the transcribed copy will be stored on 
the secure NHS server for the duration of the study; 
after which it will be destroyed within 5 years using 
appropriate data destruction software.  
- The only data collected from you which will not be 
anonymised will be your personal contact details to 
allow the researcher to keep in touch with you 
throughout the study. These will be stored in a locked 
filing cabinet in an NHS location with restricted 
access. This will be destroyed within 3 months of the 
study ending. 
- We will also ensure that outside of the direct 
healthcare team, only the student (Richard Webb), 
Academic Supervisor 1 (and Chief Investigator) (Dr Julie 
Abayomi), Academic Supervisor 2 (Dr Ian Davies) and 
Academic Supervisor 3 (Professor Andrew Sparkes) will 
have access to your personal data during the study. 
 
We will also ensure your blood samples remain confidential 
by:- 
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- Making sure all samples are anonymised before they are 
made available to the study. It should also be noted 
that access will be under the control of the Chief 
Technician, Dr Julie Abayomi and Dr Ian Davies. 
 
- Most testing and analysis will take place at LJMU, 
however some anonymised samples will be prepared at LJMU 
and then transported on ice to Northumbria University 
for analysis by Dr John Lodge. 
 
We would also like to keep with your permission any of your 
plasma samples that are left over at the end of the study. 
Left over blood samples will be anonymised and stored for a 
maximum of 5 years under Liverpool John Moores University 
policy and may be used in further research projects pending 
ethical approval. 
 
6. Who can I contact for independent advice to help me decide 
whether or not to be involved in the study? 
 
- If you would like independent advice to help you decide 
whether nor not to be part of the study you can contact 
your diabetes specialist nurse, GP or Diabetes UK 
(www.Diabetes.org.uk). 
 
7. Who can I contact in the event of a complaint regarding 
the study? 
 
- If you have a complaint to make regarding the study you 
can contact the Chief Investigator to discuss your issue 
further. The Chief Investigator’s contact details are 
shown at the end of this form. 
  
Contact Details of Researcher  
 
Richard Webb (R.Webb@2009.ljmu.ac.uk) 
Liverpool John Moores University (IM Marsh Campus) 
Barkhill Road 
Aigburth 
Liverpool 
L17 6BD  
 
Contact Details of Chief Investigator 
 
Dr Julie Abayomi (Senior Lecturer) (J.C.Abayomi@ljmu.ac.uk) 
Liverpool John Moores University (IM Marsh Campus)  
Barkhill Road 
Aigburth 
Liverpool 
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L17 6BD 
 
Note: A copy of the participant information sheet should be 
retained by the participant with a copy of the signed consent 
form. 
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A Mixed Methods Investigation into the Eating Behaviours, 
Quality of Life and Cardiometabolic Risks in Adults with 
Type-1 Diabetes using Continuous Subcutaneous Insulin 
Infusion Therapy. 
 
Richard Webb – Liverpool John Moores University (Faculty of 
Education, Community and Leisure) 
 
You are being invited to take part in a research study. 
Before you decide it is important that you understand why the 
research is being done and what it involves. Please take time 
to read the following information. Ask us if there is 
anything that is not clear or if you would like more 
information. Take time to decide if you want to take part or 
not. 
 
8. What is the purpose of the study? 
 
The purpose of this study is to gain knowledge about how 
insulin pump therapy may affect your eating behaviours, 
quality of life and cardiometabolic risks. This information 
will be used to assess the effectiveness of pumps in relation 
to these factors and to improve the advice we give to people 
on CSII.   
 
9. Do I have to take part? 
 
No. It is up to you to decide whether or not to take part. If 
you do you will be given this information sheet and asked to 
sign a consent form. You are still free to withdraw at any 
time and without giving a reason. A decision to withdraw will 
not affect your rights/any future treatment/service you 
receive. (It should also be noted that permission for your 
participation in this study will also be asked from your 
health professional – if permission is not given you may be 
excluded from the study. Additionally, you may also be 
excluded if you have recently been involved in another study 
- you should make the researcher aware of this). 
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10. What will happen to me if I take part? 
 
If you agree to take part you will be asked to: 
 Be involved with the study for its duration (13 months). 
 Complete a food diary every 3 months for 13 months (the 
contents will be reviewed with you during a short 
interview after the completion of each diary). 
 Complete a food intake questionnaire every 3 months for 
13 months. 
 Complete a short quality of life questionnaire every 3 
months for 13 months. 
 Agree to an extra 4 teaspoons of blood being drawn after 
12hr fasting in addition to your regular diagnostic 
sample every 3 months for 13 months. 
 Allow the research team to contact your GP to make them 
aware of your participation in the study.  
 Allow the research team to access your medical records 
to gather information regarding your current age, 
gender, weight, height, lipid profile, HbA1c level and 
blood pressure at each study time point. 
 
You may also be asked to: 
 
 Be interviewed 5 times. This will occur every 3 months 
for 13 months assessing your quality of life. (Each 
interview will last for approximately 45-60 minutes 
(apart from the first interview, which may last 1-2 
hours). 
 
A flow chart has been attached to this information sheet for 
you to look at. This visually outlines these activities. 
 
11. Are there any risks / benefits involved? 
 
This study may also pose various risks and burdens to you as 
a participant. These are outlined below:- 
- Inconvenience - Some aspects of this study may demand a 
small investment of your own time. Examples are the 5 
day food diaries and interviews. To help minimise the 
inconvenience caused by this, the food diaries have been 
designed to be as user friendly as possible.  
- Interviews - Additionally, to minimise any impact 
occurring from the interviews you will be offered the 
choice of participating either at your regular clinic 
location at a time of your choice, or alternatively they 
can take place in your own home.  
Although the interviews will only be concerned with the 
impact that insulin pumps have had on your quality of 
life, it should be noted that the diabetes team from the 
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Royal Liverpool Hospital will be on hand, either at the 
clinic sessions or over the phone to offer support and 
help on any issues.  
- Blood Samples - There is also a risk that you may feel a 
slight discomfort during the drawing of the additional 4 
teaspoon volume of blood needed by the study. To 
minimise the risks of this all blood will be drawn by a 
trained phlebotomist and will be only be taken in 
addition to your regular diagnostic sample if needed.  
 
 
 
12. Will my taking part in the study be kept confidential? 
 
All your data collected from this study will be kept 
confidential. This will be done by:- 
 
- Ensuring that your name will not be used in any of the 
data derived from food diaries, food intake 
questionnaires and quality of life surveys as well as 
any results from tests carried out on your blood 
samples.  
- Ensuring all data will be stored on a secure NHS and 
university server (apart from your contact details which 
will be stored separately). 
- Interviews will be audio recorded and transcribed and 
stored anonymously on a secure NHS computer.  
- After transcribing is complete the audio tapes will then 
be destroyed and the transcribed copy will be stored on 
the secure NHS server for the duration of the study; 
after which it will be destroyed within 5 years using 
appropriate data destruction software.  
- The only data collected from you which will not be 
anonymised will be your personal contact details to 
allow the researcher to keep in touch with you 
throughout the study. These will be stored in a locked 
filing cabinet in an NHS location with restricted 
access. This will be destroyed within 3 months of the 
study ending. 
- We will also ensure that outside of the direct 
healthcare team, only the student (Richard Webb), 
Academic Supervisor 1 (and Chief Investigator) (Dr Julie 
Abayomi), Academic Supervisor 2 (Dr Ian Davies) and 
Academic Supervisor 3 (Professor Andrew Sparkes) will 
have access to your personal data during the study. 
 
We will also ensure your blood samples remain confidential 
by:- 
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- Making sure all samples are anonymised before they are 
made available to the study. It should also be noted 
that access will be under the control of the Chief 
Technician, Dr Julie Abayomi and Dr Ian Davies. 
 
- Most testing and analysis will take place at LJMU, 
however some anonymised samples will be prepared at LJMU 
and then transported on ice to Northumbria University 
for analysis by Dr John Lodge. 
 
We would also like to keep with your permission any of your 
blood samples that are left over at the end of the study. 
Left over blood samples will be anonymised and stored for a 
maximum of 5 years under Liverpool John Moores University 
policy and may be used in further research projects pending 
ethical approval. 
 
13. Who can I contact for independent advice to help me 
decide whether or not to be involved in the study? 
 
- If you would like independent advice to help you decide 
whether nor not to be part of the study you can contact 
your diabetes specialist nurse, GP or Diabetes UK 
(www.Diabetes.org.uk). 
 
14. Who can I contact in the event of a complaint regarding 
the study? 
 
- If you have a complaint to make regarding the study you 
can contact the Chief Investigator to discuss your issue 
further. The Chief Investigator’s contact details are 
shown at the end of this form. 
  
Contact Details of Researcher  
 
Richard Webb (R.Webb@2009.ljmu.ac.uk) 
Liverpool John Moores University (IM Marsh Campus) 
Barkhill Road 
Aigburth 
Liverpool 
L17 6BD  
 
Contact Details of Chief Investigator 
 
Dr Julie Abayomi (Senior Lecturer) (J.C.Abayomi@ljmu.ac.uk) 
Liverpool John Moores University (IM Marsh Campus)  
Barkhill Road 
Aigburth 
Liverpool 
L17 6BD 
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Note: A copy of the participant information sheet should be 
retained by the participant with a copy of the signed consent 
form. 
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A Mixed Methods Investigation into the Eating Behaviours, 
Quality of Life and Cardiometabolic Risks in Adults with 
Type-1 Diabetes using Continuous Subcutaneous Insulin 
Infusion Therapy. 
 
Research Student: Richard Webb (Faculty of Education, 
Community and Leisure) 
 
Please proceed to initial each box if you agree to each 
statement and sign at the end of the form. 
 
 
1. I confirm that I have read and understand the 
information provided for the above study. I have had 
the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and 
that I am free to withdraw at any time, without giving 
a reason and that this will not affect my treatment at 
the hospital. 
 
3. I understand that any personal information collected 
during the study will not identify me and will remain 
confidential. 
 
4. I agree to take part in the above study and I 
understand that it will involve me completing a food 
frequency questionnaire and a quality of life 
questionnaire. 
 
5. I will allow the research team access to my medical  
records to gather information regarding my current 
age, 
gender, height, weight, HbA1c level, lipid profile  
and blood pressure. 
 
6. I agree to complete a weighed food diary for a 5 day 
period (this is optional). 
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7. I am happy to be contacted with more information about 
taking part in an interview (this is optional). 
 
 
 
 
 
8. I consent to the removal and storage of 4 teaspoons of 
blood volume, after fasting (this is optional). 
 
 
 
9. I agree for any blood samples left over at the end of 
the study to be used for future undefined research 
pending ethical approval. 
 
 
 
Name of Participant    Date   Signature 
 
 
Name of Researcher    Date   Signature 
 
 
Name of Person taking consent  Date   Signature 
(if different from researcher) 
 
 
Note: When completed 1 copy for participant, 1 copy for 
researcher and 1 copy for patient notes. 
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A Mixed Methods Investigation into the Eating Behaviours, 
Quality of Life and Cardiometabolic Risks in Adults with 
Type-1 Diabetes using Continuous Subcutaneous Insulin 
Infusion Therapy. 
 
Research Student: Richard Webb (Faculty of Education, 
Community and Leisure) 
 
Please proceed to initial each box if you agree to each 
statement and sign at the end of the form. 
 
 
10. I confirm that I have read and understand the 
information provided for the above study. I have had 
the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
11. I understand that my participation is voluntary and 
that I am free to withdraw at any time, without giving 
a reason and that this will not affect my treatment at 
the hospital. 
 
12. I understand that any personal information collected 
during the study will not identify me and will remain 
confidential. 
 
13. I agree to take part in the above study and I 
understand that it will involve me completing food 
diaries, food intake questionnaires, quality of life 
questionnaires. 
 
14. I will allow the research team access to my medical  
records to gather information regarding my current 
age, 
gender, height, weight, HbA1c level, lipid profile  
and blood pressure at each study time point. 
 
15. I am happy to be contacted with more information 
about taking part in an interview. 
 
 
 
16. I consent to the removal and storage of 4 teaspoons 
of blood volume, after 12hr fasting. 
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17. I agree for any blood samples left over at the end 
of the study to be used for future undefined research 
pending ethical approval.  
 
 
 
Name of Participant    Date   Signature 
 
 
Name of Researcher    Date   Signature 
 
 
Name of Person taking consent  Date   Signature 
(if different from researcher) 
 
 
Note: When completed 1 copy for participant, 1 copy for 
researcher and 1 copy for patient notes. 
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EQ-5D quality of life 
questionnaire 
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EPIC food frequency 
questionnaire 
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Appendix 6 
 
Interview structures (all 
studies) 
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Qualitative Interview Outline (Cross-Sectional 
Pump User) 
 
Complete interview consent form!!!!!!!! 
Hello there, I’d just like to welcome you here and say thank you for giving up your 
time to participate in this interview. It is very much appreciated.  
My name is Richard Webb and I am a research student from Liverpool John 
Moores University. I am studying for a PhD in nutrition and I am looking at the 
impact that diabetes and insulin pumps have had on you. I am not a medic or a 
healthcare professional and I do not work for any medical company. I should also 
make you aware that by taking part in this interview your access to treatments and 
services will not be affected and I am not here to judge you or your service.   
The reason I am running these interviews with patients is to try and understand 
patients’ thoughts and feelings surrounding diabetes and how insulin pumps may 
impact upon patients’ quality of life. The information collected from these 
interviews will be analysed to give an insight into quality of life, which may 
hopefully help with future service improvements. 
Before we begin I would just like to go over the food diary you have filled in (if 
required) to ensure it is completed correctly and we will then commence with the 
interview. 
(Then proceed to discuss the accuracy of the food diaries with the participant if 
required). 
 
Introduction to Quality of Life Interview 
- Could you please tell me you name and age?  
- Thinking back, what was life like before diabetes? 
Probe: Tell me about when you found out that you had diabetes – How was that? 
Probe: What is it like living with your diabetes? 
- How did you first become associated with the diabetes clinic? 
Probe: Think back to when you were first diagnosed – could you please tell me 
about your experience with treatments? 
     - How did you find the transition onto a pump? 
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Activities (Regular / Leisure activities / Work / Mobility) 
Thinking about since receiving the pump: 
- How do you think the pump has affected your regular day to day activities, 
such as work and house chores etc.? 
- In what ways do you think the pump has affected your mobility? (For 
example, running errands or getting to and from places). 
- How do you feel the pump has impacted upon your quality of life with 
regards to your leisure activities (such as socialising, sports and holidays 
etc.)? 
 
Diet (Day to day eating behaviours / Appetite) 
Since receiving the pump: 
- Have you noticed any change in your day to day eating habits? 
- How has your appetite been since using the pump? 
 
Health (General health / Self-care / Self-esteem) 
Again, thinking about when you were given the pump: 
- How do you feel the pump has affected your health, in terms of your 
diabetes control? 
- What pain or discomfort have you found to be associated with it? 
- Did you look forward to receiving and using the pump? 
Probe: Why was this?  
 
Relationships (Partner / Healthcare Professional / Family) 
- Do you think the pump has affected the relationship you have with your 
healthcare professional in any way at all? 
 
- How about your relationship with your family? 
Probe: Could you perhaps give a little more detail about that please? 
- Have you noticed any changes in the relationship between you and your 
partner after receiving the pump?  
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- What about with your friends?  
 
Ending Questions 
- Thinking back over the interview and your thoughts and feelings, what 
would you say to others considering going onto insulin pump therapy. 
- We would like to help other patients with Type 1 diabetes in the future. 
From your experiences, have you any other advice for us on how to make 
the transition onto the pump therapy any better? 
- How do you feel about the future in general? 
- Have we discussed everything? Are there any questions or have you got 
anything else to add? 
 
- Thank you for your time. It is much appreciated. 
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Qualitative Interview Outline (Cross-Sectional Non 
- Pump User) 
Complete interview consent form!!!!!!!! 
Hello there, I’d just like to welcome you here and say thank you for giving up your 
time to participate in this interview. It is very much appreciated.  
My name is Richard Webb and I am a research student from Liverpool John 
Moores University. I am studying for a PhD in nutrition and I am looking at the 
impact that diabetes and insulin pumps have had on you. I am not a medic or a 
healthcare professional and I do not work for any medical company. I should also 
make you aware that by taking part in this interview your access to treatments and 
services will not be affected and I am not here to judge you or your service.   
The reason I am running these interviews with patients is to try and understand 
patients’ thoughts and feelings surrounding diabetes and how insulin pumps may 
impact upon patients’ quality of life. The information collected from these 
interviews will be analysed to give an insight into quality of life, which may 
hopefully help with future service improvements. 
Before we begin I would just like to go over the food diary you have filled in (if 
required) to ensure it is completed correctly and we will then commence with the 
interview. 
(Then proceed to discuss the accuracy of the food diaries with the participant if 
required). 
 
Introduction to Quality of Life Interview 
- Could you please tell me you name and age?  
- Thinking back, what was life like before diabetes? 
Probe: Tell me about when you found out that you had diabetes – How was that? 
Probe: What is it like living with your diabetes? 
- How did you first become associated with the diabetes clinic? 
Probe: Think back to when you were first diagnosed – could you please tell me 
about your experiences with different treatments? 
     - Do you know about insulin pumps at all?  
     - What are your views about them? 
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Activities (Regular / Leisure activities / Work / Mobility) 
- Does your diabetes affect your regular day to day activities, such as work 
and house chores etc.? 
- Do you think your diabetes affects your mobility at all? (For example, 
running errands or getting to and from places). 
- How do you feel your diabetes impacts upon your quality of life with regards 
to your leisure activities (such as socialising, sports and holidays etc.)? 
Now think about if you were offered an insulin pump: 
- Do you think a pump would change any of these things in any way? 
 
Diet (Day to day eating behaviours / Appetite) 
- Have you noticed any changes in your day to day eating habits upon using 
previous treatments since you were diagnosed? 
- How has your appetite been using previous treatments?  
Now think about if you were offered an insulin pump: 
- How do you think using an insulin pump may affect these? 
 
Health (General health / Self-care / Self-esteem) 
Again, think if you were offered a pump: 
- How do you feel a pump may affect your health, in terms of your diabetes 
control? 
- What pain or discomfort do you think may be associated with it? 
- Would you look forward to receiving and using the pump? 
Probe: Why might this be?  
 
Relationships (Partner / Healthcare Professional / Family) 
- Do you think that your diabetes has ever affected your relationship with 
anyone; such as friends, family, partner or healthcare professionals? 
Probe: Why do you think this is? 
- Do you think having a pump might change those in any way? 
Probe: Could you perhaps give a little more detail about that please? 
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Ending Questions 
- Thinking back over the interview and your thoughts and feelings, what 
would you say to others considering going onto insulin pump therapy. 
- How do you feel about the future in general? 
- Have we discussed everything? Are there any questions or have you got 
anything else to add? 
 
- Thank you for your time. It is much appreciated. 
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Qualitative Interview Outline (Longitudinal) 
 
Complete interview consent form!!!!!!!! 
Hello there, I’d just like to welcome you here and say thank you for giving up your 
time to participate in this interview. It is very much appreciated.  
My name is Richard Webb and I am a research student from Liverpool John 
Moores University. I am studying for a PhD in nutrition and I am looking at the 
impact that diabetes and insulin pumps has had on you. I am not a medic or a 
healthcare professional and I do not work for any medical company. I should also 
make you aware that by taking part in this interview your access to treatments and 
services will not be affected and I am not here to judge you or your service.   
As part of this study you will be expected to take part in four interviews (once 
every three months), lasting for no longer than one hour each (apart from the first 
interview which may last up to two hours, although this may be carried out over 
two sessions depending on your feelings). 
The reason I am running these interviews with patients who have recently been 
accepted onto insulin pump therapy is to try and understand patients’ thoughts and 
feelings surrounding diabetes and how insulin pumps may impact upon patients’ 
quality of life over the course of a year. The information collected from these 
interviews will be analysed to give an insight into quality of life, which may 
hopefully help with future service improvements. 
Before we begin I would just like to go over the food diary you have filled in to 
ensure it is completed correctly and then we will then commence with the 
interview. 
(Then proceed to discuss the accuracy of the food diaries with the participant). 
 
Introduction to Quality of Life Interview 
- Could you please tell me you name and age?  
- Thinking back, what was life like before diabetes? 
Probe: Tell me about when you found out that you had diabetes – How was that? 
Probe: What is it like living with your diabetes? 
- How did you become associated with the diabetes clinic and your insulin 
pump? 
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- Think back to when you were first offered the pump. Why did you opt for the 
treatment? 
Probe: What did you inspect it to involve? 
- How have your impressions changed after thinking about it for a while? 
 
Activities (Regular / Leisure activities / Work / Mobility) 
Thinking about when you will get the pump: 
- How do you think the pump will affect your regular day to day activities, 
such as work and house chores etc.? 
- In what ways do you think the pump will affect your mobility? (For example, 
running errands or getting to and from places). 
- How do you feel the pump might impact upon your quality of life with 
regards to your leisure activities (such as socialising, sports and holidays 
etc.)? 
 
Diet (Day to day eating behaviours / Appetite) 
When you receive the pump: 
- Do you think there will be any change in your day to day eating habits? 
- How do you think your appetite will be after using the pump? 
 
Health (General health / Self-care / Self-esteem) 
Again, thinking about when you will be given the pump: 
- How do you feel the pump will affect your health, in terms of your diabetes 
control? 
- Imagine you already have the pump. What pain or discomfort do you think 
might be associated with it? 
- Are you looking forward to receiving and using the pump? 
Probe: Why is this?  
 
Relationships (Partner / Healthcare Professional / Family) 
- How do you think the pump will affect the relationship you have with your 
healthcare professional in any way at all? 
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- How about your relationship with your family? 
Probe: Could you perhaps give a little more detail about that please? 
- What changes do you feel may occur in the relationship between you and 
your partner after receiving the pump?  
 
Ending Questions 
- Thinking back over the interview and your thoughts and feelings, what 
would you say to others considering going onto insulin pump therapy. 
- We would like to help other patients with type 1 diabetes in the future. From 
your experiences, have you any other advice for us on how to make the 
transition onto the pump therapy any better? 
- Have we discussed everything? Are there any questions or have you got 
anything else to add? 
 
- Thank you for your time. It is much appreciated. 
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Permission to use Fig 1.1 – Image of immunological, environmental and genetic determinants of Type 1 diabetes (Hober, 2010). 
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Dear Richard, 
  
Thank you for filling in the Permission Form. 
  
I approve this copyright request. Conditions of use can be found here. 
In order to correctly cite the IDF Diabetes Atlas, please use the following rules. 
  
Please send us any new studies that you believe should be included in the next version of the 
Atlas. High quality studies are welcome for all countries; while we welcome updated data for all 
countries, we are especially interested in studies from these countries mentioned here. 
  
If you would like to receive support from our worldwide community, register to D-NET! This new 
online platform is developed by IDF to connect diabetes professionals worldwide and to make 
them able to share and learn from each other. (http://d-net.idf.org) 
  
Kind regards, 
Marie-Astrid Thielens 
  
  
Submitted on Tuesday, October 6, 2015 - 13:01 Submitted by anonymous user: [127.0.0.1] 
Submitted values are: 
  
Name of organisation: Liverpool John Moores University Contact name: Richard Webb Contact 
email: R.webb@2009.ljmu.ac.uk Article, extract, chart, table or publication that you wish to 
reproduce: Map 
2.5 image from Diabetes Atlas (6th ed.) 
Are you seeking permission for: a full-length reproduction Target language: English In what type 
of publication or event do you wish to use/reproduce/translate an IDF material? Other 
Circulation: PhD thesis uploaded to university repository (for public access) Issues per year: N/A 
Target audience: Academic / Public Price of publication (if applicable): N/A Distribution territory: 
Global How do you finance your publication? Other If "Other" or "Corporate partner", please 
specify: University funded PhD project 
  
  
The results of this submission may be viewed at: 
http://www.idf.org/node/30294/submission/43749 
  
  
Marie-Astrid Thielens | Assistant Policy and Programmes 
tel +3226795590 | Marie-Astrid.Thielens@idf.org 
  
International Diabetes Federation 
166 Chaussée de La Hulpe, B-1170 Brussels, Belgium 
tel +32-2-5385511 | fax +32-2-5385114 
info@idf.org | www.idf.org | VAT BE 0433.674.528 
 
  
IDF | Promoting diabetes care, prevention and a cure worldwide 
Permission to use Fig.1.2 – Map showing diabetes prevalence (IDF Atlas, 2015).  
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  Permission to use Fig 1.3, 1.4 and 1.5 – Graphs showing insulin profiles of difference regimens (Accu-Chek, 2016).  
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 Permission to use Fig 3.1 – A diagram showing NHS clinical audit process (UH Bristol, 2009).  
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Permission to use Table 3.1 – Table showing mixed methods typologies (Creswell, 2009).   
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Permission to use Table 3.2 – Table showing Toronto quality of life model (Quality of Life Research Unit, 2016).   
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Permission to use Fig 6.1 and 6.2 – Goldberg equations and S-Factor equations (Black, 2000).   
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Permission to use Table 7.1 – Table showing AOCS lipoprotein size and densities (AOCS, 2015).   
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Permission to use Table 7.2 – Table showing lipoprotein subclass densities and sizes (Berneis, 2002).  
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Permission to use Fig. 7.3 – Diagram showing the structure of a lipoprotein particle (Antisense, 2010).   
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Permission to use Table 7.4 – Table showing HDL density ranges (Harman, 2013).   
